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1. The bone marrow microenvironment
Red blood cells, cells of the various leukocyte lineages and platelets are continu-
ously replenished by cells originating from hematopoietic stem cells in the bone mar-
row in a tightly controlled process called hematopoiesis. This process takes place in 
flat bones such as the pelvic girdle and the sternum and in the medullary cavity of 
the long bones, such as the femur. Bone-marrow composes of both hematopoietic 
and supporting cells originating from hematopoietic stem cells and stromal stem 
cells, respectively. Already in 1867, Conheim, a German pathologist, described non-
hematopoietic cells that originated from the bone-marrow cavity and migrated to 
sites of cell repair.(Cohnheim, 1867) In 1968 Friedenstein identified a type of plastic 
adherent stroma cells with fibroblast-like appearance in the bone-marrow and they 
managed to expand these cells in vitro.(Friedenstein, 1968) These cells differentiated 
towards connective tissue including osteoblasts, chondrocytes and adipocytes when 
transplanted into a mice model.(Owen, 1988) A common precursor for the connective 
tissue in the bone-marrow microenvironment, bone, fat and cartilage was proposed.
(Prockop, 1997) 
With increased insight in the different components of the bone-marrow stroma 
diverse names were used to annotate the expanded cells based on their way of isola-
tion and capacity to differentiate into different mesenchymal tissues. Bone-marrow 
stroma contains a heterogeneous cell population which is defined by expression of 
characteristic cell markers and the lack of hematopoietic markers, by adherence to 
plastic and by differentiation capacity according to criteria proposed by The Inter-
national Society for Cellular Therapy (ISCT).(Horwitz, 2005) The definition mesen-
chymal stromal cells is used for cells obtained by expansion of a heterogeneous cell 
population. This population should not be annotated as stem cells because of the 
lack of evidence supporting the single cell differentiation capacity of cells defined in 
this particular way. To properly define mesenchymal stem cells, single cell sorting 
using amongst others, CD146, has been proposed.(Sacchetti, 2007) Other names 
used to refer to bone-marrow stromal cells are adventitial reticular cells (ARC) or 
CXCL12-abundant reticular cells (CAR-cells),(Sugiyama, 2006a) named after their 
subendothelial position or high ligand production, respectively. Characterization of 
intracellular expression of nestin or osterix has also been applied to define particular 
subsets of stromal cells.(Mendez-Ferrer, 2010; Schepers, 2013) In addition, the term 
skeletal stem cells, is used in the context of tissue replacement using bone-marrow 
derived stem cells for transplantation with or without prior in vitro expansion. In this 
thesis, the abbreviation MSC will solely refer to mesenchymal stromal cells as defined 
by the ISCT criteria (Table 1 and Figure 1).(Horwitz, 2005)
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2. Hematopoietic regulation in the bone-marrow 
microenvironment
The observation that hematopoietic stem cells (HSC) or progenitor cells (HPC) do 
not expand and survive in vitro without extensive support led to the hypothesis 
that the stromal cells do not only form the structural network of the bone-marrow, 
but also contribute in the support and control of hematopoiesis. A balance between 
hematopoietic stem cells in a quiescent state and stimulation of hematopoietic stem 
cells to proliferate and differentiate is essential. Exogenous factors as erythropoietin 
(EPO), thrombopoietin (TPO) and inflammatory cytokines contribute to this process 
in combination with MSCs derived factors including both cell-cell interaction (e.g. via 
ALCAM(Chitteti, 2013)) as well as soluble factors (e.g. stem cell factor (SCF)(Barker, 
1997), CXCL12(Dar, 2006) and wnt-signalling(Schreck, 2014)). Beside these factors 
a critical role for adrenergic stimulation of stromal cells has been suggested. Nestin 
expressing stromal cells were found to be closely situated to adrenergic nerves in the 
bone-marrow environment.(Mendez-Ferrer, 2010) Adrenergic stimulation leads via 
increased expression of CXCL12 in stromal cells to increased myeloid proliferation 
Table 1. Expression profile of MSCs
Positive Intermediate Negative






CD: cluster of differentiation; HLA: human leukocyte antigen.
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Figure 1. Differentiation capacity of MSC. All MSCs described in this study fulfil the ISCT criteria(5) of 




















explaining the circadian rhythm of hematopoiesis and the increased monocyte and 
neutrophil counts after tissue injury.(Courties, 2015; Mendez-Ferrer, 2008)
The impact of an abnormal bone-marrow microenvironment on hematopoiesis has 
been clearly demonstrated by Raaijmakers et al.(Raaijmakers, 2010) Disturbance of 
the micro RNA regulation, by knock-down of Dicer1 specifically in osteoblast progeni-
tors, resulted in an MDS-like hematopoiesis. In the same study, selective knock-down 
of the Sbds gene (Schwachmann-Diamond Blackfan Syndrome) resulted in increased 
dysplasia and apoptosis in the hematopoietic compartment. Others have used similar 
murine models to demonstrate disturbed hematopoiesis after selective knock-down 
of SCF, the 5HT4 serotonin receptor, the retinoblastoma gene or the retinoic acid 
receptor-γ.(Ding, 2012; Schepers, 2012; Walkley, 2007) 
In addition, different groups have looked at the effect of malignant hematopoietic 
cells on the stromal microenvironment in murine studies. Schepers et al. demon-
strated in a mice model of chronic myeloid leukemia (CML) that the bone marrow 
microenvironment is altered in gene-expression and has a decreased capacity to 
support hematopoiesis.(Schepers, 2013) In a similar murine model Zhang et al. 
showed decreased CXCL12 gene expression in stromal cells after exposure to CML. 
This ligand is upregulated in the bone-marrow of patients with CML at diagnosis 
compared to patients in remission and in healthy controls.(Zhang, 2012a) After the 
induction of acute myeloid leukemia (AML) in a murine model the number of nestin+ 
MSCs decreased, which could be rescued by adrenergic agonists.(Arranz, 2014)
The use of MSCs to accelerate hematopoietic recovery has been evaluated in 
clinical studies based on the capacity of MSCs to support engraftment in sheep and 
murine models.(Almeida-Porada, 2000; Noort, 2002) Initially, autologous MSCs were 
expanded from patients with breast cancer for infusion during autologous hema-
topoietic stem cell transplantation ((HSCT). In this phase I-II trial, MSC infusion was 
feasible and safe and the rapid hematopoietic reconstitution suggested a supportive 
role for MSCs.(Koc, 2000) Infusion of allogeneic MSCs at the time of HLA-matched 
sibling HSCT in adults with hematologic malignancies resulted in rapid reconstitution 
of absolute neutrophil counts and platelets, but no dose-dependent effect of MSCs 
was observed.(Lazarus, 2005) Ball et al. compared the hematopoietic reconstitution 
in 13 children receiving co-transplantations of haplo-identical HSC and third party 
MSCs, with 52 historical controls receiving HSC from a haplo-identical donor only. 
The reconstitution of platelets and absolute neutrophil counts was comparable, but 
lymphocyte recovery was faster in the children receiving MSCs.(Ball, 2007) No ben-
eficial effect of MSCs was observed in a pediatric cohort receiving MSCs at the time 
of umbilical cord blood transplantation.(Bernardo, 2011) MacMillan et al. reported 
similar findings comparing children receiving MSCs plus umbilical cord blood to um-
bilical cord blood only.(MacMillan, 2009) In these studies no MSC engraftment after 
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infusion was detected. Interestingly, a case report describing a boy with Wiskott-
Aldrich Syndrome demonstrated increased hematopoiesis at the side of intraosseous 
MSC infusion based on histology.(Resnick, 2010) In a large clinical trial including 55 
patients receiving a haplo-identical HSCT in the treatment of leukemia patients were 
randomized for co-infusion of MSCs. Platelet recovery was significantly faster in the 
MSC group (22 days) compared with controls (28 days), but no beneficial effect was 
observed for leukocyte recovery.
2.1 Myelodysplastic syndrome 
Pediatric myelodysplastic syndrome (MDS) is characterized by cytopenias, myeloid 
dysplasia, and a risk of transformation to AML. The spectrum of disease ranges 
from refractory cytopenia of childhood (RCC) with <5% bone marrow blasts and <2% 
peripheral blood blasts, via refractory anemia with excess blasts (RAEB), with 5-19% 
bone marrow blasts or 2-19% peripheral blood blasts, to RAEB in transformation 
(RAEBt), with 20-29% bone marrow blasts or peripheral blood blasts.(Hasle, 2003; 
Hasle, 2004; Niemeyer, 2008) In the study described in this thesis we only included 
patients with primary MDS. Patients with secondary MDS, classified as secondary to (I) 
inherited or acquired bone marrow failure syndromes or (II) radio- or chemotherapy, 
were not eligible for inclusion. In addition, patients with Down Syndrome related MDS 
form a unique entity and these were also excluded from the study.
The treatment for pediatric MDS varies between the different subtypes. RCC-MDS 
without chromosome 7 abnormalities or complex chromosome abnormalities has 
a favorable prognosis and watchful waiting can be advocated. However, eventually 
these patients will need to undergo allogeneic HSCT when becoming transfusion 
dependent or suffering from neutropenia. In children with RAEB-(t) MDS did not 
benefit from intense chemotherapy, because of high toxicity and a remission induc-
tion <60%.(Woods, 2002) Therefore, HSCT is the therapy of choice in these patients. 
Recently, immune suppressive therapy has been suggested based on adult data and 
the role of T cells in the pathogenesis of RCC-MDS.(Aalbers, 2014)
2.2 Juvenile myelomonocytic leukemia
Juvenile myelomonocytic leukemia (JMML) is an aggressive leukemia occurring in 
young children, at a median age of 2 years.(Loh, 2011)) Children typically present with 
hepatosplenomegaly, fever and monocytosis. The diagnosis was previously based on 
clinical criteria. The adapted criteria involve molecular diagnostics as shown in Table 
2.(Locatelli, 2015) Hypersensitivity of the JMML cells to granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and hyperactivity of the RAS-RAF-MAPK signaling 



















tion is detected in this pathway.(de Vries, 2010) Monosomy 7 is the most common 
karyotype abnormality detected in 25% of the patients. 
HSCT is the first line treatment. Despite myeloablative conditioning, the one year 
relapse rate ranges between 30 and 50%.(Locatelli, 2005; Locatelli, 2015) In subsets 
of patients, particularly those with germline CBL or PTPN11 mutations and in a subset 
of patients with N-RAS mutations and low HbF, spontaneous resolution is observed 
and a wait and see approach can be advocated.(Locatelli, 2015) 
3. Immunomodulation
The immunomodulatory effects of MSCs were first studied in animal models. In 
a baboon-model of allogeneic skin transplantation delayed rejection in case of co-
injection of MSCs was observed.(Bartholomew, 2002) The number of MSCs present 
in bone-marrow is relatively low and therefore in vivo immunomodulatory effects are 
difficult to assess and remain largely unrecognized. However, expansion of MSCs 
from different tissues, e.g. bone-marrow, fat, Wharton’s jelly and synovial fluid, is 
well established and the immunomodulatory effects of MSCs are extensively charac-
Table 2. Clinical and laboratory diagnostic criteria of JMML
I. Clinical and hematologic features (all 4 features mandatory)
 • Peripheral blood monocyte count 13x109/L
 • Blast percentage in peripheral blood and bone marrow, 20%
 • Splenomegaly
 • Absence of Philadelphia chromosome (BCR/ABL rearrangement)
AND
II. Oncogenetic studies (1 finding is sufficient)
 • Somatic mutation in PTPN11 or K-RAS or N-RAS (exclude germline mutations)
 • Clinical diagnosis of NF-1 or germline NF1 mutation
 • Germline CBL mutation and loss of heterozygosity of CBL‡
III. Only for those patients (10% of the whole number) without any oncogenetic
parameter, beside the clinical and hematologic features listed under I, at
least 2 of the following criteria have to be fulfilled:
 • Monosomy 7 or any other chromosomal abnormality
 • HbF increased for age
 • Myeloid precursors on peripheral blood smear
 • Spontaneous growth or GM-CSF hypersensitivity in colony assay
 • Hyperphosphorylation of STAT5
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terized in vitro.(Le, 2012) The increased use of MSCs in clinical studies reveals in vivo 
effects of MSCs after infusion.(Karlsson, 2008; Ringden, 2007) In addition, animal 
models have given insights in the immunomodulatory effects of MSCs.
3.1 Complex interactions
Mitogen and antigen induced proliferation of T-lymphocytes is suppressed by MSCs 
in a dose-dependent manner.(Krampera, 2003) Cell proliferation, assessed by flow 
cytometry or 3H-thymidine incorporation, of CD4+ and CD8+ T-lymphocytes is down 
regulated. In in vitro mixed lymphocyte reaction (MLR) suppression by MSCs is inde-
pendent of HLA match between responder cells, stimulatory cells and MSCs.(Bocelli-
Tyndall, 2007) Further evaluation of T cell subsets using flow cytometry revealed a 
suppressive effect on both central memory as well as effector cells.(Krampera, 2003; 
Karlsson, 2008) Whereas the majority of the cell populations is suppressed by MSCs, 
induction of regulatory T cells has been reported.(Mougiakakos, 2011; Ghannam, 
2010) 
Both direct contact and soluble factors have been suggested to play a part in the 
suppressive effect. The potential licensing of MSCs to become suppressive is not fully 
elucidated. In this concept, MSCs need to be in contact with pro-inflammatory factors 
such as interferon-γ or with activated monocytes producing interleukin-1 (IL-1).(Groh, 
2005) Indirect down-regulation via an increase of regulatory T cells is another poten-
tial pathway.(Jitschin, 2013) Presumably more than one system is essential because 
depletion of various cell populations or the use of antibodies interfering with specific 
pathways has only resulted in partial blocking of the inhibitory effect. 
Preclinical studies exploring the potential for MSCs in auto-immune diseases show 
that murine and human MSCs suppress proliferation, differentiation and antigen 
production by B cells.(Corcione, 2006; Che, 2012) The suppressive mechanism is 
dependent on cell-cell contact and soluble factors with an important role for CCL2.
(Schena, 2010; Rafei, 2008; Che, 2014) In contrast, Traggiai et al., reported a stimu-
latory effect of MSCs on proliferation and antibody production using different culture 
conditions for B cells.(Traggiai, 2008a) This dual effect of MSCs on B cells needs 
further exploration for tuning MSC therapy in auto-immune diseases.
A controlled response during inflammation is critical to retain a balanced immune 
system. MSCs contribute to this process via interaction with the innate immune 
response.(Le, 2012) Interestingly, MSCs have been shown to react differently to toll 
like receptor 3 (TLR3) and TLR4 activation.(Waterman, 2010) Stimulation of the TLR3 
receptor with double stranded RNA leads to pro-inflammatory responses and pro-
longed survival of neutrophils in vitro.(Raffaghello, 2008) Lipopolysaccharide (LPS) 
induced activation of MSCs via TLR4 results in increased production of CCL2, IL-6 



















skewing of monocyte differentiation towards anti-inflammatory macrophage type II 
protects the body from overreacting. This has been demonstrated in a murine model 
resembling sepsis.(Nemeth, 2009) An increased IL-10 production by macrophage 
type II led to decreased neutrophil infiltration and decreased tissue damage after 
MSC infusion. 
Another example of the precisely balanced immune system is the interaction 
between MSCs and natural killer (NK) cells. MSCs suppress the in vitro activation 
and cytotoxicity of resting NK cells during stimulation with IL-2 or IL-15 in a dose de-
pendent manner controlling inflammation.(Spaggiari, 2006; Sotiropoulou, 2006) The 
suppressive effect of MSCs is dependent on HLA-G5, IDO and PGE2.(Spaggiari, 2008; 
Selmani, 2008) Low expression of HLA class I makes MSCs from a third party donor a 
potentially suitable tool to establish immunosuppression after allogeneic transplan-
tation because MSCs may escape from recognition by alloreactive T cells responses. 
Low expression of HLA class I in combination with expression of ligands for the NK 
cell activating receptors DNAM1, NKG2D and NKp30 renders MSCs susceptible for 
lysis by activated NK cells. Blocking of these activating receptors decreases the NK 
cell cytotoxicity. Pre-treatment of MSCs with interferon-gamma (IFN-γ), resembling 
an inflammatory environment, increases HLA-class I expression causing decreased 
susceptibility to NK cell lysis but increased susceptibility to T cell mediated lysis. 
The in vivo effect of MSCs on T-lymphocyte subsets, B cells, monocytes and mac-
rophages will probably depend on the immune modulatory signals produced by the 
environment and other cells of the immune system. 
3.2 MSC treatment in acute inflammatory disease
3.2.1 Hematopoietic stem cell transplantation
Since 1968, allogeneic HSCT has evolved and improved.(Bach, 1968; Gatti, 1968) It 
is standard of care in multiple protocols for malignant and non-malignant diseases.
(Mallhi, 2015) In non-malignant disease the donor derived stem cells repopulate the 
bone-marrow and constitute a new hematopoietic system without the inborn errors 
affecting, e.g., red blood cell development or lymphocyte function. The treatment of 
hematologic malignancies consists of tumor eradication using chemotherapy with or 
without irradiation, also leading to destruction of the patients own hematopoietic sys-
tem. HSCT is subsequently performed with donor derived hematopoietic stem cells. 
An important beneficial impact of the alloreactive donor derived immune system is 
the so called graft-versus-leukemia (GvL) effect attacking the residual malignant cells.
(Horowitz, 1990) However, alloreactivity may also give high morbidity due to evoking 
acute graft-versus-host disease (aGvHD), which may run a severe course and evolve 
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into chronic GvHD requiring immunosuppressive treatment for a long period of time.
(Ball, 2008c) 
Hematopoietic stem cells (HSC) for HSCT in children are derived from bone-marrow, 
peripheral blood after mobilization and umbilical cord-blood either from related or 
unrelated donors.(Milano, 2015; Handgretinger, 2008) Whereas HLA-matched related 
HSC can be transplanted with limited risks of aGvHD, product manipulation should be 
performed on grafts derived from haplo-identical donors to reduce the aGvHD risk. 
In addition, in vivo depletion of lymphocytes by anti-thymocyte globulin or anti-CD52 
(alemtuzumab) is performed to decrease this risk. After HSCT, patients are treated 
with various types of immunosuppressive regimens to prevent or treat aGvHD. 
Immune reconstitution is important to establish the GvL effect, but in the first 
period after transplantation it is also of the utmost importance for prevention or 
elimination of viral reactivations. Infections (reactivations) of cytomegalovirus (CMV), 
Epstein-Barr virus (EBV) and human adenovirus (HAdV) may run a severe course, caus-
ing high morbidity and mortality in patients immunocompromised early after HSCT.
(Broers, 2000; Boeckh, 2003; Walls, 2003; van Tol, 2005a) Viral reactivations are 
further complicated in cases of steroid treatment for aGvHD.(Cantoni, 2010)
3.2.2 MSC in treatment of aGvHD
Acute GvHD is a complex disease consisting of multiple steps and involving various 
intercellular interactions and, thereby, a complication with an unpredictable outcome. 
It involves triggering of the immune response, amplification of the response and, 
finally, inflammation and tissue damage.(Ferrara, 2009) Different triggers have been 
proposed for the initiation of aGvHD. HLA mismatch between patient and donor is 
the best described factor involved in triggering aGvHD.(Petersdorf, 2013) Genetic 
polymorphisms, e.g., associated with cytokine production and receptor function, 
predispose for the strength of the reaction.(Dickinson, 2008) Danger associated 
microbial peptides (DAMPs) and pathogen associated microbial peptides (PAMPs) 
have been described to initiate aGvHD. Vossen et al. describe a cohort of children in 
which total gut decontamination prevents aGvHD in HLA matched sibling recipients.
(Vossen, 1990; Vossen, 2014) Next to viral and bacterial derived PAMPs and DAMPs 
endogenous DAMPs such as adenosine triphosphate (ATP) derived from conditioning 
induced apoptotic cells might be involved in the first steps of aGvHD.(Wilhelm, 2010) 
After presentation of antigens to T-lymphocytes these cells proliferate, differenti-
ate and home to the site of inflammation amplifying a pro-inflammatory cytokine 
cascade and neutrophil recruitment resulting in tissue damage of gut, skin and liver.
(Holtan, 2014) Table 3 shows the clinical criteria for staging and grading of aGvHD.
(Ball, 2008c) Albeit a clinical diagnosis, a tissue biopsy should be taken to exclude 



















Acute GvHD grade I did not require treatment. Systemic steroids are the first line of 
treatment for aGvHD grade II, but patients who fail to reach remission upon steroid 
treatment, about 50% of the cases, show high morbidity and mortality.(Deeg, 2007; 
Davies, 2009) MSCs were first used in a 9 years old boy who did not respond to 
steroids, ciclosporin, Psoralen and ultraviolet-A light (PUVA), infliximab and dacli-
zumab. He responded well to infusion of third party MSCs with a decrease in stool 
and bilirubin levels.(Le Blanc, 2004) Subsequently, a multi-center compassionate use 
trial was initiated in Stockholm, Rome and Leiden. In total 55 patients, adults and 
children, were included at various time-points after onset of severe, steroid refrac-
tory, aGvHD.(Le Blanc, 2008) While administration of steroids was continued, single 
or multiple infusions of MSCs were given. Complete response, defined as no aGvHD 
at day 28 after (the first) MSC infusion, occurred in 30 out of 55 patients. Patients 
with complete response had a lower transplant related mortality (37%) compared to 
patients with partial or no response (72%).This hallmark trial revealed no adverse 
effects of MSC infusion. A trend towards better survival in the pediatric cohort was 
observed. 
The effectiveness of MSC infusion in steroid refractory aGvHD has not been studied 
in a placebo controlled trial. However, multiple smaller studies describe the benefi-
cial effects of MSC infusion. Detailed case studies discuss the occurrence of increased 
viral reactivations and gastro-intestinal stenosis after MSC infusion.(Ball, 2008a; 
Karlsson, 2008) However, solid conclusions on a causal relationship between MSC 
infusion and these adverse events could not be drawn. 
3.3 MSCs in chronic inflammatory diseases 
Inflammatory diseases like systemic juvenile idiopathic arthritis and inflammatory 
bowel disease have a high morbidity in children caused by disease related events 
in combination with treatment related toxicity.(Beukelman, 2011; Bandzar, 2013) 
Although usage of monoclonal antibodies directed to inflammatory cytokines or 
Table 3. aGvHD staging and grading
Skin Liver GI tract
Stage Rash Bilirubin (μmol/L) Diarrhea (mL/day)
0 No Rash <34 <500
1 <25% 34-50 500-1000
2 25-50% 50-102 1000-1500
3 >50% 103-255 >1500
4 Erythroderma (with bullae) >255 Severe abdominal pain/ileus
Blue: overall grade I; Green: overall grade II; Orange: overall grade III; Red: overall grade IV
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their receptors (biologicals) improve response to therapy, patients remain on lifelong 
therapy.(Nigrovic, 2011; Yokota, 2008) Attempts to treat and cure chronic inflamma-
tory diseases using autologous or allogeneic HSCT showed promising results, but 
high treatment related mortality hampered further clinical trials.(Brinkman, 2007; 
Passweg, 2004) Effects of MSCs have been reported in animal models of autoim-
munity, such as amelioration of experimental autoimmune encephalitis in a murine 
model, raising the possibility of MSCs use in the treatment of autoimmune diseases.
(Zhang, 2005) In a collagen induced arthritis (CIA) mice model a worsening of disease 
was seen after administration of an allogeneic MSC cell line(Djouad, 2005), albeit 
other murine studies using allogeneic MSCs showed significant clinical improvement 
in CIA.(Augello, 2007) Similarly, animal models of immune colitis/enteropathy and 
systemic lupus erythematosus (SLE) responded successfully to MSC treatment.(Gon-
zalez, 2009; Parekkadan, 2008; Sun, 2009; Zappia, 2005) Pilot studies have demon-
strated potential beneficial effects in adults with Crohn’s disease.(Ciccocioppo, 2011; 
Duijvestein, 2010) In a prospective study including 78 patients with SLE, a beneficial 
effect on disease intensity and induction of clinical remission has been reported.
(Wang, 2013a) However, for use in further clinical studies safety and better insights 
in the mechanism of action of MSCs is critical. 
Chronic GvHD (cGvHD) occurring after HSCT is a devastating disease with major 
disabilities in affected children.(Baird, 2010) The immunopathophysiology of cGvHD 
is poorly understood. Following HSCT in adult patients, alloreactive donor T cells were 
considered primarily responsible for the development of cGvHD, but randomized 
studies failed to demonstrate that elimination of donor T cells in the graft reduced 
the rates of cGvHD.(van Els, 1990) There is no direct correlation between the numbers 
of minor histocompatibility antigen specific T cells and cGvHD occurrence.(Bueger 
de, 1993) Recently, B cells have been recognized as being implicated in cGvHD and 
a coordinated T/B cell response to minor histocompatibility antigens(Zhang, 2006; 
Schultz, 1995), H-Y antigen antibodies(Miklos, 2004) and the production of specific 
soluble factors (e.g. BAFF) (Baird, 2010; Sarantopoulos, 2009) may all contribute to 
the development of the clinical syndrome of cGvHD. In total 47 adults and children 
receiving MSCs for cGvHD were reported in literature.(Ringden, 2006; Zhou, 2010; 
Weng, 2010; Perez-Simon, 2011; Herrmann, 2012; Muller, 2008; Lucchini, 2010; 
Fang, 2007) Complete remission was documented in 28% and partial remission in 
34% of treated patients, which percentages are substantially lower than the efficacy 
of MSC treatment observed in aGvHD.(Le Blanc, 2008; Kebriaei, 2009) Due to the vari-































































DC T T T T 
NK NK 












Altered BM micro-environment (IV) Normal BM micro-environment (V) 
MDS/ JMML (VI) 
Normal situation (I) 
Figure 2. A simplified overview of the different parts in this thesis I: MSCs are in close contact with 
the hematopoietic stem cells (HSC) and contribute to a balanced immunological status. II: During in-
flammation, e.g. acute Graft-versus-Host disease, antigen presentation by dendritic cells (DC), derived 
from monocytes (Mo) causes an increase in NK cells (NK) and cytotoxic T cells (T), in combination 
with relatively low percentages of T-regulatory (Treg) cells resulting in an increase of inflammatory 
cytokines as TNF-α, IL-1 and IFN-γ. III: After bone-marrow harvest from a healthy donor, MSCs can be 
expanded in vitro. Infusion of MSCs has been reported to suppress T cell proliferation, increase T-
regulatory cells, suppress NK cell cytotoxicity and reduce the differentiation of monocytes to dendritic 
cells. This thesis focusses on the effect and side-effects of MSC treatment in children.
In addition, we hypothesize that MSCs contribute to disease progression in children with MDS or 
JMML, either by IV: an intrinsically altered micro-environment or V: by alterations induced by affected 




4. Aim of this thesis
Mesenchymal stromal cells (MSCs) support hematopoiesis in the bone marrow, are 
involved in tissue repair and modulate immune responses. The MSC function may 
be affected by malignant cells such as in MDS and JMML. The focus of this thesis 
is to study the impact of MSCs on virus-specific immune recovery and aGvHD after 
pediatric allogeneic HSCT. In addition, the function of MSC derived from children 
suffering from a chronic inflammatory disorder, i.e., systemic juvenile idiopathic 
arthritis, or from a childhood malignant disease, i.e., MDS and JMML, respectively, 
has been investigated (Figure 2).
The first chapters of this thesis describe the pre-clinical studies on the biological 
characteristics of patient derived MSCs. We characterized the mesenchymal stromal 
cells derived from different pediatric diseases. MSCs expanded from bone-marrow 
of healthy children were used as a control. Chapter 2 reports our findings on MSCs 
derived from children with systemic juvenile idiopathic arthritis. MSC treatment has 
been suggested in chronic inflammatory diseases. An investigation of the immune 
modulatory capacities of patient derived MSCs was performed to explore the poten-
tial of autologous MSC treatment in this disease. We specifically aimed to extensively 
define the effect of MSCs on different cell populations of the immune system. 
In the studies described in Chapter 3 and 4, we focused on the role for MSCs in 
the pathogenesis and sustainment of pediatric hematologic disease. Children with 
MDS and JMML were included and bone-marrow was collected at diagnosis and after 
hematopoietic stem cell transplantation. MSCs were extensively characterized by 
gene-expression analysis. To investigate the possible functional impact of differen-
tial gene-expression, assays were performed to investigate the immunomodulatory 
capacity and hematological support of MSCs. 
The next chapters report our findings on the effect of MSCs in a clinical study. To 
be able to study the effect of MSCs it is essential to properly determine start- and 
end-points in steroid refractory acute Graft-versus-Host disease (aGvHD). Therefore, 
gut biopsies taken at diagnosis and, when indicated, after treatment of aGvHD were 
analyzed. In addition, soluble biomarkers in serum samples at different time-points 
after HSCT and initiation of MSC treatment were measured to monitor the response 
to treatment in a less invasive manner. These results are described in Chapter 5. Sup-
pression of immune responses to control aGvHD potentially decreases the response 
to viral reactivation in children after hematopoietic stem cell transplantation. Finally, 
in Chapter 6, we focused at a potential side-effect of MSC treatment. In vitro experi-
ments studying the effect of MSCs on virus specific T cell proliferation and activation 
were performed. In addition, the occurrence of viral reactivations in a cohort of 22 



















T cells were characterized ex vivo from children with a viral reactivation prior to and 
after MSC infusion. 
In Chapter 7 our main findings and the future role for MSCs in treatment and 
understanding of pediatric diseases are discussed.

 Chapter 2.
Mesenchymal stromal cells isolated 
from children with systemic juvenile 
idiopathic arthritis suppress innate and 
adaptive immune responses.
Cytotherapy 2013; 15 (3): 280-291
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Background aims: Infusion of mesenchymal stromal cells (MSCs) has been reported 
to be an effective treatment modality for acute Graft-versus-Host disease, and MSCs 
haven been considered for use in the treatment of patients with autoimmune dis-
eases. Before contemplating clinical studies with MSCs in patients with systemic 
juvenile idiopathic arthritis (sJIA), the immunomodulatory capacity of MSCs in this 
setting needs to be explored. A comparative analysis of bone marrow derived MSCs 
from children with sJIA and healthy paediatric controls was performed.
Methods: MSCs were successfully expanded from 11 patients with sJIA and 10 
controls. The phenotype, differentiation and immunomodulatory capacity of these 
MSCs were compared. The effect of immunosuppressive drugs on MSC function was 
also investigated.
Results: MSCs from patients with sJIA and controls showed no differences in their 
suppressive effect using control peripheral blood mononuclear cells. Furthermore, 
the suppression of the response of peripheral blood mononuclear cells from patients 
with sJIA autologous sJIA MSCs and allogeneic control MSCs was comparable. The 
immunosuppressive effect of both groups of MSCs was diminished in the presence 
of indomethacin (p<0.05). MSCs from patients with sJIA and controls suppressed IL-2 
induced natural killer cell activation to a similar extent. In addition, MSCs of patients 
with sJIA and controls inhibited the differentiation of monocytes to dendritic cells.
Discussion: This is the first explorative study in a significant cohort of patients with 
sJIA to evaluate the effect of MSCs on adaptive and innate immune responses. The 
comparable immunosuppressive characteristics of MSCs derived from patients with 























Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease of un-
known aetiology that is characterized by spiking fever, exanthema, anaemia, hepa-
tosplenomegaly and arthritis.(Petty, 2004) The outcome of disease and response to 
therapy is unpredictable. Improvements in treatment outcome with the use of diverse 
biological therapies, as anti-interleukin (IL)-1 therapy, have been reported.(Lequerre, 
2008; De Benedetti F., 2009; Woo, 2008; Martini, 2006; Beukelman, 2011; Quartier, 
2011; Nigrovic, 2011; Yokota, 2008) Despite these observations, the disease pro-
gresses and/or requires additional therapy in 27% of children treated with etaner-
cept.(Prince, 2011) Moreover, patients treated with these new drugs may experience 
adverse effects. Recent data relate the use of tumor necrosis factor (TNF)-blocking 
agents in patients with JIA and other inflammatory diseases to the development of 
lymphoma and other cancers in children.(Horneff, 2011; Kwon, 2005; Diak, 2010)
Previous studies in children with refractory JIA undergoing autologous hematopoi-
etic stem cell transplantation following chemotherapy and T cell depletion show a 
progression free survival of 52% after 5 years.(Farge, 2010) However, high morbid-
ity due to macrophage activation syndrome, viral infections and transplant-related 
mortality occurred.(Brinkman, 2007) Therefore, new treatment modalities need to be 
explored for therapy-resistant patients. 
Mesenchymal stromal cells (MSCs) are multipotent non-hematopoietic stromal cells 
with anti-inflammatory and anti-proliferative capacities.(Krampera, 2003; Bocelli-
Tyndall, 2009) MSC can be expanded easily from different tissues including bone 
marrow (BM), and remain genetically stable even after numerous passages.(Bernardo, 
2007c) No unique marker has been identified for the isolation of MSCs; however, 
specific criteria to identify MSC have been accepted.(Dominici, 2006; Horwitz, 2005) 
T cell and natural killer (NK) cell proliferation, immunoglobulin production by B cells 
and dendritic cell maturation are suppressed by MSC in in vitro experiments.(Bocelli-
Tyndall, 2007; Sotiropoulou, 2006; Traggiai, 2008b) The mechanisms underlying 
these immunomodulatory functions are not fully understood. However, experimental 
data suggest that cell-cell contact and soluble factors may both be involved in an 
overall inhibition of the induction of effector functions.(Beyth, 2005; Gieseke, 2010; 
Krampera, 2003; Meisel, 2004; Rasmusson, 2005; Selmani, 2008; Uccelli, 2008)
The profound immunomodulatory characteristics of MSCs make them potential 
candidates for use in the treatment of inflammatory diseases. Clinical trials using 
allogeneic MSCs in the treatment of steroid resistant acute graft versus host disease 
(aGvHD) have shown promising results.(Le Blanc, 2008) Moreover, the feasibility and 
safety of autologous MSC infusions have been demonstrated in phase I clinical tri-
als.(Garcia-Olmo, 2005; Duijvestein, 2010; Sun, 2009; Sun, 2010; Karussis, 2010) 
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However, the efficacy and safety of MSC treatment has yet to be determined in larger 
cohort studies.(Dazzi, 2011)
Previously, an aberrant suppressive capacity of MSCs from patients with severe 
aplastic anaemia was previously reported.(Bacigalupo, 2005) In addition, functional 
aberrations in synovium-derived MSCs from adults with rheumatoid arthritis have 
been described, suggesting that MSCs from patients with inflammatory diseases may 
not be comparable to those derived from healthy donors.(Jones, 2010) Therefore, 
before contemplating clinical studies of autologous MSC infusions in children with 
treatment-resistant sJIA, the immunomodulatory properties of MSCs of these patients 
need to be characterized. To our knowledge this is the first study describing com-
parable characteristics of MSCs from a relatively large cohort of children with sJIA 
compared to age-matched healthy controls (HC). 
Methods
Expansion of MSCs
Bone marrow (BM) of children with sJIA (n=13) was used to initiate MSC cultures ac-
cording to a protocol approved by a local ethical committee. Fresh BM was harvested 
from five patients at time of diagnosis. To expand the study population, frozen bone 
marrow mononuclear cells (BMMC) from patients with sJIA (n=8) were used for MSC 
cultures. Classification of sJIA was according to the guidelines from the International 
League of Associations for Rheumatology.(Petty, 2004) Fresh BM of 10 paediatric 
donors of an allogeneic hematopoietic stem cell graft was used as HC. Parental and 
patient informed consent forms were signed for each patient and control. 
After Ficoll separation BMMC were plated at a density of 0.16x106 cells/cm2 in 
polystyrene culture flasks. Cells were cultured in Dulbecco’s modified Eagle medium 
with Glutamax (DMEM; Invitrogen, Paisley, UK) supplemented with 100 U/mL penicil-
lin, 100 μg/mL streptomycin (P/S; Invitrogen) and 10% fetal bovine serum (FBS; VWR 
International, Bridgeport, NJ, USA). Medium was refreshed every three to four days. 
Cultures were harvested at 80% confluency by treatment with trypsin (Invitrogen), 
replated and maintained for maximally six passages at 37°C and 5% CO2. 
Characterization of MSCs
All MSC cell lines were phenotypically characterized at their second or third passage 
using antibodies against CD3, CD45, CD86, HLA-DR, CD31, CD34, CD73 and CD90 
(all Becton Dickinson Biosciences (BD), San Diego, CA, USA). CD105 was obtained from 





















cytometer (BD). Mean fluorescence intensity (MFI) was compared with cells stained 
with isotype-matched negative control antibodies (BD) and with unstained cells.
The osteoblast and adipocyte differentiation potential was evaluated on cells at 
passage 4-6 as described previously.(Bernardo, 2007b) After 3 weeks, fat vacuoles in 
adipocytes and calcified depositions in osteoblast were stained with Oil-Red-O (Sigma, 
St. Louis, MI, USA) or Alizarin Red (MP Biomedicals, Solon, OH, USA), respectively. 
Peripheral blood mononuclear cell cultures
To investigate the immunosuppressive effect of MSCs on peripheral blood mono-
nuclear cell (PBMC) proliferation, irradiated (30 Gy) MSCs from patients with sJIA or 
HC were seeded at 2-fold serial dilutions in flat-bottom 96-well plates. PBMC, isolated 
by Ficoll separation from buffy coats of healthy blood bank donors (Sanquin, Am-
sterdam, the Netherlands), were added (100.000 cells/well) after 4 hours. Cells were 
stimulated with 2 μg/mL phytohemagglutinin (PHA; Murex, Châtillon, France) and 
cultured at 37°C and 5% CO2 for 5 days. Fifty microliters of culture supernatant was 
harvested at day 4 for cytokine analysis. The concentrations of interferon (IFN)-γ and 
TNF-α in supernatants were measured using standard protocols of enzyme-linked im-




















1 M 5 7.7 3 19 1.7 - -
2 F 12 0.3 4 11 2.0 - -
3 F 7 42.9 2 11 2.9 0.2 Anti-TNF-α
4 F 11 2.4 2 124 2.0 1.0 -
5 M 4 12.9 11 45 2.0 1.0 MTX; Cyclosporin
6 M 11 104.0 11 33 1.7 0.5 -
7 M 7 26.3 32 85 2.0 0.2 Anti-TNF-α
8b M 13 116.7 1 77 1.6 0.3 Azathioprine
9 M 7 74.9 6 46 0.4 0.5 MTX
10b F 5 23.9 8 71 2.0 1.0 MTX; Cyclosporin
11 M 5 0.8 5 91 1.3 - -
12 F 3 0.5 17 130 1.7 - -
13 F 1 3.8 10 14 2.5 - -
ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drugs; TNF, tumour ne-
crosis factor; MTX, methotrexate
a all patients were treated with indomethacin, except UPN 11 who was treated with diclofenac.
b no expansion of MSC was achieved from bone marrow samples of this patient.
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munosorbent assay kits (Sanquin). Cells were pulsed with 3H-thymidine (1 μCi/well; 
Perkin Elmer, Wellesley, MA, USA) for the final 16 hours and counted with a β-counter 
(Perkin Elmer). All cultures were performed in triplicate in RPMI 1640 (Invitrogen) 
medium with 10% pooled human AB serum (Sanquin) and P/S (total volume 200 μL/
well). 
To investigate the influence of drugs used in the treatment of sJIA, indomethacin 
(5 μM; Sigma), dexamethasone (100 ng/mL; Sigma) and the soluble TNF-α receptor 
adalimumab (10 μg/mL; Abbott Laboratories, Abbott Park, IL, USA) were added at 
culture initiation. 
NK cell cultures
NK cells were isolated from PBMC derived from healthy blood bank donors by nega-
tive selection using an NK isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). 
An NK cell purity greater than 95% was reached. NK cells (1.0x106/well) were stimu-
lated with 30 IU/mL IL-2 (Chiron Corporation, Emeryville, CA, USA). NK cells were 
co-cultured with or without irradiated MSCs in 24 well plates at an MSC:NK ratio of 
1:5 or 1:40 in RPMI 1640 supplemented with 10% human AB serum and P/S. 
At day 5, NK cells were harvested and counted and cell marker expression and cy-
totoxicity were assessed. The expression of CD69 (BD) and NKG2D (Beckman Coulter, 
Brea, CA, USA) was determined by flow cytometry. Cytotoxicity was determined in a 
standard 4-hour chromium release assay using various target cells (2.500 cells/well) 
i.e., Daudi cells, which are only sensitive to killing mediated by activated NK cells, 
and Epstein-Barr virus transformed B cells (EBV-BLCL) coated with antibodies through 
pre-incubation with anti-thymocyte globulins (ATG; Genzyme, Cambridge, MA; 50 
μg/mL for 20 minutes) to measure antibody dependent cell mediated cytotoxicity 
(ADCC). Target cells were labelled with 100 μCi sodium-51-chromate (Perkin Elmer) 
for 1 hour. Effector cells were incubated with target cells at ratios ranging from 
40:1 to 0.3:1 in triplicate. Spontaneous and maximum release were determined by 
incubating target cells with medium or Triton X100 (5%; Merck Chemicals, Darm-
stadt, Germany), respectively. Subsequently, chromium release in the supernatant 
was assessed in a β-counter. Specific lysis was determined as follows: (experimental 
release-spontaneous release) / (maximum release-spontaneous release) x 100%. 
Dendritic cell cultures
Monocytes were isolated from PBMC derived from healthy blood bank donors with a 
positive CD14 selection kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Cell purity 
greater than 90% was reached in all isolations. Monocytes (0.5 x 106) were cultured 
in 24-well plates for 5 days in RPMI 1640, 10% FCS and 1% P/S supplemented with 





















mL IL-4 (both from Tebu-Bio, Le Perray en Yvelines, France) to induce dendritic cell 
(DC) differentiation. At day 5, cells were harvested or similar concentrations of IL-4 
and GM-CSF, and CD40-ligand (0.25 ug/mL Beckman-Coulter, Marseille, France) and 
IFN-γ (500 U/mL, Boehringer, Mannheim, Germany) were added to mature the DC for 
2 extra days. All cells harvested on day 5 and 7 were analyzed using flow cytometry 
for CD14, CD1a, CD80, CD86, and CD163 expression (antibodies from BD). MSC 
were co-cultured with DC at MSC:DC ratios of 1:5, 1:40 or 1:100. 
Statistics
Data were analyzed using GraphPad Prism (LaJolla, CA). For statistic analysis paired 
and unpaired t-tests were used. P-values of <0.05 were considered significant. 
Results
Characterization of MSCs
MSCs were successfully expanded from bone marrow (BM) of 11 out of 13 sJIA 
patients and 10 out of 10 HCs. Age did not significantly differ between the patients 
and HCs (mean 7.1 years, range 1-12 versus 8.9 years, range 1-19, respectively); 45% 
of the patients with sJIA and 40% of the controls were female. The characteristics 
of the patients included in the study are summarized in Table I. Samples from two 
patients, both frozen BMMC, failed to expand. The cryopreservation time of these 
samples was 10.2 and 12.3 years, respectively, versus a mean storage time of 7.5 
years for the successfully expanded samples (range 2.4-11.1 years). In addition, 
cultures of these two samples were initiated with relatively low numbers of BMMC 
(0.26x106 and 2.8x106). For MSC cultures from frozen BMMC significantly less cells 
were available compared with cultures from freshly isolated BMMC (mean 3.9x106, 
range 0.26-7.56x106 versus mean 33.1x106, range 16-60x106 BMMC, respectively). 
MSCs were characterized by adhesion to plastic and fibroblast-like appearance. In 
addition, all MSC fulfilled the phenotypic criteria, (i.e., expression of CD73, CD90 
and CD105 and no expression of CD34, CD31 and CD45) at passage 2 or 3 (Figure 
1A). All MSCs had the ability to differentiate into adipocytes and osteoblasts upon 
stimulation (Figures 1B-I). However, MSC lines derived from two patients (UPN 2 and 
5 in Table I), which were obtained from frozen material, failed to differentiate into 
the osteoblastic lineage. These two MSC cultures were initiated with relatively low 
numbers of BMMC (0.46x106 and 1.4x106, respectively). These MSC were, therefore, 
not evaluated in the immunomodulatory assays. 
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Immune modulation of PBMC by MSCs
MSCs down modulated the proliferation of PHA-stimulated PBMC in a dose-
dependent manner (Figure 2A). A significant reduction of proliferation was seen at 
all MSC:PBMC ratios used. No differences were observed between sJIA and HC MSCs 
investigated in these experiments (Figure 2A). sJIA MSC derived from patients in vivo 
treated with (n=4) and without prednisone (n=4) gave comparable results (data not 
shown). 3H-thymidine counts did not exceed background levels in MSCs and PBMC 
co-cultured in the absence of PHA, or in MSCs cultured without PBMC in the presence 
of PHA. 
Figure 1. MSCs of patients 
with sJIA and healthy con-
trols (HC) show an identical 
phenotype and differentiation 
potential. A) Representative 
FACS staining of UPN 12 is 
shown in closed histograms. 
Open histograms represent 
the staining intensity with 
isotype-matched negative 
control antibodies. B) Differ-
entiation of HC MSC (B,D,F,H) 
and sJIA MSC (C,E,G,I) to adi-
pocytes (B,C,F,G; stained with 
Oil-Red-O) and osteoblasts 
(D,E,H,I; stained with Aliza-
rin Red). Magnification 10x 





















IFN-γ and TNF-α concentrations were reduced in supernatants of PHA-stimulated 
HC PBMC co-cultured with MSCs compared with PHA-stimulated PBMC without MSCs. 
MSCs of HC and patients with sJIA equally suppressed the production of these pro-
inflammatory cytokines (Figures 2C/D).
Suppression of autologous PBMC proliferation by sJIA MSCs
PBMC of patients with sJIA were stimulated with PHA and co-cultured either with 
autologous sJIA MSC or with MSC from two allogeneic HC (Figure 2B). PBMC frozen at 
the time of BM harvest were used in these experiments. Independent of their origin, 
MSC suppressed the PBMC proliferation to a similar extent. At an MSC:PBMC ratio 
of 1:5, the average down-modulating effect of sJIA MSC on autologous sJIA PBMC 
(Figure 2B) did not differ from their effect on allogeneic HC PBMC (Figure 2A) (25.6% 
vs. 20.6%; p=0.20). 
Influence of immunosuppressive drugs on function of MSCs
Addition of dexamethasone to cultures, but not of indomethacin or adalimumab, 
to cultures significantly reduced the PHA-induced proliferation of PBMC from HC 
(p<0.01) (Figure 3A). Despite this effect, MSCs added at culture initiation retained 
their suppressive capacity in the presence of dexamethasone (Figure 3B). The same 
observation was evident for the production of cytokines (Figures 3C/D).
In contrast, indomethacin interfered significantly with the immunosuppressive 
activity of MSCs derived from either sJIA or from HC at an MSC:PBMC ratio 1:5 (Figure 
3A/B). However, the effect of indomethacin did not reach significance at an MSC:PBMC 
ratio ranging from 1:10 to 1:80 (data only shown for 1:40). IFN-γ and TNF-α produc-
tion appeared to be a more sensitive indicator for the interference of indomethacin 
with the immunosuppressive activity of MSC, because a significant lower decrease of 
the cytokine production in the presence of the drug (p<0.05) was not only observed 
at an MSC:PBMC ratio of 1:5 but also at 1:40 (Figures 3C/D). 
Adalimumab did not affect PBMC proliferation (Figures 3A/B). IFN-γ production, 
however, was clearly decreased in the presence of adalimumab alone and further 
diminished when MSCs were added to the culture. The effects of these drugs on the 
immunomodulatory capacity of MSCs were similar for MSCs derived from patients 
with sJIA and from HC (data not shown). The mean +/- standerd error of the mean 
(SEM) percentages of proliferation at a ratio of MSC:PBMC of 1:5 were 38.4% +/- 4.9% 
and 33.5 +/- 1.9% for HC-MSC and sJIA-MSC, respectively. 
Suppression of NK cell activation by MSCs
The expression of CD69 and NKG2D on NK cells was up-regulated after 5 days 
activation with IL-2 (30 IU/mL). The percentage of CD69+ cells (range 26-70%) and the 
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MFI of NKG2D expression (range 150-297), depending on the healthy donor, were set 
at 100 for NK cells cultured without MSCs to enable comparison amongst different 
experiments.
After 5 days of co-culture of NK cells with MSCs, the percentage of CD69+ NK cells 
and the expression of NKG2D were significantly reduced (p<0.05) (Figures 4A/B). 
No significant differences were observed between MSCs derived from sJIA and HC in 
down-modulation of IL-2 induced NK cell activation.
Figure 2. sJIA and healthy control (HC) derived MSCs suppress activation of patient and control derived 
PBMC. sJIA and HC-derived MSCs show no differences in the down modulation of the functional activity 
of PBMC after PHA stimulation. A) The mean and standard error of the mean (SEM) of proliferation at 
day 5 are depicted of experiments using HC (n=4) and sJIA (n=8) MSCs as modulators and PBMC of four 
healthy donors as responders. PHA-induced proliferation in the absence of MSCs was set at 100%. B) 
Autologous sJIA and allogeneic HC-derived MSCs show no differences in their down-modulating effect 
on PHA-induced proliferation of sJIA-derived PBMC. The mean and SEM of experiments with six differ-
ent sJIA PBMC are depicted. The effect of the six autologous sJIA MSCs and of two allogeneic HC MSCs 
was tested on PBMC of all six patients with sJIA investigated in this experiment. C/D) In co-cultures 
of PHA-stimulated HC PBMC with sJIA and HC-derived MSCs the (C) IFN-γ and (D) TNF-α concentrations 
in supernatants taken at day 4 are decreased. The mean concentration of cytokines in cultures of two 
PBMC donors as responders with or without MSCs from 2 HC and 4 sJIA patients as modulators are 





















The cytotoxic capacity of the cytokine-activated NK cells against Daudi target cells 
was significantly suppressed after co-culture with MSCs. In contrast, ATG-mediated 
ADCC of NK cells against EBV-BLCL was not significantly impaired, indicating that the 
intrinsic cytolytic potential of the NK cells was not affected (Figures 4C-F).
MSCs inhibit the differentiation of monocytes to dendritic cells
The monocyte population isolated by positive CD14 selection contained less than 
1% CD1a-positive cells. Upon combined GM-CSF and IL-4 exposure, monocytes dif-
ferentiated towards immature CD1a+/CD14- DC (Figure 5A). MSCs strongly inhibited 
this differentiation, as shown by retainment of CD14+ monocytes accompanied by a 
reduced appearance of CD14-CD1a+ DC, in a dose-dependent manner (Figure 5B/C). 




























































































































































































































































































































































































































































































Figure 3. Indomethacin decreases the immunosuppressive effect of MSCs. A/B) PHA-induced prolifera-
tion of healthy control PBMC in co-cultures with or without MSCs and in the presence or absence of 
different drugs is shown. A) The proliferation in the culture condition without drugs and without MSCs 
was set at 100%. B) The proliferation in the culture conditions without MSC but with drug was stan-
dardized to 100% for each of the drugs separately. The mean and SEM of 6 different MSC preparations 
(sJIA = 3; HC = 3) are depicted. C/D) Concentrations (mean +/- SEM) of (C) IFN-γ and (D) TNF-α in the 
culture supernatants of healthy control PBMC stimulated with PHA and cultured in the absence or pres-
ence of MSCs with or without drugs are depicted. One experiment, representative for MSCs derived 
from 2 HC and 2 patients with sJIA, is shown. *: p<0.05 compared with the corresponding MSC:PBMC 
ratio without drugs; #: p<0.05 compared with the condition without MSC and without drugs.
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Figure 4. sJIA derived MSCs suppress NK cell activation and cytotoxity during co-cultures. MSCs were 
co-cultured with NK cells during 5 days in the presence of IL-2 (30 IU/mL). At day 5, activation and 
cytotoxicity of NK cells were determined using flow cytometry and a chromium release assay, respec-
tively. A/B) The relative percentage of CD69 positivity (A) and the relative MFI of NKG2D expression 
(B) on NK cells isolated from PBMC of different healthy donors are depicted after co-culture of NK cells 
of three different donors with MSCs from six patients with sJIA and seven allogeneic healthy controls 
(HC) at MSC:NK cell ratios of 1:40 and 1:5. Percentage of CD69 positivity and MFI of NKG2D expres-
sion of NK cells cultured for 5 days with IL-2 in the absence of MSC was set at 100. The mean +/- SEM 
is indicated by the horizontal lines. *: p<0.05 compared to without MSC. C/D) The killing of (C) Daudi 
and (D) ATG mediated ADCC of EBV-BLCL by NK cells cultured with or without (wo) MSCs of one sJIA 
patient is shown. E/F) At an effector:target (E:T) ratio of 1:20, the killing of (E) Daudi and (F) ATG 
coated EBV-BLCL by NK cells co-cultured with MSCs at the indicated MSC:NK ratios is expressed rela-
tive to the killing by NK cells cultured without MSC which was set at 100; The effect of MSCs derived 
from five patients with sJIA and five HC was analyzed. The bars represent the mean +/- SEM. *: p<0.05 





















exposure to GM-CSF, IL-4, CD40-ligand and IFN-γ in order to further mature the DC. 
Monocytes co-cultured with MSC acquired CD163 expression (relative MFI +/- SEM 
8.8 +/- 0.3 on day 0) on day 5 (12.7 +/- 1.8 without MSCs and 47.3 +/- 3.5 with 
HC MSCs or 39.4 +/- 1.6 with sJIA MSC) (data not shown). On day 7, the expression 
of CD80 and CD86 on the total population was significantly (p<0.01 for CD80 and 
p<0.05 for CD86) lower in co-cultures with MSCs (Figure 5D). Comparable results 
were obtained for either CD1a+ or CD14+ cells (data not shown). MSCs of sJIA patients 










Figure 5. MSCs of patients with sJIA interfere with differentiation of monocytes to dendritic cells. 
Monocytes in co-culture with MSC in the presence of GM-CSF, IL-4, CD40 ligand and IFN-γ show im-
paired maturation to dendritic cells (DC). Cells were gated on forward scatter/side scatter life-gate. 
A) Representative FACS plots of combined CD14 and CD1a staining on day 0, day 5 and day 7 are 
presented. The numbers in plots represent the percentage of gated cells in the different quadrants 
reflecting CD1a+CD14− DC and CD1a−CD14+ monocytes, respectively. Monocytes were cultured in the 
absence or in the presence of MSCs at a MSC:monocyte ratio 1:5. B/C) Mean and SEM of the percentage 
(B) CD14+ monocytes and (C) CD1a+ DC are depicted. Results were obtained using isolated monocytes 
from four healthy adult donors co-cultured with allogeneic MSCs generated from BM of three healthy 
controls (HC) and four patients with sJIA. D) The CD80 and CD86 expression on the total population is 
significantly decreased in co-cultures with sJIA and HC MSC at day 7. *: p <0.05 compared to without 




In this study, the biological and functional characteristics of bone marrow derived 
MSCs from patients with sJIA were compared with those from paediatric HC. Determi-
nation of the immunomodulatory capacity of sJIA-derived MSCs is an essential step 
before considering the administration of autologous MSCs in patients with sJIA. Previ-
ously, aberrant immunomodulation was reported for BM-derived MSCs from severe 
aplastic anaemia patients.(Bacigalupo, 2005) In addition, synovial fluid-derived MSCs 
from patients with rheumatoid arthritis had a decreased differentiation capacity 
compared to MSCs from synovial fluid of patients with osteoarthritis.(Jones, 2010) 
The use of autologous MSCs in the treatment of sJIA is preferred to allogeneic MSCs 
for three reasons. Firstly, knowledge on the administration of allogeneic MSCs in 
children is limited to immunocompromised patients, such as hematopoietic stem cell 
transplantation recipients with steroid-resistant aGvHD.(Le Blanc, 2008) Secondly, 
mice models indicate the occurrence of immune rejection and specific immunological 
memory induction after administration of allogeneic MSCs in an immunocompetent 
setting which would disallow a repetitive infusion of MSCs.(Nauta, 2006; Zangi, 2009) 
Third, more recent data in patients treated for renal graft rejection demonstrate that 
primed T cells are able to lyse allogeneic MSCs.(Crop, 2011) 
Systemic JIA is considered an autoinflammatory disease caused by an inadequate 
suppression of innate immunity.(Vastert, 2009) Therefore, we evaluated the in vitro 
immunomodulatory capacities of MSCs not only by focusing on T cell function in 
a model of PHA-stimulated PBMC,(Samuelsson, 2009; Bacigalupo, 2005; Aggarwal, 
2005) but also by investigating the effect on NK cells(Spaggiari, 2006) and mono-
cytes. In both adaptive and innate experimental systems, the immunomodulatory 
effects of MSC of patients and healthy controls were indistinguishable, in accordance 
with previous reports on patients with autoinflammatory diseases.(Bocelli-Tyndall, 
2007; Bernardo, 2009; Larghero, 2008) However, in these studies, only the effect 
of MSC on lymphocyte proliferation was investigated. We have shown a decreased 
cytolytic function of NK cells after co-cultivation with MSCs of patients with sJIA and 
HC. In addition, MSCs of patients and HC inhibited the differentiation of monocytes 
towards DC, as illustrated by the generation of a low percentage of CD1a-positive 
cells and decreased levels of CD80 and CD86 expression. In contrast, monocytes 
cultured with MSCs acquired expression of CD163, a scavenger receptor associated 
with the suppressive type 2 macrophage.(Sica, 2006) 
To enable inclusion of a substantial number of patients, not only fresh BM but 
also long-term frozen BM of patients with sJIA was applied to culture MSCs. The 
expansion of MSC was successful for six of eight frozen BM samples. Previously, 





















fresh BM.(Haack-Sorensen, 2007; Casado-Diaz, 2008) In these studies, no differ-
ences were observed in expansion or differentiation capacity. However, we found 
an aberrant osteoblast differentiation in the MSCs started from frozen BM of two 
sJIA patients. The absence in osteoblast differentiation could be explained by the 
relatively low numbers of BMMC at the initiation of MSC cultures compared with these 
studies, in which they used 20 or 100x106 BMMC, respectively.(Casado-Diaz, 2008; 
Haack-Sorensen, 2007) Nevertheless, a possible influence of the disease itself or the 
long-term use of drugs can not formally be excluded based on our study results. In 
our study, no differences in immunomodulatory capacity were found between MSCs 
derived from cryopreserved and fresh BM. This is in contrast to results reported by 
Samuelson et al.(Samuelsson, 2009) describing a variable effect of cryopreservation.
Despite unsuccessful expansion of MSCs from frozen BM in two patients, the ex-
pansion of MSCs from frozen material is a promising tool for further research on rare 
paediatric diseases. 
An important issue in administration of MSCs to patients is the continuation of 
disease-specific drugs. Previously, calcineurin inhibitors and indomethacin were 
shown to suppress the immunomodulatory effect of MSCs, whereas mycophenolic 
acid has a synergistic effect with MSCs.(Aggarwal, 2005; Buron, 2009) Consistent 
with previous data(Rasmusson, 2005) our findings indicate that indomethacin sup-
presses the immunomodulatory function of MSCs. All of our patients were treated 
with non-steroidal anti-inflammatory drugs (NSAID) before aspiration of BM. Appar-
ently, in vivo exposure of MSCs to NSAID does not interfere with the suppressive 
effect of MSCs after ex vivo expansion. Dexamethasone, on the other hand, although 
having a suppressive effect on PBMC proliferation by itself, did not affect the sup-
pressive effect of MSCs, consistent with a previous report.(Buron, 2009) Adalimumab, 
a TNF-α antagonist, did not affect PBMC proliferation, but significantly decreased 
PHA-induced production of IFN-γ. Interestingly, despite the low IFN-γ production in 
cultures containing adalimumab, MSCs retain their capacity to reduce proliferation 
and IFN-γ secretion in this condition. 
It is relevant to evaluate whether patient-derived cells, independent of the course 
and actual activity of the disease and past or present medication, are susceptible to 
suppression by MSC. Therefore, we determined the effect of patient derived MSCs 
on PHA-driven T cell proliferation using autologous PBMC. Patient-derived PBMC 
were equally suppressed by MSCs compared to healthy control derived PBMC. Our 
data further show a comparable suppression of T cell responses by allogeneic and 
autologous MSCs, implying a comparable susceptibility of patient and control PBMC 
to MSCs.
Our in vitro study did not address the route of administration of these expanded 
MSCs, and the optimal use remains to be determined. Most reported clinical studies 
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of MSC treatment have used intravenous infusions to control systemic inflammatory 
diseases, and this would also seem to be a logical choice for the future use in children 
with sJIA. In contrast, however, oligo-articular disease or target joints might benefit 
from local intra-articular administration. Future prospective clinical trials should ad-
dress these issues.
In conclusion, this is the first study describing that MSCs derived from a cohort 
of patients with sJIA have similar immunosuppressive capacities compared to age-
matched HC in assays focused on adaptive (T cell) and innate (NK cell and monocyte) 
immunity. Therefore, the results of this study support the use of autologous MSCs in 
clinical trials of patients with sJIA. 
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Despite differential gene expression 
profiles pediatric MDS derived 
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normal functionality in vitro.
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Pediatric myelodysplastic syndrome (MDS) is a heterogeneous disease covering a 
spectrum ranging from aplasia (RCC) to myeloproliferation (RAEB(t)). In adult-type 
MDS there is increasing evidence for abnormal function of the bone-marrow micro-
environment. Here, we extensively studied the mesenchymal stromal cells (MSC) 
derived from children with MDS. 
MSC were expanded from bone-marrow of 17 MDS patients (RCC: n=10 and advanced 
MDS): n=7) and pediatric controls (n=10). No differences were observed with respect 
to phenotype, differentiation capacity, immunomodulatory capacity or hematopoietic 
support. mRNA expression analysis by Deep-SAGE revealed increased IL-6 expression 
in RCC- and RAEB(t)-MDS. RCC-MDS MSCs expressed increased levels of DKK3, a pro-
tein associated with decreased apoptosis. RAEB(t)-MDS revealed increased CRLF1 and 
decreased DAPK1 expression. This pattern has been associated with transformation 
in hematopoietic malignancies. Genes reported to be differentially expressed in adult 
MDS-MSCs did not differ between MSCs of pediatric MDS and controls. 
An altered mRNA expression profile, associated with cell survival and malignant 
transformation, of MSCs derived from children with MDS strengthen the hypothesis 
that the micro-environment is of importance in this disease. Our data support the 
understanding that pediatric and adult MDS are two different diseases. Further evalu-


























Pediatric myelodysplastic syndrome (MDS) represents a range of disorders char-
acterized by dysplastic morphology comprising in total less than 5% of pediatric 
hematological malignancies.(Hasle, 2004) The spectrum of MDS ranges from refrac-
tory cytopenia of childhood (RCC) to advanced MDS with excess of blasts (RAEB) with 
increasing risk of leukemic transformation.(Hasle, 2003) Survival has increased from 
30 to 60% since hematopoietic stem cell transplantation (HSCT) is applied.(Strahm, 
2011; Sasaki, 2001; Woods, 2002) The pathophysiology of MDS is not fully elucidated. 
However, genetic predisposition, acquired cytogenetic abnormalities and abnormal 
immune responses have been linked to MDS.(Strahm, 2011; Hasle, 2011) These as-
pects do not explain the entire range of disease in pediatric or adult MDS. Recently, 
it has been suggested in adult MDS that impaired interaction between hematopoietic 
precursor cells and their bone-marrow microenvironment might contribute to the 
disease.(Zhang, 2012b) In children, no conclusive data is yet available. 
Mesenchymal stromal cells (MSC) have been identified as supporting cells of he-
matopoietic stem cells (HSC) in vivo and in vitro (Morikawa, 2009; Mendez-Ferrer, 
2010; Sugiyama, 2006b) and linked to disease, as aberrant MSC function was shown 
to contribute to the pathophysiology of malignant disorders in murine models.(Raaij-
makers, 2010; Schepers, 2013) Characteristics of MSCs from adult MDS patients have 
been extensively studied focusing on cytogenetic and molecular abnormalities(Blau, 
2011; Lopez-Villar, 2009; Flores-Figueroa, 2008) as well as gene and protein ex-
pression.(Marcondes, 2008; Flores-Figueroa, 2008; Santamaria, 2012) In addition, 
abnormal immunomodulation(Wang, 2013b; Zhao, 2012b; Marcondes, 2008) as well 
as decreased hematopoietic support(Zhao, 2012b; Ferrer, 2013) by MSCs has been 
reported in MDS. However, these data remain conflicting with other studies reporting 
no abnormalities in stromal function.(Flores-Figueroa, 2008; Klaus, 2010; Alvi, 2001) 
Differences in results may be explained by a variety in MSC expansion protocols and 
experimental set-up, but also by the heterogeneity of the disease.(Aizawa, 1999) 
Studies reporting on (cyto)genetics and function of MDS-MSCs have been summarized 
in the Supplementary Tables S1 and S2.
Pediatric MDS is a very rare disease and publications on the role of stroma in the 
ontogeny and maintenance of pediatric MDS are limited to a case report on aberrant 
hematopoietic support by MSCs derived from an MDS patient with trisomy 8,(Nar-
endran, 2004) a study using stroma cells of 7 MDS patients (Borojevic, 2004), and a 
gene-expression analysis of the stromal compartment by the same research group.
(Roela, 2007) Nevertheless these scarce reports suggest an aberrant support of he-
matopoiesis associated with an altered gene expression profile of MSCs. 
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In the present study we compared MSCs derived from children with RCC and RAEB(t) 
/ MDS-AML to MSCs expanded from age-matched healthy controls. Biological char-
acteristics, e.g. differentiation capacity and phenotype were analyzed. MSC function 
in vitro was evaluated by immunomodulatory and hematopoietic assays. In addition, 
genome wide gene-expression profiles were studied using Deep-SAGE sequencing. 
Materials and Methods
Patients and MSC expansion
Children referred to our center for HSCT were included in this study according to 
a protocol (P08.001) approved by the institutional review boards on medical ethics. 
Next to bone-marrow of 10 healthy controls (HC, median age 7.4, range 1.1 – 16.4 
years) being HSCT donors, bone-marrow of 17 MDS patients (10 RCC, 2 RAEB, 4 
RAEBt, 1 MDR-AML was collected at diagnosis and prior to treatment initiation. The 
WHO classification adapted for children was used for the classification of patients.
(Hasle, 2003) MSCs from children with RAEB, RAEBt and MDR-AML were grouped as 
advanced MDS to enable the comparison between advanced and RCC-MDS. In addi-
tion, bone-marrow after HSCT was collected from 9 children (4 RCC, 1 RAEB, 1 RAEBt, 
3 MDR-AML) including 6 paired samples (Table 1). 
MSCs were expanded and characterized as previously described.(Calkoen, 2013a) 
Briefly, bone-marrow mononuclear cells (MNC) obtained after Ficoll separation were 
cultured in DMEM (Invitrogen, Paisley, UK) containing 100 U/mL penicillin/100 μg/
mL streptomycin (P/S; Invitrogen) and 10% (v/v) fetal bovine serum (FBS; VWR Interna-
tional, Bridgeport, NJ, USA). Non-adherent cells were removed by refreshing medium 
twice weekly. Upon reaching confluency MSCs were harvested, pooled and passaged 
for further expansion resulting in non-clonal MSCs. Phenotype (CD73, CD90, CD105 
positive; CD3, CD31, CD34, CD45, CD86, HLA-DR negative) and differentiation ca-
pacity towards osteoblasts and adipocytes were investigated at passage 2-3 and 5-7, 
respectively. All but anti-CD105 (Ancell Corporation Bayport, MN) antibodies were 
derived from Becton Dickinson Biosciences (BD), San Diego, CA, USA. Culture super-
natant was collected after reaching 80% confluency at passage 3-5 for measurement 
of cytokine production.
Cytogenetics
To exclude common chromosome abnormalities in MSCs and malignant cells, 
interphase fluorescence in situ hybridization (FISH) for chromosome 7 and 8 was 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































following probes: Vysis LSI D7S486/CEP7 and LSI IGH/LSI MYC, CEP8, (Abbott Labo-
ratories, Abbott Park, IL,USA).(Bronkhorst, 2011) 
Chimerism analysis
Chimerism (donor or recipient origin) was studied by cytosine adenine (CA)-repeat 
analysis in MSCs cultured from bone-marrow harvested after HSCT as previously 
described.(Lankester, 2010) 
Immunomodulatory assays
The effect of MSCs (30 Gy irradiated) on proliferation of peripheral blood (PB) MNC 
obtained from adult bloodbank donors (100 000 cells/well) after stimulation with 
phytohemagglutinin (PHA 2 μg/mL) was analyzed at MSC : PBMC ratios of 1:5 and 
1:40. MSC and PB-MNC were co-cultured in RPMI P/S, 10% (v/v) fetal calf serum (FCS) 
for 5 days with the addition of 3H-thymidine (1 μCi/well; Perkin Elmer, Wellesley, MA, 
USA) for the last 16 hours to measure proliferation using a β-counter (Perkin Elmer). 
Experiments were performed in triplicate. 
To evaluate the effect of MSCs on antigen presenting cells, monocytes were iso-
lated from PB using positive CD14 selection (Miltenyi, Bergisch Gladbach, Germany) 
and cultured with IL-4 (40 ng/mL) and GM-CSF (800 IU/mL) (both from Tebu-Bio, Le 
Perray en Yvelines, France) for 5 days to differentiate towards immature dendritic 
cells (DC). Cells were harvested or cultured for 2 additional days with IL-4, GM-CSF, 
IFN-γ (500 U/mL, Boehringer, Mannheim, Germany) and CD40-ligand (0.25 μg/mL 
Beckman-Coulter, Marseille, France) to generate mature DC. Cells were phenotyped 
by flow cytometry for the expression of CD14 and CD1a (BD) on day 0, day 5 and day 
7 after co-culturing of monocytes and MSCs at MSC : monocyte ratios 1:5, 1:40 or 
1:100 or after culturing monocytes without MSCs. 
Hematopoietic support
Short-term co-culture assays with MSCs and hematopoietic progenitor cells (HPC) 
were performed to determine the supportive capacity of MSCs for HPC maintenance 
and differentiation. Therefore, HPC were isolated from remaining material of G-CSF 
mobilized stem cell grafts from healthy transplant donors using CD34 positive se-
lection (Miltenyi). Selected cells expressed >90% CD34 after purification. Short-term 
cultures of 500 CD34 selected cells/well without or with MSCs (CD34 : MSC ratios 
1:2 and 1:20) were performed in Stemspan medium (H3000, StemCell Technolo-
gies, Vancouver, Canada) with addition of 1% P/S, stem cell factor (SCF, 100 ng/mL, 
StemCell Technologies) and Flt3-ligand (Flt3-L, 100 ng/mL, StemCell Technologies), 
because SCF and Flt3-L are not produced by MSCs. Cultures were initiated with 

























Figure 1. Immunomodulation by MDS-MSCs. A. Both healthy control (HC, n=6) and MDS-MSCs (n=5 of 
which RAEB/RAEBt n=3 and RCC n=2) significantly suppressed PHA-induced PBMC (n=4 healthy adults) 
proliferation at MSC : PBMC ratios 1:40 and 1:5. No significant differences were observed between 
MDS patients (black circles) and controls (white circles). wo MSCs: without MSCs. B-E. MSCs suppressed 
the differentiation of monocytes (CD14+ cells) towards dendritic cells (CD1a+ cells) in a dose-depen-
dent manner (hatched boxes: no MSCs added). No significant differences were observed between HC 
(white boxes) and MDS-MSCs (black boxes). Boxes represent median and 25-75 percentiles and the 
whiskers the minimum and maximum values. P-values were calculated using Wilcoxon matched-pairs 
signed rank tests (in A for comparison of different MSC ratios) and Mann-Whitney tests (in A-E for 
comparison between HC and MDS). n.s.: not significant.
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the culture medium was refreshed with the addition of growth factors on day 4, 7 
and 11. Proliferation (day 7) and differentiation (day 7 and 14) was assessed using 
3H-thymidine during the last 16 hours or flow cytometry, respectively. Antibodies 
used for flow cytometry were anti-CD34-PE, anti-CD45-FITC, anti-CD38-Percpc5.5, 
anti-CD45-Percpc5.5, anti-CD14-FITC, anti-CD33-APC, anti-GPA-PE (glycophorin A) 
and anti-CD13-PE (all antibodies from BD). 
In long-term cultures, CD34 selected cells (50 000 cells) were cultured on a conflu-
ent MSC layer for 3-5 weeks in the absence of growth factors. Cells were harvested 
and counted using trypan blue as viability stain. 
To determine the functional impact of HPC expansion and differentiation after short-
term culture, non-adherent cells were harvested after 7 days of culturing CD34+ cells 
in the absence or presence of MSCs (CD34 : MSC ratio 1:5), transferred (1000 cells/
dish) to methylcellulose containing essential growth factors, i.e. SCF, GM-CSF, IL-3, 
and erythropoietin (EPO) (H4434 StemCell Technologies), and cultured for 14 days 
(colony-forming unit assay; CFU-assay). Colonies were scored by two independent 
observers according to standard guidelines for the definition of CFU-GEMM, BFU-e, 
CFU-GM, CFU-G and CFU-M. Results are depicted as the average of duplicate wells. To 
determine a more direct effect of MSCs on HPC in CFU-assays, MSCs (30 000 or 150 
000 per dish) were added to freshly purified HPC (500 cells/dish) in methylcellulose 
containing SCF, GM-CSF, IL-3 and EPO (H4434 StemCell Technologies). The direct 
effect of MSCs on colony formation was also assessed in methylcellulose containing 
EPO (H4330 StemCell Technologies) only. Cells were harvested and phenotyped after 
scoring of colonies in the CFU-assay.
Cytokine expression
IL-6 quantification in MSC culture supernatants was performed by ELISA (Sanquin, 
Amsterdam, the Netherlands) according to the manufacturer’s instructions.
Gene expression
Total RNA was isolated at passage 2-3 using a Qiagen RNeasy Minikit (Qiagen, 
Hilden, Germany). mRNA was profiled using Deep-SAGE sequencing using Illumina 
technology.(Mastrokolias, 2012) CATG was added to the 5’ end of the 17 base pair 
sequences obtained. Data were mapped against the UCSC hg19 reference genome 
using Bowtie for Illumina (version 1.1.2) without the permission of one mismatch 
and suppression of reads if more than one best match existed. Tags aligned to the 
same gene were summed for further analysis. Gene information was added to the 
sequences with the biomaRt package in R (version 2.16.0). The expression data will 

























Expression of genes of interest was validated using independent biological samples 
by RT-PCR after generation of cDNA (cDNA synthesis kit, Roche, Basel, Switzerland) 
using the listed primers (Table S3), as previously described.(Mastrokolias, 2012) 
Expression levels were calculated relative to expression of the housekeeping genes 
GAPDH and HPRT1.
Figure 2. MDS-MSCs support maintenance and differentiation of hematopoietic progenitor cells (HPC). 
A. CD34+ cells (500 cells) of HSCT donors were cultured in the absence (wo MSCs) or presence of 
MSC (CD34 : MSC ratios 1:2 and 1:20) obtained from MDS patients or healthy controls (HC) in the 
presence of SCF and Flt3-L. Proliferation of HPC at day 7 was assessed by 3H-thymidine incorporation. 
B-C. CD34+ expression declined overtime, but MSCs supported the expansion of HPC (CD34+ cells) 
and a higher percentage of CD34+ cells was retained in comparison with cultures in the absence of 
MSCs. Results shown are from cultures at a CD34+ : MSC ratio of 1:5 starting with 10x103 HPC. Flow 
cytometry data presented in C are obtained after 14 days of culture and show plots of CD34 versus 
CD45 expression and the percentage of CD34+ cells within the CD45+ cell population. D. Whereas the 
absolute number of HPC decreased significantly in the absence of MSCs, the absolute number of HPC 
increased in co-cultures with MSCs (CD34+ : MSC ratio 1:5). Data depicted in A, B and D represent at 
least 2 independent experiments of 5 HC-MSCs and 8 MDS-MSCs (grey bars: without (wo) MSCs, white 
bars: healthy control (HC)-MSCs, black bars: MDS-MSCs). E. Non-adherent cells harvested at day 7 were 
transferred to methylcellulose to test their capability of colony formation. Graphs represent the total 
number of CFU and indicated CFU types in the CFU-assay resulting from the investigation of 4 MDS-
MSCs and 3 HC-MSCs present during the initial HPC and MSCs co-culture. wo MSCs: without MSCs. 





Graphpad 6 (Prism, La Jolla, CA) was used for data-analysis. Mann-Whitney and Wil-
coxon matched-pairs signed rank tests were performed to compare different groups. 
Differential gene expression analysis was performed in R (version 2.15.0), using the 
EdgeR (version 3.2.4) and Limma (version 3.16.7) data analysis packages.(Robinson, 
2010; R Development Core Team, 2012; Smyth, 2005) Correction for multiple testing 
was performed according to Benjamini and Hochberg.(Hochberg, 1990) Adjusted 
p-values <0.05 were considered statistically significant.
Results
Expansion and characterization of MSCs
MSCs were successfully cultured from bone-marrow of all patients and controls. 
Expanded MSCs expressed CD73, CD90 and CD105, whereas the cells did not 
express lineage markers (Supplementary Figure S1A). MSCs differentiated towards 
adipocytes and osteoblasts when cultured in culture media supporting these distinct 
directions of differentiation (Figure S1B-E). In one de novo RCC patient (UPN: MDS026) 
no osteoblast differentiation was established. Post-HSCT derived MSCs were of com-
plete patient origin in all children that were analyzed (n=6). Monosomy 7 was not 
detected in MSCs from any bone marrow harvested prior to HSCT from children with 
monosomy 7 (n=6). The MSC lines generated from the two patients with trisomy 8 in 
the hematopoietic cell compartment tested negatively for trisomy 8. 
Immunomodulation
MSCs down modulate functions of various cell types involved in innate and adap-
tive immunity.(Le, 2012) The effect of MSCs of pediatric MDS patients and healthy 
children on T cell proliferation and monocyte differentiation was investigated. MSCs 
suppressed the PHA-induced PB MNC proliferation in a dose-dependent manner. No 
differences in suppressive capacity were observed between MDS-MSC and healthy 
control (HC-)MSC (Figure 1A). 
To investigate the suppressive effect of MSCs on DC maturation, MSC-monocyte 
co-cultures were performed. The purified monocyte fraction was > 95% CD14+ and 
<1% CD1a+ at the start of MSC-monocyte co-culture. After 5 days of culture with GM-
CSF and IL-4, the monocytes lost CD14 expression and gained CD1a, characteristic 
for DC. This process further progressed from day 5 to 7 during maturation of DC 
in the presence of GM-CSF, IL-4, IFN-γ and CD40-ligand. MSCs of controls and MDS 
patients showed inhibition of the differentiation at day 5 and 7 at various MSC : 

























Figure 3. MSCs of MDS patients support colony formation in CFU-assays. A-C. MSCs (30 000 cells, or 
150 000 cells when indicated) of healthy controls (HC-MSCs), of MDS patients (MDS-MSCs) or no MSC 
(wo MSCs) were added to freshly isolated HPC (CD34+ cells, 500 cells) of HSCT donors at initiation 
of colony forming unit assays (CFU-assay). Cultures contain exogenous SCF, GM-CSF, IL-3 and EPO. 
Addition of MSCs support the increase the number of colonies (MDS n=6, HC n=4). To compare data 
from different experiments, the number of colonies in cultures without MSCs (range: 83-105) was 
set at 100. Colonies were scored and harvested for phenotyping at day 14 after culture initiation. 
The percentage (B) and number (C) of CD45+GPA− cells is increased in CFU-assays in the presence of 
MSCs, irrespectively whether MSCs were derived from MDS patients or healthy controls (HC). D. MSCs 
from MDS patients (n=3) and healthy controls (HC; n=3), co-cultured with HPC in the presence of EPO 
only, significantly increase the formation of CFU-GEMM and CFU-M, but not of the other colony types 
(read-out CFU-assay at day 14). wo MSCs: without MSCs. Bars represent mean and standard deviation. 
P-values were calculated using Mann-Whitney tests. *: statistically different (p < 0.05) from culture 
without (wo) MSCs. n.s.: not significant.
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RAEB(t)-MSC and RCC-MSC showed comparable suppressive effects in both assays 
(data not shown).
Expansion of hematopoietic progenitor cells
As part of the stromal bone-marrow compartment, MSCs play an important role in 
the regulation of hematopoiesis through interaction with HPC.(Mendez-Ferrer, 2010) 
The effect of MSCs of pediatric MDS patients and healthy children on expansion and 
differentiation of CD34+ HPC was investigated in various in vitro culture systems. 
HPC (CD34+ cells) proliferation was enhanced in the presence of MSCs in a dose-
dependent manner after stimulation with SCF and Flt3-L for 7 days (Figure 2A). 
The percentage of cells expressing CD34 declined over time, but the level of this 
decline is significantly less in cultures containing MSCs (Figure 2B-C). In co-cultures 
of HPC with MSCs, CD38 expression, associated with activation but also with loss 
of stemcellness,(Calloni, 2013; Chillemi, 2013) was significantly increased at day 
14 on both CD34+ and CD34- cells (CD34+ cells, mean and SD: without MSCs: 18.8 
+/- 1.5%; plus HC-MSCs: 46.8 +/- 8.9%; plus MDS-MSCs: 52.0 +/- 5.0%. CD34- cells: 
without MSCs 25.9 +/- 2.9%; plus HC-MSCs: 54.9 +/- 9.4%; plus MDS-MSCs: 61.5 
+/- 5.3%). In cultures with MDS-MSCs, differentiation towards myeloid-lineage cells 
was not enhanced in comparison with cultures with HC-MSCs or without MSCs (CD14+ 
cells as a percentage of CD45+ cells, mean and SD: without MSC: 16.2 +/- 2.0%; plus 
HC-MSCs 16.0 +/- 2.5%; plus MDS-MSCs: 19.0 +/- 2.2%).
The absolute number of CD34+ cells decreased significantly when HPC were cul-
tured in the absence of MSCs. In contrast, in the presence of MSCs, the HPC (CD34+) 
population expanded from day 0 to day 7. From day 7 to day 14 the CD34+ numbers 
remained unchanged compared to day 7 (Figure 2D).
Non-adherent cells (1000 cells), harvested from HPC cultures with or without MSCs 
at day 7, were transferred to methylcellulose for CFU-C analysis. Cells that have previ-
ously been co-cultured with MSCs gave rise to higher numbers of CFU-C, compared to 
HSC that have been cultured in the absence of MSCs (Figure 2E). This is in accordance 
with the increased CD34+ numbers that were observed (Figure 2D). No differences 
were found in the types of colonies that were formed and this was independent of the 
presence or absence of MSCs. Overall, the impact of MSCs in these various assays of 
HPC function was similar for MDS patients and healthy controls, as well as for RAEB(t) 
versus RCC patients (data not shown).
Maintenance of hematopoietic progenitor cells
To exclude the influence of exogenous growth factors on HPC expansion and the 
capacity to mount colonies, 50x103 CD34+ cells were seeded on confluent MSC layers 

























the absence of MSCs, all CD34+ cells died. In contrast, the CD34+ cells were main-
tained when cultured in the presence of MSCs. The number of viable cells harvested 
following 3-5 weeks of culture did not differ between MDS-MSCs (n=4) and HC-MSCs 
(n=2) (Figure S2A). Non-adherent cells harvested after 3 weeks of culture in the pres-
ence of HC-MSCs or MDS-MSCs formed similar numbers of colonies in CFU-assays 
(range 12-27 vs 8-32, respectively) (Figure S2B). 
Figure 4. Heat map depicting clustering of MDS derived MSCs. Gene expression was analyzed using 
LIMMA software. MSCs of different groups (RAEB(t)-MDS, RCC-MDS and healthy controls (HC)) showed 
hierarchical clustering in a heat map of differentially expressed genes. Color intensity of the squares 
correlates with increased gene expression.
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Support of colony formation
To study the direct influence of MSCs on colony formation by freshly isolated HPC, 
MSCs (30x103 or 150x103 cells/well) were added to purified HPC (500 cells/well) 
in methylcellulose containing growth factors, i.e. SCF, GM-CSF, IL-3, and EPO. The 
total number of colonies at day 14 was increased by the addition of MSCs (p=0.01). 
A significant increase was seen in CFU-GEMM, CFU-GM and CFU-M (Figure 3A). The 
proportion of CFU-GM colonies was increased when cells were cultured in the pres-
ence of MSCs compared to CFU-C assays in the absence of MSCs. In accordance with 
this, the percentage of CD45+GPA- myeloid cells was increased in the non-adherent 
cell population (colonies) harvested at day 14 from cultures containing MSCs (Figure 
3B-C). No differences in the supportive effect on colony formation and HPC differen-
tiation were observed between MDS-MSCs (n=6) and HC-MSCs (n=4). When HPC were 
cultured in the presence of HC-MSCs (n=3) or MDS-MSCs (n=3) in methylcellulose with 
erythropoietin and without GM-CSF, SCF and IL-3 the number and size of colonies 
was significantly increased in comparison with cultures without MSCs (Figure 3D). 
In conclusion, HC-MSCs and MDS-MSCs have similar effects on colony formation in 
vitro.
Gene and protein expression
In functional assays no evidence was obtained for a disturbed MSC function in 
children with MDS. However, these functional studies are limited and the results do 
formally not exclude the possible existence of biologically relevant differences be-
tween MDS-MSCs en HC-MSCs. To further investigate this Deep-SAGE was performed 
on total RNA identifying the expression of all mRNA from the 3’-end. 
MSCs derived from RCC (n=4), RAEB(t) (n=4) and healthy controls (HC, n=8) were 
analyzed. A median of 15.9x106 reads (range 9.5x106 – 30.6x106) was obtained. 
Between 59.3% and 68.4% (median 65.6%) of reads were aligned to the genome using 
Bowtie; with a median of 55.4% (min 45.3%; max 57.6%) of the reads being mapped 
to an exon. 
A heat map reflecting the top 50 differentially expressed genes demonstrates 
clustering of healthy control, RCC and RAEB MSCs (Figure 4). The gene expression 
profile of RCC clustered more towards healthy controls than RAEB(t). After correction 
for multiple testing, IL6 and dickkopf 3 homologue (DKK3) were significantly higher 
expressed in RCC-MSCs compared to HC-MSC (p=0.002 and p=0.005, respectively). 
Death-associated protein kinase 1 (DAPK1) expression was decreased (p=0.049) in 
RAEB(t)-MSCs compared to HC-MSCs, whereas cytokine receptor-like factor 1 (CRLF1) 
and IL6 expression were increased (p=0.009 and p=0.048, respectively). Differential 
expression of IL6, DKK3, DAPK1 and CRLF1 was confirmed by RT-PCR (Figure 5A). In 

























obtained at diagnosis was significantly increased in all MDS cases (n=10) compared 
to supernatants of healthy control MSCs (n=8) (p <0.001; Figure 5B). 
Deep-SAGE and RT-PCR showed that IL-6 expression was elevated in MSCs of both 
RCC and RAEB(t) obtained prior to HSCT. Of note, after HSCT, IL6 and DAPK1 expres-
sion levels in MSCs were comparable to HC-MSCs (Figure 5C). IL-6 concentration in 
MDS-MSCs culture supernatant was, although lower than in MSC samples generated 
Figure 5. Differential mRNA expression by MSCs of MDS patients. A: Aberrant gene expression de-
tected by Deep-SAGE was confirmed by RT-PCR. IL-6 expression was increased in MSCs of both RCC 
and RAEB(t) MDS patients at diagnosis compared to MSCs of healthy controls (HC). In contrast, DKK3 
was specifically increased in RCC-MDS, whereas CRLF1 and DAPK1 were significantly altered in RAEB(t)-
MDS derived MSCs. Data were normalized using GAPDH and HPRT1 as house-keeping genes (HC-MSCs 
n=10, RCC-MSCs n=7 and RAEB(t)-MSCs n=4). B: Increased IL-6 gene expression in MSCs of MDS pa-
tients pre-HSCT (n=10) compared to HC-MSCs (n=8) was confirmed by ELISA quantifying IL-6 secreted 
by MSCs in culture supernatant. IL-6 concentration was still elevated in supernatant of MSCs generated 
from bone-marrow obtained after HSCT, although there is a trend to normalization (n=7). C: Gene 
expression analysis demonstrated a normalized mRNA expression in MDS-MSCs after HSCT compared 
to HC-MSCs for IL-6 and DAPK1. RCC: refractory cytopenia; RAEB(t): refractory anemia with excess 
of blasts (in transformation); HC: healthy control; DKK3: dickkopf 3 homologue; CRLF1: cytokine 
receptor-like factor 1; DAPK1: death-associated protein kinase 1; HSCT: hematopoietic stem cell trans-
plantation; Boxes represent median and 25-75 percentiles with whiskers marking the range; Mann-
Whitney statistical tests were performed to compare the different groups; *: p <0.05; **: p <0.01; ***: 
p <0.001. n.s.: not significant.
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from bone-marrow taken pre-HSCT, still significantly higher than in supernatant of 
HC-MSC (Figure 5B). DKK3 and CRLF1 expression in MSCs expanded after HSCT from 
RCC and RAEB(t) patients, respectively, was not significantly altered compared to 
MDS-MSCs before HSCT or to HC-MSCs (data not shown). 
Potential candidate genes based on their reported differentially expression in adult 
MDS-MSCs, i.e. AURKA, AURKB, SCF, G-CSF and GM-CSF (Zhao, 2012a; Santamaria, 
2012; Oliveira, 2013; Ferrer, 2013), were specifically analyzed and no differences 
were observed comparing RCC-MSCs, RAEB(t)-MSCs and HC-MSCs. 
Similarly, a comparable expression level of CXCL12, Dicer1 and Drosha in pediatric 
MDS-MSCs versus HC-MSCs was confirmed by RT-PCR (data not shown). 
Discussion
The spectrum of pediatric MDS ranges from aplasia to myeloproliferative disease. 
The pathophysiology of the disease has been attributed to different cytogenetic 
abnormalities.(Gohring, 2010) Previous studies in mice and in human adults have 
linked the interaction of hematopoietic progenitors and the micro-environment to the 
progression of disease in several hematopoietic disorders.(Zhang, 2012b; Schepers, 
2013) In adult MDS specific alterations in the MSCs have been reported as sum-
marized in Table S1. Data on pediatric MDS are limited (Table S2). In this study, we 
compared the MSC characteristics and function in children with different types of 
MDS with healthy controls. Differences were neither observed with respect to the 
differentiation capacity of MSCs, their immunomodulatory capacity using T cell pro-
liferation and monocyte differentiation to dendritic cells as read-out, nor regarding 
their impact on maintenance and differentiation of hematopoietic progenitor cells. In 
addition, cell viability in co-cultures was equally increased by both groups of MSCs, 
as assessed by trypan-blue staining (data not shown). 
However, evaluation of total mRNA expression profiles demonstrated gene expres-
sion differences between MSCs derived from pediatric MDS patients and controls. 
Cytogenetic abnormalities present in the hematopoietic cells could not be detected 
in the stromal compartment, and, therefore, this cannot explain the differential gene 
expression. The partial normalization of IL6 and DAPK1 expression in MSCs after 
HSCT in these patients demonstrates that the expression differences can be reversed. 
Of note, using chimerism analysis, the presence of donor MSCs in the expanded cells 
has been excluded. 
Differential gene expression between pediatric MDS in general and healthy con-
trols was most prominent for IL6. This gene has previously been reported to be 

























8.(Zhao, 2012b; Narendran, 2004) In contrast, other studies in adults did not show 
differential IL6 expression between MDS patients and healthy controls.(Zhao, 2012b; 
Klaus, 2010; Flores-Figueroa, 2002; Flores-Figueroa, 2008) IL6 has been described to 
increase myeloid differentiation via STAT3 activation and support multiple myeloma 
cell growth and survival.(Minami, 1996; Zhang, 2010; Csaszar, 2013; Gunn, 2006) 
STAT3 up-regulation was not observed in this pediatric MDS cohort. In addition, IL-6 
is one of the cytokines responsible for bone-remodeling in inflammatory and malig-
nant disease.(Ara, 2010; Dayer, 2010) Suppression of monocyte to dendritic cells 
differentiation is dependent on IL-6. (Melief, 2013) However, we did not observe a 
correlation between the degree of the suppressive effect of MSCs and the level of IL-6 
expression, suggesting that IL-6 is not the sole factor hampering this differentiation.
Besides IL6 (RCC- and RAEB(t)-MDS), DKK3 (RCC-MDS), CRLF1 and DAPK1 (RAEB(t)-
MDS) were differentially expressed by MSCs of healthy controls versus MDS. DKK3 and 
CRLF1 have been associated with increased cell survival by suppressing apoptosis 
in MSCs and neuroblastoma cells, respectively.(Song, 2006; Looyenga, 2013) Dif-
ferential expression of these genes did not correlate with MSC expansion rates (data 
not shown). In addition, increased CRLF1 in combination with IL-6 has been described 
in idiopathic pulmonary fibrosis causing inflammation, but suppression of fibrosis.
(Kass, 2012) DAPK1 down-regulation, associated with malignant transformation, has 
been described in the hematopoietic cells in adult RAEB(t)-MDS potentially attributing 
to aberrant methylation.(Raval, 2007; Qian, 2010; Wu, 2011; Claus, 2012; Karlic, 
2013) We demonstrate a similar expression profile in our MSCs, with expression 
in RCC-MDS being similar to HC-MSC, and down-regulation in RAEB(t)-MSCs. After 
successful HSCT, DAPK1 expression was normalized. The allogeneic HSCT procedure 
leading to elimination of derailed cells and restoration of hematopoiesis through 
donor HPC might contribute to normalization of the stromal environment in the 
hematopoietic niche, including MSCs of recipient origin. 
Analysis of total mRNA expression profiles not only revealed differences between 
RCC and RAEB(t)/MDR-AML in children, but also enabled us to specifically focus on 
genes previously reported to be differentially expressed in adult MDS. Genes of inter-
est included micro-RNAs reported by Santamaria et al.(Santamaria, 2012) as well as 
genes encoding cytokines, their receptors, chemokines and adhesion molecules. In 
contrast to what has been described for adult MDS, AURKA, AURKB, SCF, G-CSF, GM-
CSF, CXCL12, Dicer1 and Drosha were not differentially expressed in our cohort of 
pediatric MDS patients compared to healthy controls. Lack of differences in expres-
sion levels of Dicer1, Drosha and CXCL12 was further confirmed by RT-PCR (data not 
shown). This supports the current understanding that pediatric and adult MDS are 
two different diseases as previous studies have highlighted the differences between 
adult and pediatric MDS, e.g. in response to treatment and rarity and prognostic 
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value of (epi-) genetic mutations in the hematopoietic compartment.(Glaubach, 2014; 
Hasle, 2004; Hirabayashi, 2012) Besides IL-6, genes included in the clustered analysis 
did not encode for molecules known to be involved in MSC signaling as reviewed by 
Le Blanc and Mougiakakos.(Le, 2012)
Our MDS cohort is heterogeneous containing RCC as well as advanced MDS patients. 
Bone-marrow post HSCT was not available in all cases, because of informed consent 
was limited to bone-marrow sampling on clinical indication namely relapse risk and 
non-engraftment. Correlation of mRNA expression in MSCs obtained at diagnosis 
with MSCs at MDS relapse after HSCT was not feasible due to low sample numbers in 
combination with limited numbers of relapse after HSCT.
Our findings demonstrate differences in mRNA expression between pediatric MDS 
and age-matched healthy control derived MSCs. This is in accordance with published 
data on MSCs derived from adults with MDS, however, as expected, not all abnor-
malities described in adults were present in pediatric MDS. In addition, different 
expression levels of specific genes were not associated with functional aberrations 
in assays pointing to immunomodulation and hematopoiesis, potentially caused by 
compensatory mechanisms or insufficient sensitivity of our tests. Growth differences 
between MSC precursors and use of non-clonal MSC populations may lead to loss of 
information and, thereby, to potential loss of differences between pediatric MDS and 
healthy control derived MSCs. Unfortunately, data on the interaction of MSCs with 
MDS patient derived hematopoietic stem cells was limited by the available material. 
However, preliminary data do not reveal differences in co-cultures of MDS-RAEB HPC 
with MDS patient or healthy control derived MSCs. 
Studying the pathogenesis of MDS has been complicated by the poor engraftment 
of human MDS HPC in immunodeficient mice.(Thanopoulou, 2004) However, co-
transplantation of stromal cells and intramedullary transplantation of hematopoietic 
cells has led to increased engraftment.(Kerbauy, 2004) Knockout models resulting 
in an MDS-like phenotype or the of use of scaffolds with patient-derived MSCs to 
resemble the human bone-marrow microenvironment might be instrumental in fur-
ther exploring the potentially functional implications of these differences in future 
studies.(Groen, 2012; Walkley, 2007; Raaijmakers, 2010)} 
In conclusion, our data show that the gene expression profile is different in MSCs of 
children with MDS. It remains to be elucidated whether the abnormalities are a cause 
or a consequence of the disease. Normalization of the aberrant gene expression seen 
in patients derived MSCs after allogeneic HSCT is an argument favoring the latter 
possibility. Induced abnormalities in the MSCs by dysplastic cells might be targets to 
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Supplementary Figure 1. Phenotype and differentiation capacity of MDS-MSC. A: MSC of MDS pa-
tients (e.g. UPN MDS015, passage 2) express the characteristic phenotype of MSC: CD73+, CD90+ and 
CD105+ and negative for the indicated lineage-specific markers. Red line indicates the staining inten-
sity obtained with a negative isotype-matched control. B-E: MSC of healthy controls (B, D HC012, pas-
sage 5) and MDS patients (C, E MDS002, passage 7) differentiate towards osteoblasts (B, C Alizarine 

























Supplementary Figure 2. MSC of MDS patients maintain hematopoietic cells in the absence of growth 
factors. CD34+ cells (HPC, 50 000 cells) of HSCT donors were seeded on a confluent layer of MSC 
(white bars: healthy control (HC)-MSC, black bars: MDS-MSC) or in wells without (wo) MSC (grey bars) 
and cultured for 3 to 5 weeks. A. Viability of non-adherent cells obtained after harvesting was as-
sessed by trypan blue staining. No viable cells were present in culture conditions without MSC. B. Non-
adherent cells harvested after 3 weeks of co-culture with healthy control (HC)-MSC (n=2) or MDS-MSC 
(n=4) were tested in CFU-assays (1500 cells/dish) to investigate their differentiation capacity. Results 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Gene-expression and in vitro function of 
mesenchymal stromal cells are affected 
in juvenile myelomonocytic leukemia.
Haematologica. 2015 Nov;100(11):1434-41.
Calkoen FGJ, Vervat C, Vijfhuizen L, Eising E, ‘t Hoen PAC, 




An aberrant interaction between hematopoietic stem cells and mesenchymal stro-
mal cells has been linked to disease and shown to contribute to the pathophysiology 
of hematologic malignancies in murine models. Juvenile myelomonocytic leukemia 
is an aggressive malignant disease affecting young infants. Here we investigated the 
impact of juvenile myelomonocytic leukemia on mesenchymal stromal cells. Mesen-
chymal stromal cells were expanded from bone marrow samples of patients at diag-
nosis (n=9) and after hematopoietic stem cell transplantation (n=7; from 5 patients) 
and from healthy children (n=10). Cells were characterized by phenotyping, differen-
tiation, gene expression analysis (of controls and samples obtained at diagnosis) and 
in vitro functional studies assessing immunomodulation and hematopoietic support. 
Mesenchymal stromal cells from patients did not differ from controls in differentia-
tion capacity nor did they differ in their capacity to support in vitro hematopoiesis. 
Deep-SAGE sequencing revealed differential mRNA expression in patient-derived 
samples, including genes encoding proteins involved in immunomodulation and 
cell-cell interaction. Selected gene expression normalized during remission after suc-
cessful hematopoietic stem cell transplantation. Whereas natural killer cell activation 
and peripheral blood mononuclear cell proliferation were not differentially affected, 
the suppressive effect on monocyte to dendritic cell differentiation was increased 
by mesenchymal stromal cells obtained at diagnosis, but not at time of remission. 
This study shows that active juvenile myelomonocytic leukemia affects the immune 
response related gene expression and function of mesenchymal stromal cells. In 
contrast, the differential gene expression of hematopoiesis-related genes could not 
be supported by functional data. Decreased immune surveillance might contribute to 

























The bone-marrow (BM) niche represents the supportive environment for hema-
topoietic stem cells (HSC).(Mendez-Ferrer, 2010; Morikawa, 2009) Mesenchymal 
stromal cells (MSCs), being precursors to osteoblasts, adipocytes and chondrocytes 
and a cellular constituent of the niche, are crucial for maintenance of quiescent HSC.
(Sugiyama, 2006b) MSCs, or differentiated sub-populations of these cells, are used 
in vitro as a model for the BM microenvironment. Soluble factors as well as direct 
cell-to-cell contact have been described to play a role in normal MSC-HSC interaction.
(Greenbaum, 2013; Wang, 2010) 
Hematopoietic malignancies such as leukemia originate in the BM. Although leu-
kemic blast cells can be detected throughout the body during disease, the leukemic 
stem cells are thought to remain in the BM, and more specifically in the hematopoi-
etic stem cell niche.(Ayala, 2009) It is widely accepted that malignant cells have a 
negative impact on the normal hematopoiesis causing anemia and thrombocytope-
nia. However, the effect of the malignant cells on the BM microenvironment has not 
been studied extensively. 
Recent studies in mice have demonstrated that myeloid neoplasms affect the nor-
mal niche structure.(Schepers, 2013; Zhang, 2012b; Arranz, 2014) These alterations 
contribute potentially to the formation of the leukemic niche in which leukemic stem 
cells are difficult to target by conventional chemotherapy or irradiation.(Kurtova, 
2009) Studies describing MSC characteristics in human myeloproliferative neoplasms 
are mostly limited to adult patients, demonstrating conflicting results with regard to 
genetic abnormalities, gene-expression and MSC function.(Zhao, 2012b; Raaijmak-
ers, 2012; Klaus, 2010; Flores-Figueroa, 2008)
Juvenile Myelomonocytic Leukemia (JMML) is an aggressive leukemia occurring in 
young children, predominantly in infants between 0 and 4 years of age. Patients 
usually present with hepatosplenomegaly, fever and monocytosis.(Niemeyer, 1997) 
Monosomy 7 is the most common karyotype abnormality detected in 25% of cases, 
and numerous leukemogenic mutations have been identified mainly involving the 
RAS-RAF-ERK pathway, e.g. PTPN11, K-RAS and c-CBL.(Niemeyer, 2008; de Vries, 
2010) Hematopoietic stem cell transplantation (HSCT) is the standard first line treat-
ment. Unfortunately, the one year relapse rate ranges between 30 and 50%.(Locatelli, 
2005; Locatelli, 2015)
We hypothesize that the aggressive and therapy resistant characteristics of JMML 
may point towards an altered BM microenvironment based on previous experimental 
data suggesting support of a neoplasm by the stromal compartment.(Zhang, 2012b; 
Arranz, 2014) In the current study we aimed to identify stromal factors involved in 
the support of JMML. MSCs of patients with JMML were obtained at diagnosis and after 
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HSCT and expanded from BM. These patient derived MSCs were compared to healthy 
pediatric donor derived MSCs by investigating their capacity of immunomodulation 
and hematopoietic support and their gene expression profiles.
Methods
A detailed version of the Methods section is available online at the Haematologica 
website.
Patients
Children referred to our center for HSCT were included in this study according to 
a protocol approved by the institutional review board (P08.001). BM of 9 consecutive 
children with JMML was collected prior to treatment initiation. In addition, BM after 
HSCT was collected from 5 of these 9 children. The patients were classified following 
previously described criteria.(de Vries, 2010; Loh, 2011) BM samples were sent to the 
EWOG-MDS-reference center in Freiburg, Germany for mutation analysis. BM samples 
of healthy pediatric HSCT donors (n=10) were used as control group (HC). Informed 
consent was obtained from all parents. This study was conducted according to the 
Declaration of Helsinki.(World Medical Association, 2013)
MSC expansion and characterization
MSC were expanded from fresh BM and characterized as previously described.
(Calkoen, 2013a) Monosomy 7 by FISH and chimerism by variable number of cy-
tosine adenine (CA) repeat analysis were determined in expanded MSC before and 
after HSCT, respectively.(Lankester, 2010; Bronkhorst, 2011) MSC gene expression 
and function was investigated using MSCs obtained at passage 2-3 and 3-5, respec-
tively.
Functional assays
The effect of MSCs on proliferation of peripheral blood mononuclear cells (PBMCs) 
was investigated in co-cultures stimulated with phytohemagglutinin (PHA) by measur-
ing 3H-thymidine incorporation. 
The suppressive effect of MSC on NK cell activation was determined by stimulation 
of purified NK cells with IL-2 in the absence or presence of MSCs for 5 days. NK cells 
were harvested and activation was measured by flow cytometry investigating DNAM-
1, NKp30 and NKp44 expression.
To evaluate the effect of MSCs on antigen presenting cells, monocytes were isolated 
























immature dendritic cells (DC) or mature DC, respectively. Cells were phenotyped for 
the expression of CD14 and CD1a after co-culture.
Short-term co-culture assays with MSCs and hematopoietic progenitor cells (HPC) 
were performed to determine the supportive capacity of MSCs for HPCs maintenance 
and differentiation. Therefore, HPCs were isolated from healthy transplant donors 
using CD34 positive selection. Proliferation (day 7) and differentiation (day 7 and 14) 
were assessed using 3H-thymidine incorporation and flow cytometry, respectively. 
To determine a direct effect of MSCs on HPC differentiation into colony-forming-
units (CFU), MSCs were added to freshly purified HPCs in methylcellulose containing 
growth factors and cultured for 14 days (CFU-assay). 
Gene expression
Total RNA was isolated from MSCs and mRNA was profiled using Deep-SAGE (serial 
analysis of gene expression) sequencing using Illumina technology.(Mastrokolias, 
2012) Data were mapped against the UCSC-hg19 reference genome using Bowtie, 
with permission of one mismatch and only retaining unique mappings. 
Expression of genes of interest was validated using independent biological samples 
by RT-qPCR after generation of cDNA using the listed primers (Supplementary Table 
1), as previously described.(Mastrokolias, 2012) Expression levels were calculated 
relative to the average expression of two housekeeping genes.
Statistical analysis
Mann-Whitney and Wilcoxon matched-pairs signed rank tests were performed to 
compare different groups in functional assays and in the validation of mRNA ex-
pression. Differential gene expression analysis was performed in R, using EdgeR, 
Globaltests and Limma data analysis packages.(Robinson, 2010; R Development Core 
Team, 2012; Smyth, 2005) Correction for multiple testing was performed according 
to Benjamini and Hochberg.(Hochberg, 1990) STRING software was used for analysis 




MSCs were successfully expanded from all 9 patients with JMML (Table 1) at diag-
nosis and 10 healthy controls (HC). In addition, 7 BM samples collected after HSCT, 
derived from 5 of the 9 JMML patients included, were used for MSC expansion (Table 
1). These MSCs were of patient origin as tested by CA-repeat analysis. Median age 
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at diagnosis was 2.1 years (range 0.5 - 3.5), whereas the age of healthy controls 
ranged between 1.1 and 16.4 years (median 7.4). Children with different genetic 
mutations were included as shown in Table 1. Monosomy 7, present at diagnosis in 
two children, was not detected in the MSCs at diagnosis.
MSC expansion and characterization
All expanded MSC populations fulfilled the criteria proposed by Horowitz et al. 
(Horwitz, 2005), i.e. differentiation towards adipocytes and osteoblasts, a charac-
teristic phenotype (CD73+, CD90+, CD105+, HLA-DR- and no expression of lineage 
markers) and adherence to plastic. Representative examples of differentiation of 
Table 1. Patient characteristics

























JMML002 M 9 c-CBL
MUD/
BM Flu, Bu, ATG
Yes (41) No
JMML003 M 32








PTPN11 (exon 3 
c182 A>T) IRD/BM Bu, Cy, Mel





Monosomy 7 + NF1 




Bu, Cy, Mel, 
ATG
No No







PTPN11 gene (exon 
13 1508 G>C 503 
G>A
MUD/
CB Flu, Bu, ATG
Yes (52) Yes (5)
JMML008 F 35
PTPN11 gene (exon 




Bu, Cy, Mel, 
ATG
No No
JMML009 M 12 Monosomy 7/RAS
MUD/
PBSC Flu, Bu, ATG
No No
Donor: MUD: matched unrelated donor; IRD: identical related donor. Graft type: BM: bone-marrow; CB: 
cord blood; PBSC: peripheral blood stem cells. Conditioning: Thio: thiotepa; Flu: fludarabine; Treo: 
treosulfan; ATG: anti-thymocyte globulin; Bu: busulfan; Cy: cyclophosphamide; Mel: melphalan. 1: 
Bone-marrow (BM) sample after HSCT was obtained after remission induction; 2BM sample after HSCT 
























MSCs prior to and after HSCT are shown in Figure 1A-B. Besides these criteria, MSCs 
have been described to suppress PHA-induced PBMC proliferation. MSCs derived from 
patients and controls did not differ in their immunosuppressive capacity of PHA-
induced PBMC proliferation (Figure 1C).
Hematopoietic support
MSCs have been described to play an important role in the tight regulation of he-
matopoiesis in the bone marrow. We investigated the capacity of JMML-MSCs derived 
at diagnosis to support hematopoiesis in vitro. HPC proliferation induced by SCF 
and Flt3-L was enhanced in the presence of MSCs and dependent on the HPC : MSC 
ratio (Figure 2A). JMML-MSCs and healthy control MSCs did not differ in this respect. 

















Figure 1. Expansion and characterization of MSCs from JMML patients at diagnosis and post-HSCT 
and healthy controls. MSCs were expanded and differentiation capacity towards adipocytes (A) and 
osteoblasts (B) was evaluated. MSCs were cultured with differentiation factors for 3 weeks and Oil 
Red O and Alizarine Red was used to stain fat and calcium deposition, respectively (examples are 
representative for MSCs of 9 JMML patients at diagnosis and 5 JMML patients after HSCT). C. Healthy 
Control (HC)-MSCs and JMML-MSCs showed a comparable dose-dependent suppressive effect on PBMC 
proliferation after PHA stimulation. Boxes indicate the mean proliferation at the indicated PBMC:MSC 
ratio relative to the proliferation induced without (wo) MSCs. Error bars represent standard deviation. 
Experiments were performed with n=7 JMML-MSCs and n=4 HC-MSCs. Statistics were performed using 
Mann-Whitney tests: **: p<0.01.
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culture was significantly better maintained in the presence of MSCs (Figure 2B). Cells 
that lost CD34 expression expressed lineage markers such as CD14. The frequency 
of CD14+ cells amongst CD45+ lineage-committed cells was significantly higher after 
7-14 days of culture of CD34+ cells with MSCs (Figure 2C). The supportive effect by 
MSCs was comparable between MSCs of JMML patient and MSCs of healthy controls.
To evaluate the effect of MSCs on functional differentiation of HPCs, MSCs were 
added to semi-solid cultures of isolated HPCs in methylcellulose containing growth-
factors. Both the total number of CFU and the different types of colonies increased 
in the presence of MSCs (Figure 2D). The percentage of CD45+CD235a- cells was 
increased after culture with MSCs suggesting support of differentiation and prolif-
eration of myeloid cells at the cost of CD45-CD235a+ erythroblasts in this culture 
condition (Figure 2E). Indeed, also in this culture configuration the percentage of 
monocytes (CD14+ cells) was significantly increased in the presence of both control 
as well as JMML-MSCs (Figure 2F). Also in these differentiation assays, no difference 
was observed between JMML-MSCs and healthy control MSCs.
Gene expression analysis
Because the functional tests executed so far did not reveal differences between JMML 
and healthy control (HC) MSCs, we explored possible differences in mRNA expression 
profiles by performing Deep-SAGE sequencing, a next generation sequencing-based 
approach with higher sensitivity than traditional microarrays (de novo JMML n=8; 
HC n=8).(Hoen ‘t, 2008) The median number of obtained reads that fulfilled quality 
control criteria was 15.9x106 reads (range 11.4x106 - 30.6x106). A median of 65.6% 
of all reads aligned uniquely to the reference genome (range 59.3% - 68.4%). The 
percentage of the aligned reads mapping to an annotated exon was 84.5% (range: 
74.7% - 86.3%). 
The differentially expressed genes (n=162; p<0.001) are listed in Supplementary 
Table 2. A heat-map of the top 100 differentially expressed genes shows clustering 
of the JMML and HC derived MSCs (Supplementary Figure 1). After correction for 
multiple testing, in total 43 genes were differentially expressed between JMML and 
HC-MSCs (criterion: false discovery rate (FDR) < 0.05, see Supplementary Table 2) 
The top 6 genes (Dickkopf-1 (DKK1), ectonucleotide pyrophosphatase/phosphodies-
terase 2 (ENPP2), DEAD (Asp-Glu-Ala-Asp) box helicase 17 (DDX17), monooxygenase 
DBH-like 1 (MOXD1), Adenomatosis Polyposis Coli Down-Regulated 1-Like (APCDD1L) 
and tumor necrosis factor alpha-induced protein 2 (TNFAIP2)), that were expressed 
at intermediate to high levels (> 100 reads per million sequenced reads, in both 
patients and controls) were selected for RT-qPCR validation (Figure 3). 
In addition, three out of the 162 differentially expressed genes were previously 



























































































































































































Figure 2. JMML-MSCs support the proliferation and differentiation of HPCs in vitro. A. Both in the pres-
ence of JMML patient and healthy control (HC) derived MSCs the proliferation of CD34+ cells (HPCs) 
was increased after 7 days of culture. MSCs alone did not show 3H-thymidine incorporation (data not 
shown). B. HPCs lost the expression of CD34 after 14 days of culture; however, in the presence of 
MSCs (HPC : MSC ratio 1:5) the decline in CD34 expression was diminished. C. HPCs acquired lineage 
markers, e.g. CD14, but no differences were seen between JMML-MSCs and HC-MSCs. D. A significantly 
(p<0.05) increased number of colonies was seen in CFU-assays in the presence of MSCs (HPC : MSC 
ratio 1:60). E-F. Cells harvested after colony formation contained increased percentages of CD235a 
negative and CD14 positive cells within the CD45+ cell population. Boxes indicate the mean and error 
bars represent standard deviation. Experiments were performed with n=4 JMML-MSCs and n=2 HC-
MSCs. Statistics were performed using Mann-Whitney tests: *: p<0.05; **: p<0.01; n.s.: non-significant.
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CXCR7 and IL-6, Figure 3G, 3F and 3H, respectively). CXCL12 (Figure 3G), previously 
reported to be of importance in HSC - MSC interaction and mobilization of HSCs, was 
found to be significantly decreased in JMML-MSCs.(Sugiyama, 2006b) Whereas the 
commonly involved receptor CXCR4 was not differentially expressed, expression of 
the alternative receptor CXCR7 was significantly decreased in JMML-MSCs (Figure 3F). 
String analysis of the top differentially expressed genes (data not shown) revealed 
that many of the genes upregulated in JMML-MSCs are associated with the IL-1 su-
perfamily (IL-1β, IL-6 (Figure 3H), PTHLH, CLU, ATF3, PENK, RGS3 and RGS16). DKK1 
expression (Figure 3B), related with osteolysis, was also increased. In contrast, ex-
pression of genes in the leptin pathway was decreased (LEP, LEPR, KISS1, SLC25A27, 
RXRA and CBLB). Results of gene-ontology (p<0.001 after Holms correction and at 
least 100 covariates) are listed in the Supplementary Table 3. Pathways related to 
immune responses and protein ubiquination, involved in cell regulation of cellular 
interaction,(Hammond-Martel, 2012) were predominantly affected. 
Normalization of gene expression in JMML-MSCs after HSCT
Genes of interest, identified by Deep-SAGE, were studied in patient samples after 
HSCT. BM obtained at remission was available for MSC expansion of 4 patients, 5 
samples in total. RT-qPCR was used to study gene expression in these samples. ENPP2, 
DDX17, CXCR7, CXCL12 and TNFAIP2 expression was decreased in JMML-MSCs at 
diagnosis, however, expression was restored to the level of HC-MSC in samples after 
HSCT (Figure 3A, D, F, G, I). DKK1, MOXD1 and IL-6 expression was increased in 
JMML-MSCs at diagnosis, but normalized in JMML-MSCs post-HSCT (Figure 3B, C, and 
H). APCDD1L (Figure 3E), a paralog of the WNT inhibitor APCDD1,(Shimomura, 2010) 
was the only gene studied, of which the abnormal (increased) expression at diagnosis 
remained unchanged after HSCT. BM at time of relapse post HSCT was only available 
in two patients and therefore not included in the gene-expression analysis.
Immunomodulation
Differential expression of IL-6 and other genes in the IL-1 superfamily suggests 
a differential effect of JMML patients derived MSCs on the innate immune system. 
Escape from NK cell surveillance is an important survival mechanism in tumorigen-
esis. However, HC-MSCs and JMML-MSCs derived from BM obtained at diagnosis 
suppressed NK cell activation to a similar extent (Figure 4A).
The suppressive effect of MSCs on monocyte to dendritic cell (DC) differentiation 
has been described to be IL-6 dependent.(Melief, 2013) Therefore, we analyzed the 
monocyte to DC differentiation in the absence and presence of MSCs at different 
MSC : monocyte ratios. The addition of both sources of MSCs resulted in decreased 




































































































































































































































































































































































Figure 3. Gene expression of differentially expressed genes in MSCs of JMML patients at time of diag-
nosis and after HSCT. Genes identified by Deep-SAGE sequencing were validated by RT-qPCR in JMML-
MSCs expanded from bone-marrow samples obtained prior to (n=9) and after HSCT at time of remis-
sion (n=5) and in MSCs derived from healthy donors (HC, n=10). Expression levels were expressed 
relative to that of the average of the housekeeping genes HPRT1 and GADPH. The results are indicated 
as median (horizontal line) and interquartile range (whiskers) on a logarithmic scale. Statistics were 
performed using Mann-Whitney tests.
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ing the DC marker CD1a on day 5 of co-culture; these cells remained CD14+ (Figure 
4B-C). JMML-MSCs had a significantly stronger suppressive effect on monocyte to 
immature DC differentiation than HC-MSCs. This was supported by the observation 
that CD163 expression on CD14+ cells, a marker associated with anti-inflammatory 
monocytes and macrophages, was higher after co-culture with JMML-MSCs (MFI: 49.3 







































































Figure 4. JMML-MSCs expanded from bone-marrow at diagnosis have an increased suppressive ef-
fect on monocyte to immature dendritic cell differentiation but not on NK cell activation. A. NK cell 
activation induced by IL-2 (30 IU/mL), measured by mean fluorescence intensity (MFI) of staining for 
DNAM-1, NKp30 and NKp44 expression on day 5, was suppressed in the presence of MSCs of healthy 
controls (HC) and JMML patients. MSC: NK cell ratio 1:5 (JMML-MSCs n=4 and HC-MSCs n=4). B-C. An 
increased suppressive effect of JMML-MSCs was observed on the differentiation of monocytes (CD14+ 
cells, B) to immature dendritic cells (CD1a+ cells, C) during 5 days of stimulation with IL-4 and GM-CSF 
(JMML-MSCs n=6, grey boxes, and HC-MSCs n=6, white boxes). D) JMML-MSCs derived from bone-mar-
row after hematopoietic stem cell transplantation (HSCT) showed a trend towards a lower suppressive 
effect on the monocyte to immature DC differentiation than JMML-MSCs derived from bone-marrow 
obtained at diagnosis. Paired samples of JMML-MSCs at diagnosis and after HSCT (n=2) and HC-MSCs 
(n=3) were investigated using monocytes from two donors as target populations (MSC : monocyte ratio 
1:40). Results in panel A-C are depicted as mean (horizontal line) with interquartile distance (boxes) 
and range (whiskers). Statistics were performed using Mann-Whitney tests in panel A-D. *: p<0.05; **: 
























The differential suppressive effect of JMML-MSCs compared to HC-MSCs disap-
peared after two additional days in culture with growth-factors (IFN-γ and CD40-L) to 
support the differentiation of immature DCs to mature DCs (data not shown). 
Gene-expression, i.e. IL-6, in MSCs obtained after HSCT was comparable to healthy 
controls. Therefore, the effect of JMML-MSCs expanded from BM after HSCT on mono-
cyte to immature DC differentiation was studied. The percentage of CD14+ cells in 
co-cultures of monocytes with JMML-MSCs derived from BM obtained after HSCT dur-
ing remission was variable and not different from that in co-cultures with HC-MSCs. 
In addition, MSC derived during remission showed a trend to a lower percentage of 
CD14+ cells compared to the percentage observed in co-cultures with JMML-MSC at 
diagnosis.(Figure 4D). 
Discussion
A genetic mutation in the RAS-pathway is identified in 90% of JMML patients.(de 
Vries, 2010) However, the etiology of therapy resistance and the high relapse rate 
after HSCT remains unknown. The aggressive nature of the disease in combination 
with the high burden of malignant cells may lead to a disturbance of the BM micro-
environment. 
As a model for the BM microenvironment, we used BM derived MSCs. In our study, 
MSCs of JMML patients had a comparable differentiation capacity compared to MSCs 
of healthy controls. In contrast to previously reported studies in adult MDS, adipocyte 
and osteoblast differentiation was not adversely affected.(Zhao, 2014) This is in line 
with the unaffected differentiation capacity of MSCs derived from BM of children with 
MDS.(Calkoen, 2015) However, gene expression analysis revealed increased DKK1 
expression in JMML derived MSCs. DKK1, related with osteolysis and WNT signaling, 
has been described to be upregulated in MSCs derived from patients with multiple 
myeloma.(Corre, 2007) Identification of this protein, also expressed by multiple my-
eloma cells,(Qian, 2007) led to therapeutic strategies using antibodies or vaccination 
against DKK1 with a beneficial effect in murine models.(Heath, 2009; Qian, 2012) 
The control group differed from the patients regarding age at BM collection. How-
ever, data were validated using selected controls aged 1 to 4 years (n=4). We did not 
observe an age dependent effect on gene-expression in our patient or control MSCs. 
In this study, the suppressive effect of JMML-MSCs on differentiation from mono-
cytes to immature DCs was significantly stronger compared to MSCs of healthy 
controls. The increased IL-6 expression by JMML-MSCs suggests a causal relation be-
cause IL-6 has been described to be essential in the suppressive mechanism.(Melief, 
2013) Previously, pediatric MDS derived MSCs showed an even stronger increase in 
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IL-6 expression, whereas no effect on monocyte to DC differentiation was observed.
(Calkoen, 2015) Inhibition of differentiation towards professional antigen presenting 
cells might contribute to the escape of JMML cells from the immune system and might 
explain the usually progressive course of this disease. NK cells are involved in the in-
nate defense against malignant transformed cells. Whereas IL-6 production has been 
reported to suppress NK cell cytotoxicity against neuroblastoma and lymphoblastoid 
cells, facilitating tumor escape,(Xu, 2013; Tanner, 1991) the suppressive effect of 
MSCs on NK cell activation was comparable between JMML-MSCs and HC-MSCs. In 
previous studies, we demonstrated a correlation between the suppressive effect of 
MSCs on NK cell activation marker expression, i.e. DNAM-1, NKp30 and NKp44, and 
cytotoxicity.(Calkoen, 2013a) 
JMML clinically presents with anemia and thrombocytopenia in combination 
with monocytosis and leukocytosis. Previously, the misbalance in hematopoiesis 
in patients with hematologic malignancies was suggested to be caused by factors 
excreted by malignant cells.(Aoyagi, 1994) In addition, disturbed support of hema-
topoiesis by MSCs might contribute to dysplasia in these patients. CXCL12 expres-
sion was decreased in JMML-MSCs as was also previously shown in studies on MSC 
from adult CML and pediatric ALL patients.(van den Berk, 2014; Zhang, 2012b) The 
CXCL12-CXCR4 interaction is an important mechanism in hematopoietic support and 
decreased CXCL12 expression has been linked to dysplasia in mice and adult chronic 
myeloid leukemia.(Zhang, 2012b; Arranz, 2014) Our in vitro hematopoiesis ex-
periments did not reveal differences in support of proliferation and differentiation of 
HPCs between JMML and control derived MSCs. Both JMML and healthy control MSCs 
have a strong supportive effect on hematopoiesis involving multiple pathways, e.g. 
CXCL12, G-CSF and SCF. Therefore, aberrant expression of one of these molecules 
could be compensated by other pathways in our in vitro experiments. In this study, 
we used in vitro and polyclonal expanded MSCs and as a consequence differences in 
vivo between healthy controls and JMML derived MSCs might be lost during culture. 
However, Zhang et al. demonstrated sustained decreased expression of CXCL12 in 
vivo and in in vitro expanded MSCs.(Zhang, 2012b) Further in vivo characterization 
of the MSCs in mice models modelling the hematopoietic niche with human MSCs, 
such as previously used in e.g. multiple myeloma, might help to identify more subtle 
differences.(Groen, 2012) 
The different gene expression profile observed in JMML-MSCs versus HC-MSCs is 
more likely the consequence than the cause of the disease, with JMML cells interact-
ing with the stromal compartment. This conclusion is supported by the observation 
that after allogeneic HSCT, in which hematopoietic progenitor cells become of donor 
























note, the MSCs after HSCT remain of patient origin, suggesting that the aberrant MSC 
gene expression pattern before HSCT is induced by JMML cells. 
In conclusion, our data demonstrate an effect of JMML cells on MSCs during ac-
tive disease. In vitro hematopoietic support and maintenance of CD34+ HPCs by 
JMML-MSCs were not affected despite differential gene expression. However, immu-
nosuppression was affected via a stronger decrease of monocyte to immature DC 
differentiation by JMML-MSC.
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Methods for online publication
Patients
Children referred to our center for HSCT were included in this study according to 
a protocol approved by the institutional review board (P08.001). Bone marrow of 9 
children with JMML was collected prior to treatment initiation. In addition, bone mar-
row after HSCT was collected from 5 of these 9 children. The patients were classified 
following the criteria described by Loh et al.(Loh, 2011) Bone marrow samples were 
sent to the JMML-reference center in Freiburg, Germany for genetic analysis. Bone 
marrow samples of healthy pediatric hematopoietic stem cell donors (n=10) were 
used as control group (HC). Informed consent was obtained from the children and/or 
their parents or guardians. This study was conducted according to the Declaration of 
Helsinki.(World Medical Association, 2013)
MSC expansion and characterization
MSCs were expanded and characterized as previously described.(Calkoen, 2013a) 
Briefly, bone marrow mononuclear cells (MNC) obtained after Ficoll separation were 
cultured in DMEM (Invitrogen, Paisley, UK) containing 100 U/mL penicillin/100 
μg/mL streptomycin (P/S; Invitrogen) and 10% (v/v) fetal bovine serum (FBS; VWR 
International, Bridgeport, NJ, USA). Non-adherent cells were removed by refreshing 
medium twice weekly. Upon reaching confluence MSC were harvested and passaged 
for further expansion. Phenotype (CD73, CD90, CD105 positive; CD3, CD31, CD34, 
CD45, CD86, HLA-DR negative) and differentiation capacity towards osteoblasts and 
adipocytes were investigated at passage 2-3 and 5-7, respectively. All but anti-CD105 
(Ancell Corporation Bayport, MN) antibodies were derived from Becton Dickinson 
Biosciences (BD), San Diego, CA, USA. 
To investigate common chromosome abnormalities in MSCs and malignant cells, 
interphase fluorescence in situ hybridization (FISH) for chromosome 7 was performed 
on MSC from patients with known monosomy 7 using the Vysis LSI D7S486/CEP7 (Ab-
bott Laboratories, Abbott Park, IL,USA) probe.(Bronkhorst, 2011) Chimerism of MSCs 
obtained after HSCT (donor or recipient origin) was studied by variable number of 
cytosine adenine (CA)-repeat analysis in MSCs cultured from bone marrow harvested 
after HSCT as previously described.(Lankester, 2010) MSC function was investigated 
using MSCs obtained at passage 3 to 5 and MSC gene expression was analyzed using 

























Effect of MSCs on PHA-induced PBMC proliferation
The effect of MSCs (30-Gy irradiated) on proliferation of peripheral blood mono-
nuclear cells (PBMC) obtained from adult bloodbank donors (100.000 cells/well) after 
stimulation with phytohemagglutinin (PHA, PeproTech, London, UK, 2 μg/mL) was 
analyzed at MSC : PBMC ratios of 1:5 and 1:40. MSCs and PBMC were co-cultured in 
RPMI P/S, 10% (v/v) fetal calf serum (FCS) for 5 days with the addition of 3H-thymidine 
(1 μCi/well; Perkin Elmer, Wellesley, MA, USA) for the last 16 hours to measure pro-
liferation using a β-counter (Perkin Elmer). Experiments were performed in triplicate. 
Effect of MSCs on NK cell activation
The suppressive effect of MSCs on NK cell activation was determined using NK cells 
isolated from PBMC of bloodbank donors with manual MACS cell separation technol-
ogy and negative selection (Miltenyi Biotec, Bergisch Gladbach, Germany). NK cell 
purity (CD56+CD3- cells, using anti-CD3-PerCPC5.5 and anti-CD56-APC (Immunotech, 
Marseille, France)) was over 95%. NK cells (0.1 x 106/well) were cultured with (0.02 
x 106/well) or without MSCs in the presence of IL-2 (30 IU/mL, Chiron Corporation, 
Emeryville, CA, USA) for 5 days. NK cells were harvested and activation was measured 
by flow cytometry investigating the mean fluorescence intensity (MFI) of DNAM1 
(BD), NKp30 (Immunotech) and NKp44 (Immunotech) expression using PE-labelled 
antibodies.
Effect of MSCs on monocyte differentiation
To evaluate the effect of MSCs on antigen presenting cells, monocytes were iso-
lated from PBMC of blood bank donors using positive CD14 selection (Miltenyi Biotec) 
and cultured with IL-4 (40 ng/mL) and GM-CSF (800 IU/mL) (both from Tebu-Bio, Le 
Perray en Yvelines, France) for 5 days to differentiate towards immature dendritic 
cells (DC). Cells were harvested or cultured for 2 additional days with IL-4, GM-CSF, 
IFN-γ (500 U/mL, Boehringer, Mannheim, Germany) and CD40-ligand (0.25 μg/mL 
Beckman-Coulter, Marseille, France) to generate mature DC. Cells were phenotyped 
by flow cytometry for the expression of CD14 and CD1a (both antibodies from BD) on 
day 0, day 5 and day 7 after co-culturing of monocytes and MSC at MSC : monocyte 
ratios 1:5 or 1:40 or after culturing monocytes without MSCs. 
In vitro hematopoietic support of MSCs
Short-term co-culture assays with MSCs and hematopoietic progenitor cells (HPC) 
were performed to determine the supportive capacity of MSCs for HPC maintenance 
and differentiation. Therefore, HPC were isolated from remaining material of G-CSF 
Chapter 4.
82
mobilized stem cell grafts from healthy transplant donors using CD34 positive 
selection (Miltenyi). After purification, >90% of selected cells expressed CD34. To 
investigate the effect of MSCs on proliferation of CD34+ cells, short-term cultures of 
1000 CD34 selected cells/well without or with MSCs (MSC : CD34+ cell ratios 1:1 and 
10:1) were performed in Stemspan medium (H3000, StemCell Technologies, Van-
couver, Canada) with addition of 1% P/S, stem cell factor (SCF, 100 ng/mL, StemCell 
Technologies) and Flt3-ligand (Flt3-L, 100 ng/mL, StemCell Technologies), because 
SCF and Flt3-L are not produced by MSCs. To investigate the effect of MSCs on dif-
ferentiation of CD34+ cells, cultures were initiated with 10x103 CD34+ cells at a CD34+ 
cell : MSC ratio of 1:5. Half of the culture medium was refreshed with the addition of 
growth factors on day 4, 7 and 11. Proliferation (day 7) and differentiation (day 7 and 
14) were assessed using 3H-thymidine during the last 16 hours or flow cytometry, 
respectively. Antibodies used for flow cytometry were anti-CD13-PE, anti-CD14-FITC, 
anti-CD33-APC, anti-CD34-PE, anti-CD45-FITC, anti-CD45-Percpc5.5, anti-CD163-PE 
and anti-CD235a-PE (all antibodies from BD).
To determine a direct effect of MSCs on HPC differentiation into colony-forming 
units (CFU), MSC (30.000 per dish) were added to freshly purified HPC (500 cells/dish) 
in methylcellulose containing SCF, GM-CSF, IL-3 and EPO (H4434 StemCell Technolo-
gies), and cultured for 14 days (CFU-assay). Colonies were scored by two independent 
observers according to standard guidelines for the definition of CFU-GEMM, BFU-e, 
CFU-GM, CFU-G and CFU-M. Results are depicted as the average of duplicate dishes. 
After scoring of colonies in the CFU-assay, cells were harvested and phenotyped for 
the expression of CD45, CD14 and CD235a by flow cytometry as described above.
Gene expression
Total RNA was isolated from MSCs obtained at passage 2 to 3 using a Qiagen 
RNeasy Minikit (Qiagen, Hilden, Germany). mRNA was profiled using Deep-SAGE 
sequencing using Illumina technology.(Mastrokolias, 2012) CATG was added to the 
5’ end of the 17 base pair sequences obtained. Data were mapped against the UCSC 
hg19 reference genome using Bowtie for Illumina (version 1.1.2) with the permission 
of one mismatch and suppression of reads if more than one best match existed. Tags 
aligned to the same gene were summed for further analysis. Gene information was 
added to the sequences with the biomaRt package in R (version 2.16.0). 
Expression of genes of interest was validated using independent biological samples 
by RT-qPCR after generation of cDNA (cDNA synthesis kit, Roche, Basel, Switzer-
land) using the listed primers (Supplementary Table S1), as previously described.
(Mastrokolias, 2012) Expression levels were calculated relative to expression of the 

























Graphpad 6 (Prism, La Jolla, CA) was used for data-analysis. Mann-Whitney and Wil-
coxon matched-pairs signed rank tests were performed to compare different groups 
in functional assays. Validation of gene-expression amongst the different groups 
was compared using Mann Withney tests. Differential gene expression analysis was 
performed using the following data analysis packages in R (version 2.15.0): EdgeR 
(version 3.2.4) for data normalization, Globaltests (version 5.12.0) for gene-ontology, 
and Limma (version 3.16.7) for correction of multiple testing performed according to 
Benjamini and Hochberg.(Robinson, 2010; R Development Core Team, 2012; Smyth, 
2005; Hochberg, 1990) STRING version 9.1 software was used for analysis of protein 
interaction (string-db.org).(Franceschini, 2013) Adjusted p-values <0.05 were consid-
ered statistically significant.


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































GO:0002252 0.0001 immune effector process 8.65E-09 305
GO:0002253 0.0005 activation of immune response 3.27E-08 235
GO:0050778 0.0005 positive regulation of immune response 3.29E-08 283
GO:0007186 0.0006 G-protein coupled receptor signaling pathway 3.98E-08 520
GO:0043254 0.0011 regulation of protein complex assembly 6.57E-08 152
GO:0007005 0.0015 mitochondrion organization 9.59E-08 201
GO:0051091 0.0015 positive regulation of sequence-specific DNA 
binding transcription factor activity
9.66E-08 161
GO:0002250 0.0027 adaptive immune response 1.67E-07 148
GO:0002460 0.0028 adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domains
1.77E-07 133
GO:0035270 0.0037 endocrine system development 2.33E-07 120
GO:0002449 0.0038 lymphocyte mediated immunity 2.42E-07 113
GO:0002443 0.0040 leukocyte mediated immunity 2.51E-07 148
GO:0016567 0.0041 protein ubiquitination 2.60E-07 513
GO:0031396 0.0043 regulation of protein ubiquitination 2.70E-07 160
GO:0051260 0.0061 protein homooligomerization 3.84E-07 205
GO:0031625 0.0083 ubiquitin protein ligase binding 5.30E-07 134
GO:0044389 0.0083 small conjugating protein ligase binding 5.30E-07 134

























Supplementary Figure 1. JMML and healthy control (HC) MSCs have a different gene-expression pro-
file. In this heat-map the 100 differentially expressed genes detected by Deep-SAGE sequencing are 
depicted demonstrating clustering of healthy control (HC) derived bone-marrow (BM) MSC (n=8) and 





host disease in children: histology 
for diagnosis, mesenchymal stromal 
cells for treatment and biomarkers for 
prediction of response.
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Steroid non-responsive acute graft-versus-host disease (aGvHD) following hema-
topoietic stem cell transplantation carries a poor prognosis. Various groups have 
reported beneficial effects of mesenchymal stromal cell (MSC) infusion as salvage 
treatment. Response to treatment is typically evaluated using the diagnostic clinical 
criteria for aGvHD. In this study we report the usefulness of additional gastrointes-
tinal biopsy specimens paired with serum biomarkers. In a cohort of 22 pediatric 
patients, persistent or recurrent diarrhea was seen in 18 children treated with MSC 
infusion for steroid-refractory aGvHD. To exclude other causes of gastrointestinal 
pathology, patients were biopsied for histological analysis. Eight out of 12 patients 
exhibited residual tissue damage and villous atrophy, but no active aGvHD. Serum 
biomarkers have been identified as an alternative tool for monitoring the response 
to aGvHD treatment. The value of biomarkers for inflammation, tissue and endothe-
lial cell damage was evaluated in our cohort. Although predictive for response to 
treatment and survival, these markers lack the necessary specificity and sensitivity 
to predict response to MSC therapy. Objective endpoints for clinical trials on the 
treatment of steroid-refractory aGvHD remain to be defined. Thus, we recommend 


























Acute graft-versus-host disease (aGvHD) is a major complication after allogeneic 
hematopoietic stem cell transplantation (HSCT) mediated by alloreactive donor T lym-
phocytes targeting skin, gut and liver.(Couriel, 2004a; Goker, 2001) Gastrointestinal 
(GI) aGvHD is clinically graded according to volume of diarrhea, severity of abdominal 
pain and presence of paralytic ileus.(Ball, 2008c) Children with the most severe forms, 
namely grade III-IV aGvHD, have substantially reduced survival, especially those re-
fractory to initial treatment with systemic steroids.(Deeg, 2007; Davies, 2009) 
Mesenchymal stromal cells (MSCs) are non-hematopoietic cells capable of inducing 
immunosuppressive and anti-inflammatory effects.(Aggarwal, 2005; Krampera, 2003) 
MSCs were first administered to a child with steroid refractory aGvHD in 2014, leading 
to resolution of symptoms.(Le Blanc, 2004) Subsequent studies reported response rates 
to MSC therapy for aGvHD ranging from 30% to 80% with a trend toward better response 
in children.(Le Blanc, 2008; Kebriaei, 2009; Prasad, 2011; von Bonin, 2009; Lucchini, 
2010) These studies used different end-points to document the response to MSC infu-
sion, such as best ever response(Le Blanc, 2008) or response on day 28 to 32 after 
treatment initiation.(Kebriaei, 2009; Prasad, 2011; von Bonin, 2009; Lucchini, 2010) 
One as-yet unpublished study, that randomized patients for treatment with either MSCs 
and steroids or with steroids only did not confirm these observations.(Martin, 2010) 
Nonetheless, in all studies to date irrespective of outcome, response to MSCs treat-
ment has been based upon assessment of clinical parameters, originally developed 
for the diagnosis of aGvHD.(MacMillan, 2002) As such, multiple MSC infusions have 
been administered to patients with persistent diarrhea in the absence of confirmatory 
histological evidence of GI aGvHD. However, persistent diarrhea has been described 
after resolution of GI aGvHD documented by histology.(Ball, 2008b) In addition, 
studies of the effect of MSC infusion in other inflammatory bowel disease, such as 
Crohn’s disease, included endoscopic evaluation after MSC infusion as an endpoint 
of treatment response.(Ciccocioppo, 2011; Duijvestein, 2010) This indicates that the 
assessment of serial gastrointestinal biopsies might be necessary to determine for 
evaluating the response to experimental interventions in these patients. Obtaining 
biopsy specimens might be feasible in all cases, however, and thus alternative predic-
tors of response should be explored.
Serum biomarkers, including IL-8, TNF receptor 1 (TNFr1), IL-2 receptor alpha (IL-
2rα), and hepatocyte growth factor (HGF), have been identified as supportive markers 
to substantiate the diagnosis and predict response to treatment and outcome of 
aGvHD.(Paczesny, 2009; Paczesny, 2013) In addition, serum concentrations of tissue-
specific biomarkers, including regenerating islet derived 3 alpha (REG3α),(Ferrara, 
2011) soluble cytokeratin 18 (CK18) fragments (sCK18f)(Luft, 2007) and thrombo-
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modulin (sTM)(Luft, 2011) for GI aGvHD and elafin(Paczesny, 2010) for skin aGvHD, 
have been correlated with local tissue damage. However, the usefulness of these 
markers has not been investigated systematically or compared with serial biopsy 
specimens during MSC treatment of steroid-refractory aGvHD.
In our center, a substantial pediatric cohort has been treated with MSCs for 
steroid-refractory aGvHD involving the gut in an institutional ethically approved non-
randomized study. GI biopsy specimens were obtained at the onset of aGvHD and 
after MSC infusion. The present study focused on the relevance, safety and feasibility 
of performing GI endoscopy to obtain biopsy specimens during experimental trials 
on aGvHD, and investigated the added value of different biomarkers in objectively 
evaluating the effect of MSC infusion.
Patients and materials
Patients
Children diagnosed with grade III/IV steroid refractory aGvHD after allogeneic he-
matopoietic stem cell transplantation (HSCT) were treated with MSCs (protocol LUMC-
MEC: P05-089). For the purpose this study, steroid-refractory aGvHD was defined as 
progression of symptoms at 72 hours or no improvement or worsening at 7 days 
after initiation of methylprednisolone (2 mg/kg/day). All eligible pediatric patients 
(n=22), age 0-18 years, who underwent HSCT in the pediatric stem cell transplant unit 
of Leiden University Medical Center between January 2005 and November 2012 were 
included in this study. Five of these patients were previously reported in a multicenter 
analysis of outcome of MSC therapy for aGvHD.(Le Blanc, 2008) Patients referred to 
our center solely for MSC infusions only were not included in this analysis. General 
patient and transplant characteristics are summarized in Table 1. Median duration of 
follow-up of survivors after HSCT was 379 days (range, 242 to 2708 days). 
MSC expansion, characterization and quality control have been described previ-
ously.(Le Blanc, 2008) Patients received third party, bone marrow-derived expanded 
MSCs in doses ranging from 1.0 to 2.0x10e6 MSCs/kg at a median of 12 days after 
initiation of steroids. A median of 2 (range, 1 to 3) MSC infusions was given. Subse-
quent MSC infusions were administered in 18 patients for persistence or after recur-
rent symptoms during reduction of pharmaceutical aGvHD therapies at a median of 
14 days (range, 7 to 42 days), with the majority (14 of 18) receiving a subsequent 
infusion within 28 days after the first MSC infusion. No patient received additional 
pharmacological immunosuppression after MSC infusion. Six patients with a partial 
response who remained steroid-dependent, received a third MSC infusion at a median 
























Table 1. Characteristics of 22 children mith severe gastrointestinal aGvHD
Characteristic Value
Follow-up (days; median; range) 344 (121 - 2587)
Diagnosis ALL/AML 9
Other hematologic malignancies 6
Nonmalignant disorder 7
Relapse after HSCT 3
Age at HSCT median (range) 6.3 (0.7 - 18.1)
Sex (M/F) 12/10
Donor HLA-identical related 7
Matched Unrelated donor 5
Mismatched Unrelated donor 10
Stem cell source (BM/PBSC/CB) 13/4/5
Donor sex (M/F) 12/10
Conditioning TBI based MAC 5
Busulphan based MAC 14
Other MAC 2
RIC 1
Serotherapy + rATG/Campath 13/3
GvHD prophylaxis CsA 7
CsA + MTX 10
CsA + prednisolon (1 mg/kg) 5
aGvHD organs involved GI only 2
GI and skin 10
GI and liver 5
GI, skin and liver 5
aGvHD grade III 14
IV 8
aGvHD GI stage 2 2
3 16
4 4
Median days between start aGvHD and first MSCs 12 (5 - 59)
Other 2nd line therapy Total 6
Steroids 3-5 mg/kg 5
MMF / Tacrolimus 3
ALL acute lymphatic leukemia; AML acute myeloid leukemia; HSCT hematopoietic stem cell transplan-
tation; HLA human leukocyte antigen; BM bone marrow; PBSC peripheral blood stem cells; CB cord 
blood; TBI total body irradiation; MAC myeloablative condtioning; RIC reduced intensity conditioning; 
rATG rabbit antithymocyte globulin; GvHD Graft-versus-Host Disease; CsA cyclosporin A; GI: gastroin-
testinal; MTX methotrexate; MSCs mesenchymal stromal cells; MMF mycophenolate mofetil.
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Endoscopy, biopsies and pathology report
The diagnosis of GI aGvHD was histologically confirmed in 19 patients according to 
published criteria,(Washington, 2009) at 5 days after the first MSC infusion in 1 child 
and prior to the start of MSC therapy in the other 18 children. Endoscopic procedures 
to obtain biopsy specimens were performed by 2 experienced pediatric gastroenter-
ologists. Five patients underwent 2 endoscopic procedures before MSC infusion, 2 of 
whom underwent an additional endoscopy after negative aGvHD results obtained by 
proctoscopy. Biopsy specimens were obtained from the rectum (n=14), the lower GI 
tract (n=5), or upper and lower GI tracts (n=5). One patient refused endoscopy and 
in 2 patients no biopsy specimens were obtained during endoscopy because of mas-
sive inflammation and ulceration and an increased risk of perforation. All 3 of these 
patients met the clinical criteria for aGvHD. A liver biopsy was performed in 1 child to 
confirm liver involvement. Increased bilirubin levels in combination with confirmed 
GI and or skin aGvHD was considered toindicate hepatic aGvHD in 9 patients in whom 
other underlying liver pathology (e.g. concomitant viral infections, veno-occlusive 
disease or drug toxicity) had been excluded. 
Patients with persistent or recrudescent of diarrhea after MSC infusion underwent 
endoscopic to obtain biopsy specimens. Histological examination of these specimens 
was performed by 2 pathologists with access to clinically relevant details, using 
apoptosis, necrosis and denudation as characteristics for aGvHD.(Washington, 2009) 
An expert panel with extensive experience in pediatric GI pathology evaluated all 
biopsy results. In case of viral infections detected through standard PCR monitoring 
of serum or plasma for viral reactivation,(Echavarria, 2001) additional staining was 
performed to exclude viral enteritis.
Definitions
Clinical grading of aGvHD was done according to the adapted Seattle criteria.(Ball, 
2008c) The response to MSC treatment was documented at 28 days after the first MSC 
infusion, as suggested by MacMillan et al..(MacMillan, 2010) A complete response 
(CR) was defined clinically as resolution of all symptoms of aGvHD; partial response 
(PR) as improvement by at least 1 overall grade and no response (NR) as worsening 
of disease or no improvement. 
Two different time-points related to the course and initial treatment of aGvHD 
before MSC infusion were defined: (1) onset of GI aGvHD, and (2) start of systemic 
methylprednisolone administration.
Biomarkers
Serum samples were collected and stored at -20oC under protocols approved by the 
























tions were measured in samples obtained before conditioning, on the day of HSCT, 
and weekly starting 2 weeks before the onset of aGvHD. Additional samples were 
obtained immediately prior to the first MSC infusion, and weekly thereafter for 4 
weeks, followed by 2 weekly sampling for another 4 weeks. 
Systemic biomarkers (TNFr1, IL-2rα, HGF and IL-8), organ specific markers (CK18, 
sCK18F and REG3α), and sTM were monitored in all patients using enzyme linked 
immunosorbent assays (ELISA) in accordance with the manufacturer’s instructions. 
Manufacturer details, serum dilutions, and lower and upper detection limits are 
provided in supplementary Table 1 (Table S1).
Statistical analysis
Survival analysis and non-relapse mortality (NRM) were modeled with log-rank 
Mantel-Cox tests. The Mann-Whitney test was used to compare serum biomarker 
concentrations among groups with differing response to treatment. Receiving operat-
ing curves (ROC) with area under the curve (AUC) were constructed to define the 
discriminatory value of the biomarkers. Differences in serum biomarker concentra-
tions at various time points were assessed with the paired Wilcoxon signed-rank test. 
The chi-squared test was performed on categorical data. Graphpad 5 (Prism, La Jolla, 
USA) and SPSS 20 (IBM, NY, USA) were used for the statistical analyses. 
Results
Effect of MSCs and clinical evaluation of included patients
All 22 patients had worsening of symptoms or stable disease after the start of 
systemic steroid administration (2 mg/kg/day). Only 6 patients received additional 
immunosuppression with high-dose steroids (5 mg/kg/day), tacrolimus, or mycophe-
nolate mofetil as second-line therapy before MSC infusion; however, no improvement 
of skin, liver or gut symptoms was seen. The remaining children received only MSC 
infusion as additional immunosuppressive therapy.
The response documented at day 28 after the first MSC infusion was CR in 11 
patients (50%), PR in 6 patients (27%) and NR in 5 patients (23%). Overall survival was 
significantly better in patients with CR(p=0.027) compared with those with PR and 
NR (Figure 1A). Patients with CR had a significantly lower NRM (p=0.01) than those 
with PR and NR, as reported previously (Figure 1B).(Le Blanc, 2008) Response rates 
categorized according to aGvHD grade, GI stage, and organs affected are summa-
rized in Table S2. The response rate for GI aGvHD was not dependent on the overall 
aGvHD grade, the stage of GI GvHD, or involvement of other organs. Children with CR 
were more likely to undergo HSCT for a malignant disease and with a graft from an 
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HLA-identical sibling donor, and as such, significantly more children with CR received 
either no serotherapy or serotherapy with ciclosporin A only (Table S3). 
Monitoring of viral load using PCR in serum revealed infection in 14 patients, in-
cluding 7 cases of cytomegalovirus infection, 7 cases of adenovirus infection, and 5 
cases of Epstein-Barr virus infection. The presence of viremia did not influence the 
response to MSC treatment. Three patients who achieved CR relapsed from their 
underlying malignancy at days +332, +358, and +511 after HSCT, including 2 of 
4 children who underwent HSCT for relapsed or refractory acute myeloid leukemia 
or acute myeloid leukemia/myelodysplastic syndrome and in 1 of 5 children who 
underwent HSCT for high-risk or relapsed acute lymphoblastic leukemia.
GI biopsy specimens collected after MSC infusion are highly informative
Persistent diarrhea was observed in 18 children after the first MSC infusion. Accord-
ing to the study protocol, these patients were eligible for additional MSC infusions. 
Twelve of these patients underwent GI endoscopy (3 lower GI and 9 lower and upper 
GI) with biopsy at a median of 33 days (range, 19 to 59 days) after the first MSC 
infusion. The clinical decision making process for these patients is summarized in 
the flowchart in Figure 2A. In 4 out of these 12 patients, GI histology showed ac-
tive aGvHD. These 4 patients received additional MSC infusions, and 3 subsequently 
achieved CR.
At the start of the study, persistent diarrhea was an indication for subsequent 
MSC infusions, and 4 children received MSCs accordingly despite reports of negative 


















































Figure 1. Clinical response to MSC salvage therapy. Response to MSC treatment of children with ste-
roid refractory aGvHD of the gastrointestinal (GI) tract was documented clinically on day 28 after first 
MSC infusion. Patients with CR have significantly better overall survival (A) and (B) lower non-relapse 
mortality. Log-rank Mantel-Cox tests were performed for statistical analysis. CR: complete response; 
























22 patients treated with 
MSCs for GI aGVHD 
18 with persistent / 
recurrent diarrhea
1 patient died within 7 
days after 1st MSCs
1x NR
12 patients underwent 
endoscopy
6 patients did not have an 
endoscopy before 
additional MSCs were 
infused: 3x CR; 3x NR
8 patients had no 
histological signs of 
aGVHD 
4 patients had active 
aGvHD and received 
additional MSCs: 
3x CR; 1x NR
In 4 patients a negative 
PA result was not 
awaited and additional 
MSCs were infused: 
2x CR; 2x PR.
4 patients did not receive 
MSCs after a negative PA 
results: 
2x CR; 2x PR.





Figure 2. Flow diagram of patients with persistent symptoms. A) The decision to infuse additional 
MSCs was guided by the results obtained by endoscopy with biopsies in children with persistent or 
recurrent diarrhea. B) Endoscopic evaluation of grade IV aGvHD prior to MSC infusion showing hem-
orrhage, denudation of the epithelium and ulceration. Histological examination was consistent with 
aGvHD. C) Repeat endoscopy 22 days after MSC infusion showed evident healing of mucosa despite 
persistent diarrhea. Histological examination did not reveal active GvHD. CR: complete response; PR: 
partial response; NR: no response.
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MSC infusions based on negative findings on endoscopy (Figure 2B-C). Accordingly, 
the study protocol was amended to provide subsequent MSC infusion only to patients 
with histopathological features of aGVHD. 
A protocol violation and 2 refusals led to MSC infusion without prior endoscopic as-
sessment, and these 3 patients achieved CR. Three other patients were deemed unfit 
owing to worsening symptoms with multiple comorbidities and died from ongoing 
aGvHD despite additional MSC infusions.
One patient with documented Klebsiella bacteremia deteriorated after the endo-
scopic procedure despite appropriate antibiotic therapy. He died from multiple organ 
failure with no evident aGvHD in postmortem samples. No infectious complications 
associated with the procedure or any documented side effects, such as hemorrhage, 
GI perforation, or intra operative complications, occurred in any of the other patients 
Serum biomarkers concentrations are increased at the onset of aGvHD
The serum concentrations of the different biomarkers at the 2 different time 
points related to the course and initial treatment of aGvHD were compared with 
those measured at 7 days before these respective time points. All of the biomarkers 
in the panel for aGvHD defined by Paczesny et al.(Paczesny, 2009) were increased 
significantly during the progression of aGvHD to grade II or higher requiring systemic 
steroid therapy (Figure S1A-D). In addition, levels of CK18, sCK18F and REG3α were 
significantly elevated at the onset of GI symptoms (Figure S1E-G). In agreement with 
findings reported by Luft et al.(Luft, 2011), sTM serum concentrations were not 
increased at this time point (Figure S1H). Before HSCT all but 1 patient had an sTM 
concentration above the cutoff of 8 ng/mL, which has been proposed to be predictive 
for NRM (Figure S2).(Luft, 2011)
GI biomarkers display different patterns amongst patients
Longitudinal analysis of the data obtained for the various GI biomarkers revealed 
large interindividual variations. Five children with extensively documented and histol-
ogy confirmed GI aGvHD had a REG3α concentration <50 ng/mL. Response to MSC 
infusion was not related to the different patterns shown in Figure S3A-C.
No increase in CK18 and sCK18F concentrations were seen despite the occurrence 
of GI aGvHD (Figure S3E and H). A subset of patients with elevated CK18 and sCK18F 
exhibited a steep decline in serum concentrations at the start of MSC infusion (Figure 
S3D and G, respectively). Interestingly, no patients who achieved CR demonstrated 
this phenomenon (Figure S3F and I).
Although higher concentrations of sCK18F have been reported in patients with liver 
involvement,(Harris, 2012) we were unable to confirm this finding in patients with 
























TNFr1 concentration at onset of aGvHD is predictive for response to 
MSC infusion
In this analysis, we compared serum concentrations of all biomarkers between the 
patients who achieved CR (n=11) and those who achieved PR/NR (n=11). TNFr1 con-
centration at the start of systemic corticosteroid therapy were lower in patients who 
achieved CR at day 28 after first MSC infusion (p=0.049) (Figure 3A). A TNFr1 cutoff 
of 4100 pg/mL was predictive for CR and PR/NR, with a sensitivity of 63.6% (95% 
confidence interval (CI), 30.8% to 89.1%) and specificity of 72.7% (39.0% to 93.9%) at 
onset aGvHD and a sensitivity of 60.0% (95% CI: 26.2% to 87.8%) and specificity of 
81.9% (48.2% to 97.7%) at day 7 after first MSC infusion, as defined by ROC-curves 
(Figure 3A). Concentrations of other biomarkers (e.g., IL-2rα and REG3α) did not dif-
fer between patients with CR and those with PR/NR (Figure 3B-C).
At the onset of GI aGvHD and the start of MSC therapy, the ratio of sCK18F to total 
CK18 was similar in the CR and PR/NR groups (ratio ±0.4). After initiation of MSC 
therapy, the sCK18F : CK18 ratio, including all values with sCK18F > 200 U/L, was 
significantly lower in the PR/NR group (Figure 3D). 
Serum biomarkers predict survival
We compared serum concentrations of the various biomarkers at the different time 
points between patients who were alive (n=14) and those who were not alive (n=8) 
at 1 year after HSCT. Relapse-related death did not occur during the first year after 
HSCT in this cohort. Patients with aTNFr1 concentration below the median level at the 
start of systemic corticosteroids had significantly better survival (p=0.012) compared 
with those with a concentration above the median level (Figure S4). 
At day 28 after the first MSC infusion, HGF, TNFr1, IL-8 and REG3α concentrations 
were significantly increased in patients not alive at 1 year post HSCT (Figure 4A-D). 
Applying the median values as cutoff levels (HGF: 2063 pg/mL, TNFr1: 3980 pg/mL, 
IL-8: 80 pg/mL, and REG3α: 36 pg/mL), TNFr1 and REG3α concentrations were predic-
tive of survival censored for relapse (Figure 4A-D). No significant differences in IL-
2rα, CK18 or sCK18F concentrations were observed between the 2 groups (p=0.941, 
p=0.086, p=0.881, respectively; data not shown). 
Biomarker concentrations are illustrative at time of biopsy
The diagnostic value of biomarkers was compared with the histochemical evalu-
ation of GI biopsy specimens. Independently of the timing of endoscopy, IL-2rα, 
REG3α, CK18 and sCK18F concentrations were significantly higher in sera obtained 
from patients in whom GI aGvHD was histopathologically confirmed compared with 
sera from patients in whom aGvHD was histopathologically excluded (Figure 5A-B). 
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CR at day 28
PR/NR at day 28
Start
GI aGVHD First MSC MSC + 7 MSC + 28
n.s. n.s. p = .001 p = .002
p = .049 p = .053 p = .038
Figure 3. TNFr1 discriminate between patients with a CR and PR/NR upon MSC treatment. At the start 
of systemic corticosteroids and 28 days after infusion of the first MSCs serum TNFr1 concentrations 
(A), but not IL-2rα (B) and REG3α (C), are significantly lower in patients with a complete response (CR) 
on day 28 compared to patients with a partial (PR) or no response (NR). Receiver operating characteris-
tics (ROC) are shown at the different time-points for TNFr1 (A). (D) Ratio of sCK18F versus CK18 after 
MSCs discriminates between CR and PR/NR. P-values for the different time-points using area under the 
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Figure 4. Serum biomarkers 28 days after the first MSCs are predictive for survival. (A-D) HGF, TNFr1, 
IL-8 and REG3α concentrations in available samples at day + 28 after the first MSC infusion are in-
creased in patients not alive one year after transplantation. Using the median as a cut-off value, pa-
tients with low TNFr1 and low REG3α concentrations have a significantly better survival. The dotted 
horizontal line in the left panels represents the median of all values. Closed, half open and open sym-
bols were used for CR, PR and NR at day 28 after MSC infusion, respectively. Statistics were performed 
using Mann-Whitney (left panels) and Log-rank (right panels) tests.
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Figure 5. Concentrations of serum biomarkers at time of gastrointestinal biopsies. (A) Biomarker 
concentrations in serum are higher at the time of histological confirmed aGvHD compared to concen-
trations in sera taken at the time of negatively scored biopsies. A total of 45 time-points at which com-
bined biopsy and serum samples were available was evaluated independently whether this was before 
or after the first MSC infusion. (B) Sensitivity and specificity are shown by ROC curves if specificity was 
at least 80%. (C) Focusing on paired biopsy and serum samples obtained after MSC infusion, biomarker 
concentrations do not differ significantly between samples collected at the time of a positive or nega-
























sion showed a trend toward lower CK18 and sCK18F levels (p=0.08 and p=0.15, 
respectively) in biopsy-negative GI aGvHD (n=13 sample dates) compared with biopsy 
positive ongoing aGvHD (n=8) (Figure 5C). 
Discussion
Here we report the largest single-center cohort of children treated with MSCs for 
aGvHD to date in whom sequential GI biopsy specimens and serum biomarkers were 
analyzed to evaluate response to treatment. Five patients included in this study have 
been reported in a previous study on safety of MSC administration(Le Blanc, 2008) 
that did not focus on the relevance of biopsy specimens and serum biomarkers. 
Response to MSCs was scored at day +28 after the first MSC infusion, which was 
recently proposed as the optimum endpoint for evaluating response to treatment.
(MacMillan, 2010) Six patients without CR received a third MSC infusion after day +28 
and 5 of these patients subsequently achieved complete resolution of symptoms. 
Not unexpectedly, when the efficacy of MSC infusion was analyzed as the best-ever 
response, CR rates were higher compared with the response at day +28 (CR 16 vs 11, 
PR 2 vs 6, NR 4 vs 5). 
Ideally, diagnosis of aGvHD as defined by the Seattle clinical criteria ideally should 
be confirmed by a biopsy of the target organ.(Ertault-Daneshpouy, 2004) Previous 
studies of MSC therapy in children lack confirmatory biopsy data. The present 
study indicates that obtaining GI biopsies is safe and feasible in the majority (86%) 
of patients with extensive aGvHD. This is especially relevant in patients entered in 
experimental clinical studies of MSCs, extracorporeal photopheresis(Messina, 2003; 
Perfetti, 2008), anti-TNF(Couriel, 2004b; Busca, 2007), and mammalian target of 
rapamycin inhibitors(Hoda, 2010). 
Irrespective of the treatment under investigation, published data continue to define 
response based solely on clinical criteria established primarily for diagnosis. These 
criteria can be unreliable in GI aGvHD, especially in children, given that postinflam-
matory villous atrophy resulting from extensive damage of the GI epithelium is a rec-
ognized complication after severe aGvHD(Ball, 2008b). In light of this potential bias, 
the patients included in our cohort underwent both diagnostic and post-treatment 
assessment of the GI tract, including biopsy analysis in patients with persistent clini-
cal symptoms, to reliably document their response to MSCs salvage treatment. A high 
incidence (18 of 21 cases) of persistently profuse diarrhea after first MSC infusion 
was documented. On biopsy analysis, the majority of children (8 of 12) demonstrated 
no histological evidence of active aGvHD. Non-GvHD villous atrophy and introduction 
of oral feeding might have caused malabsorption and subsequent osmotic diarrhea. 
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This distinction between persistent aGvHD and diarrhea from other causes allowed 
for the pertinent use of MSC infusion and subsequently altered clinical management 
of these patients. The reliability of this approach is supported by our ability to suc-
cessfully reduce immunosuppression in patients without aGvHD after MSC infusion, 
whereas in the majority of patients with ongoing aGvHD, additional MSC infusions 
resulted in complete resolution of the disease. Moreover, feeding regimens could be 
tailored in children with post-inflammatory villous atrophy.
Owing to ethical committee and safety concerns, GI biopsies were obtained only 
for clinical indications and unlike serum biomarkers, they were not available at fixed 
time points. Because the timing of biopsy varied, an analysis based on histological 
definitions on day +28 after MSC infusion was not possible. 
Despite its demonstrated usefulness and safety profiles, endoscopy with biopsy is 
an invasive procedures general anesthesia in children. In a large multi-center study, 
especially in centers lacking pediatric gastroenterology expertise, obtaining biopsies 
might not be feasible. Thus, we determined the value of biomarkers in relation to re-
sponse as determined by clinical and pathological findings. The biomarkers studied 
in our patient cohort confirm the previously reported increase of inflammatory and 
GI specific biomarkers at the onset of aGvHD. 
Measurement of CK18 and sCK18F measured in serum at the time of biopsy has 
the potential to serve as an alternative diagnostic tool. Levels of both total protein 
and cleaved fragments were significantly increased at the time of positive GI biopsy 
compared with negative biopsy. The sensitivity (53.8% in the present study; 95% CI 
25.1% to 80.8%) and specificity (86.7% in the present study; 95% CI 69.3% to 96.2%) of 
the CK18 test remain to be validated in larger cohorts of patients, however. In addi-
tion, biomarkers not reaching statistic significance in our cohort should be evaluated 
as potential alternatives to serial biopsies in future studies. Our observed decrease 
in the sCK18F : CK18 ratio in patients not responding to MSC infusion suggests the 
occurrence of apoptosis-independent cell death after MSC infusion in these patients. 
This is in line with observations by Jitschin et al. in patients with steroid-refractory 
aGvHD or hemorrhages treated with MSC.(Jitschin, 2013) 
In accordance with von Bahr et al., we observed a lower IL-2rα concentration at day 
7 after MSC infusion, which was not correlated with the response to MSCs.(von Bahr, 
2012) This is reminiscent of the previously described decline in IL-2rα concentrations 
in both patients responding to steroids and those refractory to steroids.(Luft, 2007) 
In contrast, Dander et al. reported a correlation of biomarkers IL-2rα and TNFr1 with 
the response to MSC treatment in 10 patients with aGvHD or chronic GvHD.(Dander, 
2012) However, the timing of the measurement with regard to the sequential number 
























Selected biomarkers have demonstrated predictive value in terms of the response 
to treatment and survival at multiple time points before and after MSC infusion. 
Although these data are based on a limited number of patients, they support the 
stratification in clinical trials based on biomarkers as suggested by Paczesny et al. at 
the time of diagnosis or start of salvage therapy.(Paczesny, 2013) However, the wide 
variation in biomarker patterns observed in our patient cohort after MSC treatment 
does not allow for the substitution of a biomarker panel fo biopsy analysis to evaluate 
response and guide clinical decision making in individual patients. Our remain to be 
validated in large multicenter studies, which are currently under development. 
REG3α levels were lower in our patient cohort compared with the American cohort 
reported by Ferrrara et al., but in line with levels reported in Regensburg (Germany) 
and Kyushy (Japan) cohorts described in the same paper.(Ferrara, 2011) Unlike the 
patients in the American cohort, all of the patients in our cohort received selective 
GI decontamination with polymyxin neomycin and amphotericin B or total GI decon-
tamination with piperacillin, tazobactam and amphotericin B.(Vossen, 1990; Ferrara, 
2011) REG3α is secreted in response to bacteria, and the lower REG3α concentrations 
in our cohort might be replated to the suppression of bacterial microflora.(Ayabe, 
2000) Even at the lower levels of REG3α, the concentrations were correlated with 
aGvHD and were predictive for survival.
Along with serum biomarkers, stool and urine biomarkers also have been pro-
posed.(Rodriguez-Otero, 2012; Landfried, 2011) These materials were not available 
for analysis in the present retrospective study. Collection of uncontaminated urine 
from children with aGvHD at multiple time points is difficult, and analysis of stool 
samples for the measurement of procalcitonin in a pilot study in our center was 
complicated by insufficient material in young children (data not shown). 
The present study demonstrates the importance of critical and intensive monitoring 
of patients included in an experimental study. Before the introduction of MSC therapy, 
experience with children surviving severe aGvHD was limited. A new phenomenon, 
persistence of severe villous atrophy after resolution of aGvHD causing severe pro-
tracted diarrhea, was identified. Endoscopy with biopsy remains the golden standard 
for differentiating between active aGvHD and postinflammatory villous atrophy. In 
the later phase of this trial, additional MSC infusions were provided based only on 
clinical symptoms in combination with histological results. 
Further recommendations for steroid-refractory aGvHD that allow for comparative 
observation among various modalities of treatment are needed. Response criteria 
and timing of assessment of response remain to be defined, preferably through 
consensus of the transplant organizations, such as the Center for International Blood 
and Marrow Transplantation Research and the European Group for Blood and Marrow 
Transplantation. Based upon our findings reported here, these criteria should include 
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biopsy analysis and serial serum biomarker concentrations at diagnosis and after 
treatment in patients with persistent clinical symptoms.
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Table S1: ELISA antibodies used









HGF R&D, Minneapolis, MN, USA 2 250 16000 pg/mL
IL-8 R&D, Minneapolis, MN, USA 5 20 8335 pg/mL
IL-2Rα R&D, Minneapolis, MN, USA 5 156 10000 pg/mL
TNFR1 R&D, Minneapolis, MN, USA 20 250 16000 pg/mL
Cytokeratin M30 Peviva, Bromma, Sweden 1 75 1000 U/L
Cytokeratin M65 Peviva, Bromma, Sweden 1 200 5000 U/L
REG3α MBL International, Woburn, MA, USA 10 16 1000 ng/mL
Trombomodulin Sanquin, Amsterdam, the Netherlands 5 1 50 ng/mL
Table S2: Response at 28 days after first MSCs
CR/PR/NR
Overall Prior to MSC 11 / 6 / 5
Grade III 6 / 6 / 2
IV 5 / 0 / 3
Stage GI 2 1 / 1 / 0
3 7 / 5 / 4
4 3 / 0 / 1
Organs affected GI 2 / 0 / 0
GI + skin 2 / 4 / 4
GI + Liver 3 / 2 / 0
GI + liver + skin 4 / 0 / 1
CR: complete response; PR: partial response; NR: no response; GI: gastrointestinal
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Table S3: Differences between CR and PR/NR group
CR PR/NR P -value
N 11 11
HSCT for malignancy 10 5 P = .022
Age (years)* 12.52 (1.3 - 18.1) 4.08 (0.7 - 16.2) P = .071
Donor HLA-id related 6 1 P = .022
10/10 or 6/6 matched 9 3 P = .010
Donor source BM vs other 8 5 P = .193
time HSCT to onset aGVHD (days)* 47 (12 - 100) 28 (6 - 46) P = .061
time onset aGVHD to first MSC (days)* 14 (7 - 59) 9 (0 - 31) P = .411
Liver involvement 7 3 P = .087
Skin involvement 6 8 P = .375
Prophylaxis CsA only 7 0 P = .001
Conditioning TBI 3 2 P = .611
Serotherapy yes 5 11 P = .004
MSC as third line therapy 3 3 P = 1.00
Total number of MSC infusions 20 26 P = .135
CR: complete response; PR: partial response; NR: no response; BM: bone-marrow; HSCT: hematopoi-
etic stem cell transplantation; aGVHD: acute graft-versus-host disease; CsA: ciclosporin A; TBI: total 




















































































   
















































































































































































































































   














































































































































































































































   








































































































































































































































   








































































































































































































































   



















































































































































































































































































































































































































































































































































































Figure S2. Soluble trombomodulin (sTM) concentrations at different time points. sTM concentrations 
were higher than the cut-off value (dashed line) used by Luft et al.(17) at all time-points starting be-
fore conditioning. Samples included before start of steroids were collected 6-12 days prior to start of 


















































































































































































































Figure S3. Longitudinal patterns of gastrointestinal biomarkers. Patients are categorized according to 
low (A), intermediate (B) or high (C) levels of REG3α at the time of first MSC infusion. Different patterns 
were observed in CK18 (D-F) and sCK18F (G-I) concentrations. 5 patients showed a steep decline of 
CK18 and sCK18F after MSC infusion (D, G) and two patients had no increase in CK18 (<1000 U/L) or 
sCK18F (<400 U/L) (E, H). The remaining patients had an increase, but no rapid, consistent, decrease 
after MSC infusion (F, I). P-values were calculated using chi-squared tests. † indicate samples collected 


































Alive at 1 year
Figure S4. TNFr1 concentrations at start of aGvHD are predictive for survival. (A) Patients alive at 1 
year after HSCT have lower TNFr1 concentrations at start of systemic steroids. (B) Patients with low 
TNFr1 concentrations have significantly better survival. Wilcoxon signed rank test; horizontal line 
represents median value.
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Mesenchymal stromal cell therapy is 
associated with increased adenovirus-
associated, but not cytomegalovirus-
associated mortality in children with 
severe acute Graft-versus-Host Disease.
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Beneficial effects of mesenchymal stromal cells (MSCs) in patients with severe 
steroid-refractory acute graft-versus-host disease (aGvHD) have been reported. 
However, controversy exists about the effect of MSCs on virus-specific T cells. We 
evaluated 56 patients with grade II-IV aGvHD who responded to steroids (n=21), or 
were steroid-refractory receiving either MSC (n=22) or other second-line therapy 
(n=13). Although the overall incidence of cytomegalovirus (CMV), Epstein-Barr virus 
and human adenovirus (HAdV) infections was not significantly increased, HAdV 
infection was associated with decreased survival in children treated with MSCs. 
Therefore, we investigated in vitro the effects of MSCs on virus-specific T cells. Both 
CMV-specific and, to a lesser extent, HAdV-specific T cell activation and proliferation 
were negatively affected by MSCs either after induction of a response in peripheral 
blood mononuclear cells (PBMC) or after restimulation of virus-specific T cell lines. 
In patient-derived PBMC, CMV-specific proliferative responses were greatly decreased 
on first line treatment of aGvHD with systemic steroids and slowly recovered after 
MSC administration and tapering of steroids. HAdV-specific T cell proliferation could 
not be detected. In contrast, the proportion of CMV and HAdV-specific effector T 
cells, measured as interferon-γ-secreting cells, remained stable or increased after 
treatment with MSCs. In conclusion, although in vitro experimental conditions in-
dicated a negative impact of MSCs on CMV- and HAdV-specific T cell responses, no 
solid evidence was obtained to support such an effect of MSCs on T cell responses 
in vivo. Still, the susceptibility of steroid-refractory severe aGvHD patients to viral 
reactivations warrants critical viral monitoring during randomized controlled trials on 



























Mesenchymal stromal cells (MSCs) are multipotent non-hematopoietic cells that 
can be easily expanded in vitro. In culture, MSCs remain genetically stable and their 
low immunogenicity makes them suitable candidates for immunotherapy.(Dominici, 
2006; Bernardo, 2007c) In in vitro studies MSCs have been shown to suppress pro-
liferation and activation of T lymphocytes, B lymphocytes, natural killer cells, and 
monocytes.(Sotiropoulou, 2006; Traggiai, 2008b; Krampera, 2003; Melief, 2013) 
Although cell-cell interaction and various soluble factors have been reported to medi-
ate the in vitro (Gieseke, 2010; Meisel, 2004; Selmani, 2008; Mougiakakos, 2011) im-
munomodulatory effect of MSCs, the mechanism(s) underlying the in vivo (Ren, 2008; 
Gonzalez, 2009) suppressive capacity of MSCs remains further to be elucidated. 
In clinical studies, MSCs showed beneficial effects in patients with steroid-refractory 
acute graft-versus-host disease (aGvHD), autoimmune disorders and auto-inflamma-
tory diseases.(Sun, 2009; Le Blanc, 2008; Garcia-Olmo, 2005) Although dampening 
of alloreactive or autoimmune-driven inflammatory reactions is frequently observed 
after MSC infusion, overall down modulation of immune responses might increase 
the risk of viral infections. Infectious complications are a major cause of morbidity 
and mortality after allogeneic hematopoietic stem cell transplantation (HSCT).(Bro-
ers, 2000; Boeckh, 2003; Walls, 2003) In part, this is related to the delayed immune 
reconstitution following HSCT; however, infections can also be exacerbated by ad-
ditional immunosuppression, such as systemic steroids given for the treatment of 
aGvHD.(Cantoni, 2010)
Published data on the effect of MSCs on virus-specific T cells are somewhat 
conflicting. Karlsson et al.,(Karlsson, 2008) reported no effect of MSCs on the two 
major viral pathogens in HSCT related to T cell expansion and cytotoxicity specific 
to cytomegalovirus (CMV) and Epstein-Barr virus (EBV) specific. However, in a recent 
study, von Bahr et al.(von Bahr, 2012) commented on high peak levels of CMV DNA 
load shortly after MSC infusion, suggesting a suppressive effect of MSCs on CMV-
specific immunity. No data are available on the effect of MSCs on human adenovirus 
(HAdV) infections, which occur at a high frequency (up to 40%) in pediatric graft 
recipients(Flomenberg, 1994; Howard, 1999; Baldwin, 2000) and are lethal in up to 
50% of cases with disseminated infection.(Walls, 2003; Kojaoghlanian, 2003; Leen, 
2005; van Tol, 2005b) 
At the Leiden University Medical Center, a large cohort of children with steroid-
refractory aGvHD has been monitored closely after receiving MSC infusions. In the 
present study, the prevalence, course and outcome of viral infections after HSCT in 
this cohort were documented. These data were compared with a cohort consisting 
of children developing aGvHD responding to steroids and with a group of historic 
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controls with steroid-refractory aGvHD who did not receive MSCs as second/third line 
treatment.
Because both viral infections and aGvHD often occur coincidentally, it is important 
to further investigate the impact of MSCs on virus-specific T cell responses. Thus, we 
studied the influence of MSC in co-cultures with T lymphocytes at different stages of 
differentiation, with T cells naturally present among peripheral blood mononuclear 
cells (PBMC) and with in vitro expanded virus-specific T cell lines. We focused on 
CMV and HAdV, because of the potentially severe clinical impact of these viruses in 
pediatric HSCT. To analyze the in vivo effect of MSC on virus-specific T cell responses, 
PBMC of patients treated with MSCs after HSCT were longitudinally investigated for 
their reactivity against CMV and HAdV.
Material and methods
Patients and definitions
All patients (n=22) treated with MSC for steroid-refractory aGvHD grade II-IV from 
2004 until 2012 according to an ethical approved protocol (number LUMC-MEC: P05-
089) were included in the current study. Patients received 1 to 3 third-party, bone 
marrow derived, MSC infusions consisting of 1-2 x 106 MSCs per kg recipient body-
weight, as previously described.(Le Blanc, 2008; Calkoen, 2013b) Full resolution of 
symptoms at 28 days after the first MSC infusion was defined as complete response 
(CR). Partial response (PR) was defined as at least one grade improvement and no 
response (NR) was defined as stable disease or worsening of symptoms. Viral status 
of CMV, EBV and HAdV was routinely monitored by polymerase chain reaction on 
plasma samples. For the purpose of the study, but in contrast to the cutoff of log 3.0 
copies per milliliter commonly used to define a disseminated infection, viral infection 
or reactivation (referred to in this paper as “infection”) was defined as the presence 
of at least log 2.3 copies per milliliter, in two samples taken with a time interval of at 
least 3 days. This allowed the inclusion of all patients with viral infections. Monitoring 
frequency in the first two months after HSCT varied between weekly and every 2 
weeks thereafter until immune recovery (defined as ≥300 CD3+ T cells per milliliter of 
blood) was observed. Pre-emptive treatment with ganciclovir (CMV), rituximab (EBV) 
or cidofovir (HAdV) was initiated on detection of log ≥3 viral DNA copies per milliliter 
at two or more consecutive time points. Viral infections resolving before onset of 
severe aGvHD (defined as start of systemic steroid therapy) or occurring more than 
90 days after the first MSC infusion were not taken into account.
Control cohorts consisted of patients with grade II-IV aGvHD who either responded 


























but received second- or third-line treatment other than MSCs (historic controls: HSCT 
performed in the period 1994 to 2004, n=13). Patient and transplant characteristics 
of the study cohort and both control groups are summarized in supplementary Table 
1 (Table S1). 
Patient materials
PBMC collected weekly prior to and after MSC infusion as well as PBMC stored 
after routine immunophenotyping post HSCT (ethical approved protocols LUMC-MEC 
P01-028 and P03-061) were used for this study. Whenever possible, PBMC were in-
vestigated at the following time-points: before the start of systemic steroids, before 
the first MSC infusion, 7-14 days after first MSC infusion, 7-14 days after subsequent 
MSC infusions and 180 and 365 days after the first MSC infusion. Cryopreserved 
PBMC of patients after HSCT were used after thawing and resting for 4 hours at 
37°C, 5% CO2 in RPMI 1640 (Invitrogen, Paisley, UK) supplemented with 100 U/mL 
penicillin, 100 μg/mL streptomycin (P/S; Invitrogen), 10% human serum (HS, Sanquin, 
Amsterdam, the Netherlands).
MSC isolation and culture for in vitro experiments
Fresh bone marrow samples of 10 healthy pediatric stem cell donors were used 
for MSC expansion. Parental donor and age appropriate pediatric donor informed 
consent forms were signed in all cases. The study, approved by the ethical commit-
tee of the Leiden University Medical Center (LUMC-MEC P08-001), was performed in 
accordance with the Declaration of Helsinki.(World Medical Association, 1997) After 
Ficoll separation, bone marrow mononuclear cells were plated in polystyrene culture 
flasks at a density of 0.16 x 106 cells/cm2. Cells were cultured in Dulbecco’s modified 
Eagle medium with Glutamax (DMEM; Invitrogen) supplemented with P/S and 10% 
fetal bovine serum (FBS; VWR International, Bridgeport, NJ). Medium was refreshed 
every three to four days. Cultures were harvested at 80% confluency by treatment 
with trypsin (Invitrogen), replated and maintained for maximally 6 passages at 37°C 
and 5% CO2. All MSC cell lines were phenotypically characterized at their second or 
third passage using antibodies against CD3, CD45, CD86, human leukocyte antigen-
DR (HLA-DR), CD31, CD34, CD73 and CD90 (all Becton Dickinson Biosciences (BD), 
San Diego, CA). CD105 was obtained from Ancell Corporation (Bayport, MN). The 
osteoblast and adipocyte differentiation potential was evaluated on cells at passage 
4 to 6 as described previously.(Bernardo, 2007b; Calkoen, 2013a) After 3 weeks, fat 
vacuoles in adipocytes and calcified depositions in osteoblast were stained with Oil-




PBMC were stimulated with methylene blue photoinactivated HAdV (multiplicity of 
infection: 100) or 11 amino acids overlapping 15-mer peptide pools with HAdV hexon 
Peptivator (0.6 nM Miltenyi Biotec, Bergisch Gladbach, Germany) or CMV pp65 pep-
tides (1.0 nM, Department of Immunohematology, Leiden University Medical Center, 
the Netherlands).(Zandvliet, 2011) Phytohemagglutinin (PHA, PeproTech, London, 
UK) and interleukin-2 (IL-2 Novartis International, Basel, Switzerland) were used at 
the indicated concentrations. PBMC were stimulated directly with exogenously added 
peptides or with peptide-loaded mature dendritic cells (mDC) generated in vitro from 
purified autologous monocytes. In brief, monocytes were isolated from PBMC (3.0 x 
106/mL) by 2 hours plastic adherence and cultured for 6 days in RPMI 10% fetal calf 
serum containing 800 U/mL of granulocyte-macrophage colony-stimulating factor 
(GM-CSF; TebuBio, Le Perray-en-Yvelines, France) and 40 ng/mL of IL-4 (PeproTech). 
Immature DC (iDC) were harvested and cultured (1.0 x 105/mL) with similar concen-
trations GM-CSF and IL-4 combined with 0.25 ng/mL CD40-ligand (Beckman-Coulter, 
Marseille, France) and 500 U/mL of interferon-γ (IFN-γ; Boehringer, Mannheim, Ger-
many) for 2 days. 
Generation of virus-specific T cells
PBMC from CMV-seropositive healthy adult Sanquin Blood Bank donors and from 
donors previously screened for a measurable proliferative response to HAdV peptides 
were selected for the generation of CMV- and HAdV-specific T cell lines, respectively, 
as previously described.(Veltrop-Duits, 2006) Briefly, PBMC were stimulated with 
peptide-loaded mDC for 12 days in the presence of IL-2 (10 IU/mL) and IL-7 (5 ng/
mL, Peprotech). T cell lines were harvested on day 12 and restimulated with 30-Gray-
irradiated peptide-loaded autologous PBMC and IL-2 and IL-7 for an additional 16 
days, after which the virus-specific T cell lines were harvested and cryopreserved.
Co-culture experiments
PBMC (100,000 cells per well) were co-cultured with 20,000 or 2,500 (30-Gray ir-
radiated) MSCs or without MSCs in 96-well plates. Virus-specific T cells (20,000 cells 
per well) were co-cultured with 20,000, 4,000 or 500 (irradiated) MSCs or without 
MSCs. PBMC directly stimulated with virus-derived peptides were cultured for 7 
days. PBMC stimulated with viral peptide-loaded mDC or virus-specific T cell lines 
were cultured for 5 days after defining the optimal culture duration in preliminary 
experiments. Negative controls with cells cultured with either unpulsed mDC or with 
no exogenously added viral peptides were included. Proliferation was assessed by 
addition of 3H-thymidine (1 μCi per well; Perkin Elmer, Waltham, MA, USA) for the last 


























enzyme-linked immunosorbent assay (Sanquin) performed according to the manu-
facturer’s instruction.
Flow cytometry
Monoclonal antibodies (mAbs) used to characterize the T cells proliferating in cul-
ture were: anti-CD3 PerCPC5.5 (Becton Dickinson (BD), Mountain View, CA), anti-CD4 
APC (Beckman Coulter Immunotech, Marseille, France), anti-CD8 PE (BD), anti-CD8 
APC (Beckman Coulter). Prior to stimulation, cells were labeled with carboxyfluo-
rescein succinimidyl ester (CFSE, Invitrogen) to discriminate between proliferating 
and non-proliferating cells. To determine activation and the differentiation stages of 
virus-specific T cell lines, the mAbs anti-HLA-DR FITC (BD), anti-CD45RA PE (Beckman 
Coulter) and anti-CCR7 FITC (R&D, Minneapolis, MN) were applied. T cell differentiation 
stages were defined as “naïve”: CD45RA+CCR7+; “central memory”: CD45RA-CCR7+; 
“effector memory”: CD45RA-CCR7- and “end-stage effector cells”: CD45RA+CCR7-. 
Virus-specific T cell stimulation of patient-derived PBMC
Disseminated EBV reactivations in three HSCT patients were successfully treated with 
rituximab; therefore, functional studies focused on the detection of CMV- and HAdV-
specific T cells. To detect IFN-γ-secreting cells, ELISpot plates (Millipore, Billerica, MA) 
were coated with anti-IFN-γ antibody (Mabtech, Stockholm, Sweden) overnight. PBMC 
(0.2 x 106 cells per well) were stimulated with CMV or HAdV peptides with or without 
a low dose of IL-2 (3 IU/mL) for 20 hours. PBMC cultured without stimuli or with low 
dose IL-2 only were used as negative controls. PBMC stimulated with PHA (10 ug/mL) 
plus a high dose of IL-2 (50 IU/mL) was used as positive controls. 
IFN-γ was detected by anti-IFN-γ-biotin antibody (Mabtech) and visualized by 
streptavidin-alkaline phosphatase (Sigma, St Louis, MO) and its substrate 5-chromo-
4-chloro-3-indolyl phosphate (BCIP; Sigma). IFN-γ spots were counted with a fully 
automated, computer-assisted, video-imaging analysis system (BioSys 5000, Karben, 
Germany). Virus-induced ELISpot results were compared to background levels ob-
served in cultures without viral peptides. Values of more than 10 spots per 200,000 
cells and at least two times higher than background were considered positive. All 
conditions were performed in duplicate. 
Proliferation of 1 x 105 PBMC per well was assessed by 3H-thymidine incorporation 
performed overnight after 6 days of stimulation with CMV or HAdV peptides with a 
low dose of IL-2 (3 IU/mL). PHA (2 ug/mL) plus a high dose of IL-2 (50 IU/mL) stimula-
tion for 5 days adding 3H-thymidine at day 4 was used as a positive control.
For comparison of the different time-points, viability of PBMC was determined 
after thawing and four hours of resting using trypan blue. In addition, PHA-induced 
proliferation and IFN-γ production were considered measures of general functionality 
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of the thawed cells. In cases of negative PHA proliferation time points were excluded 
from the analysis. 
Statistical analysis
Survival analysis was modeled with Log-rank Mantel-Cox tests. Paired Wilcoxon 
signed-rank tests were used to compare subsets prior to and after MSC infusion and 
for evaluation of the in vitro effect of MSCs. Chi-squared tests were performed on 
categorical data. Graphpad 6 (Prism, La Jolla, USA) was used for data analysis, and 
p-values <0.05 were considered statistically significant.
Results
Clinical results
One-year survival after HSCT in the patients treated with MSCs was higher (62.9%) 
than in historic controls (33.3%) but lower than in children responsive to steroids 
(90.5%), and did not reaching statistical significance. The latter group, being less 
severely affected regarding the grade and gut involvement of aGvHD, differed sig-
nificantly from the MSC group (Table S1). Patients with MSCs as second-line therapy 
(n=16) showed a better one-year survival compared with patients with MSCs as third 
line therapy (n=6; 73.9% vs 33.3%, respectively p=0.049). One-year survival in the 
latter subgroup was comparable to historic controls with steroid-refractory aGvHD 
not treated with MSCs (n=13; 38.5%). 
In 14 of the 22 consecutive children treated with MSCs for steroid-refractory aGvHD 
grade III-IV viral infections were present either at the onset of severe GvHD or occurred 
within a period of 90 days after the first MSC infusion (Table 1). Seven patients had 
a CMV infection, seven patients had an HAdV infection, and five patients had an EBV 
infection; multiple viral infections occurred in 5 out of 22 enrolled patients. Overall 
survival at 1 year after HSCT, censored for relapse, was higher (but not significantly) 
in patients without viral infection (Figure 1A). Survival in historic controls (n=13, six 
children with an infection) with steroid-refractory aGvHD receiving no MSCs showed 
the same trend (Figure 1B; HAdV, n=4; CMV, n=3; EBV, n=3). In contrast, the one-year 
survival in the control cohort with steroid-responsive patients was comparable for 
children with (n=7) and without (n=14) a viral infection (Figure 1C; HAdV, n=3; CMV, 
n=4; EBV, n=3). Although, not statistically significant (p=0.09), there was a trend to 
a higher percentage of viral infections and a longer duration of viremia in the MSC-
treated children compared to patients responsive to steroids only (data not shown). 
In contrast to CMV and EBV infections, HAdV infection was significantly associated 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ent after start of MSC therapy were associated with a poor outcome; none of these 
patients (n=6) including two patients with recurrence of CMV were alive at 1 year after 
HSCT, whereas five of six patients with a CMV (n=5) or HAdV (n=1) infection present 
before and persisting during aGvHD were alive at 1 year after HSCT (Table 1). Six 













































































































































































Steroid refractory: MSC treated
Steroid refractory: other therapy
Figure 1 HAdV infections negatively affect the survival of patients treated with MSCs for steroid re-
fractory aGvHD. A-C: The one-year survival of patients in relation to viral infections (HAdV, CMV and/
or EBV) is depicted for steroid-refractory patients receiving MSCs (A) or other second-line therapy (B) 
and for steroid-responsive patients (C). D-E: HAdV, but not CMV or EBV was significantly associated 
with poor survival in patients treated with MSCs (D). This was not observed in steroid refractory pa-


























received other second-line treatment prior to MSC infusion. All these patients had a 
viral infection either prior to (n=3) or after MSC (n=3) infusion (Table 1). 
In the steroid-refractory patients receiving other second-line therapy and no MSCs, 
CMV was present prior to initiation of steroid therapy, whereas HAdV reactivated af-
ter start of aGvHD (Table e). None of the three viruses was associated with decreased 
survival, as seen for HAdV in the MSC cohort (Figure 1E).
The observed association between infections appearing after MSC infusion and 
decreased survival in these patients warranted further research into the possible 
effect of MSC infusion on anti-viral immunity. 
In vitro effect of MSC on virus-specific T cells
To determine the putative negative effect of MSCs on HAdV-specific T cells, PBMC 
obtained from healthy adult donors with demonstrable precursor frequencies of 
viral-specific T cells (data not shown) were stimulated with inactivated HAdV in the 
presence or absence of MSCs. MSCs suppressed the proliferative response, but not 
the IFN-γ production in these co-cultures (Figure 2A-B). To exclude bystander immune 
activation induced by TLR ligands or other non-specific virus-derived stimuli, experi-
ments were also performed using synthetic, good manufacturing practices-grade, 15-
mer viral peptides. In cultures of PBMC stimulated with HAdV hexon-derived peptides, 
proliferation and IFN-γ production were low, and no suppressive effect of MSCs was 
observed in either assay (Figure 2C-D). In contrast, after stimulation with synthetic 
CMV pp65-derived peptides, MSCs showed an inhibitory effect on proliferation and 
IFN-γ production (Figure 2C-D). Phenotypic analysis of T cells in CMV-stimulated cul-
tures demonstrated a suppressive effect of MSCs on both CD4+ and CD8+ T cells. This 
was assessed in proliferation assays using CFSE staining and in assays measuring the 
percentage of cells expressing HLA-DR after antigen-specific activation (Figure 2E-F). 
Stimulation of PBMC with peptide-loaded autologous monocyte-derived 
dendritic cells
Conflicting results were obtained when investigating the interaction of MSCs and 
HAdV-specific T cells after employing two ways of stimulation and using two different 
read-out systems. Consequently, we decided to stimulate PBMC from healthy adult 
donors with peptide-loaded autologous mDC. MSCs suppressed PBMC proliferation 
after stimulation with CMV-peptides or HAdV-peptide-loaded mDC (Figure 3A). 
IFN-γ production was suppressed by MSCs in co-cultures after stimulation with CMV 
PepTivator with or without IL-2, (although not significantly, p=0.06), but not after 
stimulation with HAdV PepTivator (Figure 3B). Altogether, these data suggest that 
the height of the response generated in vitro is of importance for the detection of a 
suppressive effect of MSCs.
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Inhibitory effect of MSCs on virus-specific T cell lines
To combat viral infection, activation and clonal expansion of memory T cells is 
of importance. Consequently, the effect of MSCs on virus-specific T cell lines was 
investigated. T cell lines raised against HAdV-derived peptides consisted mainly of 
CD4+ T cells. The ratio of CD4+ to CD8+ T cell in CMV-specific T cell lines varied 
(Figure S1A). The percentage of T cells expressing HLA-DR was significantly higher 
in CMV T cell lines than in HAdV T cell lines, regardless of the ratio of CD4+ to CD8+ 
T cells (Figure S1B). All cell lines were predominantly of effector memory phenotype 
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A B C D
E F
Figure 2. MSCs suppress PBMC proliferation. A-B: In cultures of PBMC stimulated with inactivated 
HAdV, proliferation at day 7 (A) was suppressed by the addition of MSCs, whereas IFN-γ concentra-
tion in supernatant obtained at day 6 (B) was not affected (n=4). C-D: After stimulation of PBMC with 
CMV (pp65 peptides) and IL-2 (3 IU/mL) proliferation (C) and IFN-γ concentrations (D) were lower in 
conditions with than without (wo) MSCs. Activation with HAdV (hexon peptides) plus IL-2 was lower 
compared to CMV plus IL-2 and was not affected by the addition of MSCs. E-F: In cultures of PBMC 
stimulated with CMV pp65 peptides, MSCs affected activation and proliferation of CD4+ and CD8+ T 
cells as demonstrated by decreased HLA-DR expression (E) and decreased CFSE dilution (F, representa-
tive picture of n=4 after stimulation with CMV pp65 peptides only), respectively. Box plots represent 
4 independent experiments. Boxes represent median with standard deviation. Whiskers indicate mini-


























Viral peptide-induced proliferation and IFN-γ production were suppressed in co-
cultures of HAdV- and CMV-specific T cell lines with MSCs (Figure 4A-B). HLA-DR 
expression on T cell lines stimulated with HAdV and IL-2 was decreased when T cells 
were activated in the presence of MSCs (Figure 4C). In contrast, the high percentage 
of HLA-DR-expressing cells on CMV-specific T cells was not altered (data not shown). 
Although T cell lines raised against HAdV consisted mainly of CD4+ T cells, both CD4+ 










































Figure 3. Effect of MSCs on proliferation of and IFN-γ production by PBMC stimulated with peptide 
loaded autologous mature dendritic cells (mDC). A: Proliferation after stimulation of PBMC with hexon 
peptides-loaded (HAdV) or pp65 peptides loaded (CMV) mDC was increased in co-cultures of MSC and 
PBMC at a ratio 1:5. In this set-up, a significant reduction in proliferation was observed. B: IFN-γ pro-
duction remained relatively low for HAdV compared with CMV, and no suppression was documented 
after stimulation with HAdV hexon-derived peptides. Box plots represent data of six different experi-
ments. Boxes represent median with standard deviation. Whiskers indicate minimum and maximum 
values. *: p<0.05 using paired Wilcoxon signed-rank tests. IL-2: 3 IU/mL.
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T cell lines; in both cases suppression by MSCs was documented (Figure 4D-E). In 
conclusion, in vitro MSCs have a suppressive effect on proliferation and activation of 
effector memory-type T cells. 
Virus-specific responses in HSCT patients
Sufficient frozen material collected at multiple time points was available from 8 
of the 14 children with viral infections in the cohort treated with MSCs for steroid-
refractory aGvHD. At the start of MSC therapy two of the seven patients with CMV 
infection had an undetectable viral DNA load (UPN17 and UPN20; Table 1 and Figure 
5A). In the period of 90 days after start of MSC therapy, these patients showed per-
sistent recurrence of viremia. In two of the five patients with CMV virema at the start 
of MSC therapy, the viremia resolved in this 90 days time window (UPN12 and UPN19) 
and persisted in the other three patients (UPN02, UPN11 and UPN15) (Table 1 and 
Figure 5A). 
Figure 4. Effect of MSCs on proliferation, IFN-γ production and HLA-DR expression by virus-specific T 
cell lines. A-B: MSCs suppressed proliferation of and IFN-γ production by virus-specific T cell lines (n=6) 
stimulated with HAdV hexon peptides or CMV pp65 peptides plus IL-2 (3 IU/mL). C: HLA-DR expres-
sion was lower in HAdV-specific T cell lines stimulated with HAdV and IL-2 in co-cultures with MSCs. 
A representative experiment of three cell lines is shown. D-E: Dose-dependent suppression by MSCs 
of proliferation of both CD4+ (D) and CD8+ (E) T cells after stimulation with HAdV plus IL-2 measured 
by CFSE dilution was observed. Boxes represent median with standard deviation. Whiskers indicate 


























In six of the seven patients with CMV infection, the frequency of IFN-γ producing 
cells was determined in the week before, 1-2 weeks after and 28 days after MSC 
infusion. These six patients received MSCs as second-line therapy. Both patients with 




































































































































































































Viral infection prior to MSC
DNA load below level of detection prior to MSC
Figure 5 Viral DNA loads increase around start of aGvHD despite the persistence of IFN-γ producing 
virus-specific T cells in patients treated with MSCs. A-B: At 28 days after MSC infusion, CMV DNA 
loads were increased in two patients, UPN17 and UPN20, (A), however, the number of CMV-specific 
IFN-γ-producing cells was not affected (B). C-D: In two children UPN12 (C) and UPN19 (D), CMV-specific 
proliferation could be detected by 3H-thymidine incorporation. Proliferation was decreased after start 
of steroids. E-F: In 5 patients HAdV DNA loads were detected at 28 days after MSC infusion (E). Plasma 
HAdV DNA load became positive in UPN06 and UPN20 at 49 days and 106 days, respectively, after 
MSC infusion. Despite the presence of IFN-γ producing cells (UPN04)(F), the load did not decrease. #: 
viral DNA load detected three days prior to MSC infusion. UPN01, UPN02, UPN05, and UPN07: no PBMC 

















































































































































































































































































































































































































































































































































































































































































































































recurrent viremia after MSC treatment (UPN17 and UPN020) had low numbers of IFN-
γ-producing cells detected by ELISpot in the 2 weeks after receiving MSCs and showed 
an increase in IFN-γ-producing cells at 28 days after MSC infusion (Figure 5B). In the 
four evaluable patients with detectable CMV DNA loads before receiving MSCs, the 
number of IFN-γ-producing cells did not change significantly after MSC infusion and 
was not associated with the course of the CMV DNA load, which remained stable in two 
cases and diminished in the other two cases. Two children had a late development of 
aGvHD (at 83 days and 92 days, respectively, after HSCT), and CMV-specific prolifera-
tion was observed prior to the start of systemic steroids. Both showed a decrease of 
proliferation after start of steroids (Figure 5C-D) with recurrence of CMV viremia prior 
to MSC infusion. Both had CR after MSC infusion which allowed tapering of steroids. 
CMV-induced proliferation restored slowly in these patients. Another child with CR 
showed CMV-specific proliferation from 53 days after MSC infusion onward (data not 
shown). In the other three children (PR, PR, and NR to MSC, respectively) virus-specific 
proliferation was not detectable despite the continued presence of IFN-γ-producing 
cells (data not shown). 
In four of the seven patients with HAdV infection, the presence of IFN-γ-producing 
cells upon ex vivo HAdV stimulation of PBMC could be analyzed longitudinally. In all 
four patients tested IFN-γ-producing T cells were detected: in two children before 
and after MSC infusion, installed as third-line therapy, and in the other two only after 
initiation of MSC therapy as second-line treatment (Figure 5F). The patient with high 
numbers of HAdV-specific IFN-γ-producing T cells (UPN04) experienced a persistent 
viremia from before the start of systemic steroids onward; however, this patient is 
the only survivor at one year. The other patients developed a HAdV infection after 
MSC infusion, and those occurred late for UPN06 (49 days after HSCT) and UPN20 
(106 days after HSCT) (Table 1 and Figure 5E). HAdV-specific proliferation was not 
detectable in any of the patients.
Discussion
Numerous studies have demonstrated the feasibility of MSC therapy for steroid-
refractory aGvHD after allogeneic HSCT and have indicated its potentially beneficial 
effects.(von Bonin, 2009; Prasad, 2011; Le Blanc, 2004; Kebriaei, 2009; Ball, 2013) 
Response rates in these nonrandomized studies varied but were higher than in re-
ported historic controls, in which various highly immunosuppressive medications 
were applied as second- or third-line treatment. Patient numbers included so far were 
too small to draw firm conclusions not only with respect to efficacy but also about the 
potential occurrence of adverse events such as leukemia relapse and viral infections. 
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Currently available data on the incidence of infections are focused on CMV.(von Bahr, 
2012) The incidence of HAdV infections, which is especially relevant to children after 
HSCT (Chakrabarti, 2002; Flomenberg, 1994; Walls, 2003), has not been addressed. 
In addition, the in vitro effect of MSCs on HAdV-specific T cells has not been reported.
In a pediatric cohort treated with MSCs for steroid-refractory, severe, aGvHD in 
the Leiden University Medical Center, the occurrence of HAdV infection after MSC 
treatment was associated with decreased survival. This was not seen in children with 
aGvHD grade II-IV who were responsive to steroids or in children receiving second-
line therapy other than MSCs. A likely explanation is the relatively shorter duration of 
immune suppression in the patients responding to steroids. The difference between 
steroid-refractory children receiving MSCs versus other second-line treatment might 
point to an effect of MSCs; however, the effect might be influenced by the compara-
tively high number of children (10 of 22) in the MSC cohort receiving a mismatched 
graft. Of note, six out of seven children with an HAdV infection in this cohort were 
transplanted with a mismatched graft, thereby affecting 6 out of 10 children trans-
planted with such a graft, in line with previously reported data.(van Tol, 2005a) Graft 
modulation, either T cell depletion or CD34+ enrichment did not differ between the 
two groups.
One-year survival in patients with steroid-refractory aGvHD receiving second- or 
third-line therapy other than MSCs (historic controls) was significantly lower than in 
patients receiving MSCs as second-line therapy (38.5% vs. 73.9%), and was compa-
rable to that of children receiving MSC as third-line therapy (33.3%), which can be 
attributed to ongoing severe aGvHD. In a study on the use of monoclonal antibodies 
for the treatment of steroid-refractory aGvHD in children, 9 of 22 patients had viremia 
(13 episodes of viral reactivation: 5 CMV, 4 EBV and 4 HAdV) compared with viremia 
in 14 out of 22 children (19 episodes of viral reactivation: 7 CMV, 5 EBV and 7 HAdV) 
included in our MSC-treated cohort.(Rao, 2009) We deliberately choose log 2.3 copies 
per milliliter as a cutoff for infection and reactivation, regardless of the virus involved, 
and chose to include patients with controlled viral infections. This might explain the 
somewhat higher viremia rate in our study cohort. In addition, when applying the 
presence of a concentration of log 3.0 copies per milliliter in at least two consecutive 
plasma samples - the widely accepted criterion for a disseminated infection – the rate 
of one-year survival for patients with (n=11) and without (n=11) viral dissemination in 
our MSC cohort is statistically different (36.4% vs 91.0%; respectively; p=0.01). 
This is the first study describing the interaction of MSCs with HAdV-specific T cells. 
Karlsson et al. have published experimental data indicating the absence of an in 
vitro effect of MSCs on CMV- and EBV-specific T cells.(Karlsson, 2008) These data 
are in contrast to results from other studies demonstrating a downmodulating ef-


























of EBV-specific T cells.(Kang, 2005; Sundin, 2006) The latter observation is in line 
with our findings of a negative impact of MSCs on proliferation of both PBMC and 
virus-specific T cell lines after stimulation with CMV pp65 or HAdV hexon derived 
peptides loaded mDC or PBMC, respectively. The in vitro suppressive effect of MSCs 
on virus-induced T cell proliferation and IFN-γ production was MSC-dose dependent 
and most evident at high ratios of MSC to target cells. This and the fact that the 
relevant in vivo effect of MSCs most probably occurs at the sites of infection and 
tissue damage might explain that no increase in CMV-related disease is observed. Of 
note, suppression of proliferation was not observed in co-culture experiments using 
MSC and T cell clones specific for CMV, HAdV or control HY minor histocompatibility 
antigen (data not shown). 
In a recent study in mice, the suppression of the induction of an ovalbumin-specific 
T cell response in vivo after infusion of MSCs was explained by a decreased homing 
of ovalbumin-pulsed dendritic cells to the lymph nodes.(Chiesa, 2011) An indirect 
effect of MSCs on lymphocyte activation and proliferation via monocytes has been 
suggested previously.(Groh, 2005) In our MSC cohort, survival of patients with infec-
tions already present at the time of MSC infusion was significantly higher than that 
of patients with an onset of infections after the initiation of MSC therapy. A negative 
impact of MSC on antigen-presenting cells involved in the induction of a response 
in vivo might be an explanation for the differences in lethality of HAdV and CMV 
infections occurring prior to and after MSC infusion, respectively. However, based on 
our data, we cannot exclude a differential effect of immunosuppressive drugs on the 
initiation of a response versus an ongoing response. 
Using CMV pentamers, Karlsson et al. were the first to show that the percentage 
of virus-specific T cells was stable prior to and after MSC infusion in two patients.
(Karlsson, 2008) Lucchini et al. came to a similar conclusion based on the analysis 
of IFN-γ-producing cells in two patients after MSC infusion.(Lucchini, 2012) However, 
one of these patients showed a decrease in the number of IFN-γ-secreting cells and a 
recurrence of CMV viremia after multiple MSC infusions. In addition, 11 of 24 patients 
had a viral reactivation that occured after initiation of MSC therapy, including three 
patients with HAdV infection. Interestingly, no viral-infection-related death occurred 
in this patient group. Our data confirm the previously reported observation that MSC 
infusion did not affect the number of circulating CMV-specific T cells and extended 
this to HAdV-specific T cells. Of note, the level of IFN-γ-producing cells amongst 
peripheral blood T cells did correlate with the course of the CMV viremia or with 
the HAdV viremia, suggesting that more in-depth analysis of T cell subpopulations 
combined with other functional aspects might be of interest.
A major difficulty in interpreting data of ex vivo analysis of virus-specific T cells 
in MSC-treated patients is the immune suppression by methylprednisolone preced-
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ing MSC infusion and continued thereafter. A decreased number of CD8+ T cells 
after initiation of methylprednisolone has been reported previously,(Aubert, 2001; 
Cwynarski, 2001) in addition to decreased cytokine production without reduction of 
T cell counts.(Ozdemir, 2002) Previous studies did not comment on the influence of 
methylprednisolone tapering on recovery of immunity. We demonstrated a similar 
number of IFN-γ-producing cells in PBMC prior to and after initiation of aGvHD treat-
ment, whereas the proliferative capacity was hampered from the start of steroid infu-
sion. This analysis could only be performed in two patients with sufficient numbers 
of PBMC prior to MSC infusion. No CMV-specific proliferation was detected up to 3 
months after MSC infusion in three patients, in whom steroids could not be tapered 
due to a lack of response to MSC infusion.
Although our in vitro data demonstrate a suppressive effect of MSCs on T cell 
proliferation, the effect of methylprednisolone in vivo is likely to be stronger. Conse-
quently, aiming for a fast reduction of methylprednisolone after MSC infusion seems 
to be of utmost importance in these patients following objective documentation 
of resolvement of the aGvHD symptoms.(Calkoen, 2013b) Interestingly, infections 
already present at the start of aGvHD did not negatively affect the outcome. Thus, 
patients with active viral infections should not be excluded from future random-
ized controlled trials on MSCs as second-line therapy of steroid-refractory aGvHD; 
however, critical viral monitoring is advised. 
Conclusion
In this study, we show an association between HAdV infections occurring after 
MSC infusion and decreased survival in patients treated for severe steroid-refractory 
aGvHD. In addition, our in vitro data demonstrate a suppressive effect of MSCs on 
proliferation and activation of, among others, HAdV-specific T cells, whereas no 
solid evidence was obtained to support a negative impact of MSCs on antiviral T cell 
driven immune responses in vivo. However, the beneficial effect of MSC therapy on 
steroid-refractory aGvHD is strongly supported by the observation that CR or PR was 
established at 28 days after start of MSC therapy in 10 of the 14 children with a virus 
infection. In conclusion, the results of the present study indicate that the benefits of 
MSCs outweigh the potentially increased risk of infections. Randomized controlled 
trials, currently under development, will not only further address the efficacy of MSC 
treatment but should also represent the ideal platform to further investigate potential 
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Figure S1: Phenotype of virus-specific T-cell lines on day 28 after culture initiation. T-cell lines raised 
against HAdV (hexon) or CMV (pp65) derived peptides were characterized by immunophenotyping. A: 
The percentage of CD4+ and CD8+ T-cells in the HAdV- and CMV-specific T-cell lines is depicted. B: The 
percentage of cells expressing HLA-DR on either CD4+ or CD8+ T-cells was higher in CMV-specific T-cell 
lines compared to HAdV-specific T-cell lines. C-D: Both HAdV-specific (C) and CMV-specific (D) T-cell 
lines consisted mainly of effector memory (EM) cells (CD45RA−CCR7−). Naïve, central memory (CM) and 


































N 22 13 21
Follow-up (days; median; range) 379 (53-2708) 166 (58-5463) 1123 (61-2575)*







Age at HSCT median (range) 6.3 (0.7-18.1) 5.2 (0.6-14.3) 9 (0.4-17.1)








Other related 0 3 0
Stem cell source (BM/PBSC/CB) 13/4/5 9/4/0 17/3/1
Graft manipulation (none/TCD/CD34 
selection)
20/1/1 10/2/1 21/0/0
Donor sex (M/F) 12/10 6/7 7/14




Other MAC 2 0 1
RIC 1 1 1
Serotherapy + rATG/Campath 13/3 5/3 12/2#
GvHD prophylaxis CsA 7 2 6
CsA + MTX 10 9 13
CsA + prednisolon 
(1 mg/kg)
5 0 1
CsA + MMF 0 1 0
none 0 1 1
Relapse 3 0 3





skin only 0 1 10***
gut only 2 0 2
gut and skin 10 8 6
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gut and liver 5 0 0
skin and liver 0 0 3
gut, skin and liver 5 4 0
aGvHD grade II 0 7*** 16***
III 14 3* 5*
IV 8 3 0**
aGvHD stage gut 0 0 1 11***
1 0 5** 7*
2 2 1 0
3 16 3* 3***
4 4 3 0
aGvHD treatment Steroids up to 2 
mg/kg
22† 13 21†
2nd line therapy Total 6†† 13*** 0*
Steroids 3-5 mg/kg 5 3 0




ALL acute lymphatic leukemia; AML acute myeloid leukemia; HSCT hematopoietic stem cell transplan-
tation; HLA human leukocyte antigen; BM bone marrow; PBSC peripheral blood stem cells; CB cord 
blood; TCD T-cell depletion; TBI total body irradiation; MAC myeloablative conditioning; RIC reduced 
intensity conditioning; rATG rabbit anti-thymocyte globulin; aGvHD acute Graft-versus-Host Disease; 
CsA cyclosporin A; MTX methotrexate; MSC mesenchymal stromal cells; MMF mycophenolate mofetil. 
# one patient received Campath and rATG. † one patient received only 1 mg/kg prednisone. †† MSC 
were given as third-line therapy. Mismatched donor defined as: 5/6 (CB) or 9/10 HLA allele-matched 
(BM/PBSC). Grading and staging of aGvHD was according to the adapted Seattle criteria. (Ball LM, 
Egeler RM BMT 2008) Both control groups were compared to the MSC-group using Chi-squared and 
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Mesenchymal stromal cells: Hope or hype?
Are mesenchymal stromal cells a hype, a promising field of research, or the 
solution for everything? The first papers about mesenchymal stromal cells (MSCs) 
reporting astonishing results on the efficacy of treatment of steroid refractory acute 
graft-versus-host disease (aGvHD) and the increase of engraftment after autologous 
hematopoietic stem cell transplantation (HSCT) led to a widespread renewed interest 
in these cells. Researchers worldwide explore the possibilities of MSCs as therapeutic 
agent in a wide range of diseases. Other research groups aim to unravel the patho-
genesis of various diseases searching for aberrations in MSC function. Both types of 
research aim to understand the characteristics of MSCs in order to improve patient 
care, either by applying animal models, using in vitro experimental approaches, or by 
performing clinical trials. In this chapter I discuss the findings described in this thesis 
in light of the progress of MSC research over the last decade.
Balance
Homeostasis in haematopoiesis, the constant goal to establish balance in gen-
eration of the various cell lineages and their functions, is strived for to enhance 
survival. Homeostasis has its boundaries in many organ systems in our body. Failing 
to remain within these limitations causes disease. A clinician will try to treat patients 
by removing the trigger that disrupts homeostasis (cure) or to restore the balance 
by adding external factors (care). The immune system, with a continuous supply of 
new cells and a requirement for adequately regulated functions, is a typical example 
of homeostasis in which over activity (auto-immune and auto-inflammatory disor-
ders), or inactivity (infection), have an immediate impact on the health status of an 
individual. In addition, it is of the utmost importance to control the immune reaction 
to pathogens in order to avoid cause organ damage by the inflammatory response. 
Studying the different aspects of the immune system has improved the understand-
ing of immunology. 
In a similar way we have tried to characterise MSCs in vitro from healthy donors and 
patients with systemic juvenile idiopathic arthritis (sJIA), myelodysplastic syndrome 
(MDS) and juvenile myelomonocytic leukemia (JMML). In addition, the therapeutic 
application of MSCs was further evaluated in children with aGvHD after allogeneic 
HSCT. The side effects of immune modulatory cell therapy on anti-viral T cell medi-
ated immunity were also studied in the latter patient cohort.
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MSCs in treatment of inflammatory disease: 
Restoring balance
Treatment of acute inflammatory disease
MSCs in aGvHD
Prospective studies including patients with steroid refractory aGvHD after allo-
geneic HSCT reported response rates to MSC treatment ranging from 30% to 80%.
(Le Blanc, 2004; Le Blanc, 2008; Kebriaei, 2009; Prasad, 2011; von Bonin, 2009; 
Lucchini, 2010) The only randomized study, as yet only reported during the 2010 
EBMT Meeting, Geneva, could not confirm these observations, with a non-significant 
difference between complete response rates of 35-40% versus 28-30% in patients 
treated with MSCs and steroids versus steroids only.(Martin, 2010) This study was 
performed by Osiris and failed to meet its primary endpoints. Unfortunately, these 
data have not been published. Although 244 patients were included in this trial, 
these were spread over a large number of hospitals. However, the beneficial results 
in pediatric patients amongst this cohort led to the US Food and Drug Administra-
tion (FDA) registration of MSCs produced by Osiris for first-line treatment of aGvHD 
in Canada and New-Zealand. In a sub-group analysis, patients with gastrointestinal 
or liver aGvHD benefitted from MSCs with higher numbers of patients achieving a 
complete or partial response. However, all other published studies have compared 
response rates to those of historical controls. Large variation exists in the time 
between onset of aGvHD and start of MSC infusion. This seems critical, because one-
year overall survival in patients with steroid-refractory aGvHD receiving MSCs as third 
line therapy was comparable to historical controls (33.3% vs 38.5%), whereas overall 
survival in patients with MSCs as second line therapy was 73.9%.(Calkoen, 2013b) 
The need for well-designed, randomized, clinical trials enabling timely MSC infusion 
is evident. Chapter 5 of this thesis emphasizes the importance of gastrointestinal 
biopsies at diagnosis and during monitoring after intervention. The results described 
in chapter 6 report the importance of documentation of side-effects. In addition, 
feasible techniques to monitor anti-viral T-cell responses are shown. 
Difficulties in study design
For inclusion of sufficient patients to assess the effectiveness of MSC infusion a 
large international collaboration is needed. A laboratory certified for cellular therapy 
is mandatory for the different centers to join the study and all cellular products 
should meet similar criteria.(Dominici, 2006) The use of platelet lysate versus fetal 
bovine serum for expansion of MSCs further complicated this debate and delayed 

















are biological products and therefore sensitive to variation in their growth factor 
concentrations.(Hemeda, 2014) Human platelet lysate has been shown to give higher 
duplication rates and senescence in higher passages.(Griffiths, 2013; Ben, 2012) 
Studies reporting differences in immunosuppressive capacity are in favour of MSCs 
expanded in fetal bovine serum.(Abdelrazik, 2011; Bernardo, 2007a) When consider-
ing MSCs for tissue replacement human platelet lysate has been shown to be superior 
in the formation of oscicles in mice.(Prins, 2009)
Different end-points to document the response to MSC infusion have been used, 
e.g., best ever response(Le Blanc, 2008) or response on day 28-32 after treatment 
initiation(Kebriaei, 2009; Prasad, 2011; von Bonin, 2009; Lucchini, 2010), potentially 
explaining the differences in response to therapy. Criteria for aGvHD are solely based 
on clinical parameters and so far the definition of response to MSC treatment has 
been based on severity of skin involvement, amount of diarrhoea and bilirubin levels.
(Ball, 2008c) However, diarrhoea is often seen in patients after HSCT caused by either 
viral reactivation or during recontamination of the gut following decontamination 
regimens. We observed a patient who had persistent diarrhoea after MSC treatment 
but had no evidence of active aGvHD as assessed by endoscopy and histology.(Ball, 
2008a) Therefore, patients included in a prospective non-randomised phase II trial 
in our centre, underwent endoscopic evaluation in case of persistent symptoms after 
MSC infusion in line with studies in Crohn’s disease.(Ciccocioppo, 2011; Duijvestein, 
2010) 
In 18 out of 21 children with steroid refractory aGvHD, persistently profuse diar-
rhoea was documented despite a first MSC infusion. In 8 out of 12 cases no histologi-
cal evidence of aGvHD was seen. No complications occurred during endoscopy with 
biopsies at diagnosis and after MSC infusion. Further clinical management was based 
upon these findings and patients were successfully tailored of immunosuppression. 
In contrast, patients with persistent aGvHD received additional MSC infusions with 
complete response in the majority of the cases. The study underlines the critical 
importance of histopathological assessment of responses to experimental treat-
ments in GvHD of the gut as clinical symptoms are unreliable as a sole indicator 
of treatment response. However, many MSC studies to date rely entirely on clinical 
parameters to document response, calling into question the reliability of the reported 
response rates. Future studies evaluating the effectivity of MSC therapy for aGvHD 
should therefore include a standard gastrointestinal biopsy in case of persistent diar-




The definition by the National Institute of Health: 
Biomarker: A characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.(NHI, 2001) 
In case of sustained or relapsing diarrhoea after MSC infusion, endoscopic evalu-
ation of the gastro-intestinal tract is the only established method to differentiate 
between ongoing aGvHD and other causes of diarrhoea. Although safe and well-
tolerated in our patient cohort, minimally invasive approaches to measure responses 
are preferred over endoscopy in critically ill patients. Identification of biomarkers in 
urine, stool and serum has been proposed. (Rodriguez-Otero, 2012; Landfried, 2011; 
Paczesny, 2009) A consortium led by Paczesny and Ferrara aimed to define serum 
biomarkers to 1) estimate the risk of severe aGvHD prior to onset, 2) predict the 
response of aGvHD to first line or second line treatment at diagnosis, and 3) define 
the response to steroid treatment after 28 days.(Paczesny, 2009; Paczesny, 2010; 
Levine, 2012; Harris, 2012; Ferrara, 2011) Pooled serum obtained prior to and dur-
ing aGvHD was compared using mass-spectrometry to identify candidate proteins. 
These data were validated in larger cohorts and the predictive value of a selection 
of these candidate proteins was analyzed. In their cohorts including hundreds of 
patients, suggested biomarkers can be used to define patients at risk for aGvHD, to 
stratify patients according to their potential to respond to therapy, and to identify 
subgroups that have responded to therapy. These results are derived from retrospec-
tive analyses and should be confirmed by prospective studies.(Paczesny, 2013) To 
define the prognostic value of these markers, included patients should receive pre-
emptive treatment based on biomarker levels. A control group of patients randomly 
assigned to receive the selected pre-emptive treatment irrespectively of biomarkers 
levels, should be included.
Measurement of serum biomarkers in our patient cohort confirmed the increase in 
biomarker concentration at onset of severe aGvHD for TNFR1, IL-2Rα, HGF and IL-8, 
and at onset of gastrointestinal aGvHD for cytokeratin 18 (CK18), soluble cytokeratin 
18 fragments (sCK18F) and regenerating islet-derived 3α (REG3α). At 28 days after 
the first MSC infusion, TNFR1 concentrations differentiated between complete (CR) 
and partial/non-responders (PR/NR). 
CK18 and sCK18F serum levels measured at the time of gastrointestinal biopsy 
were significantly increased when gastrointestinal aGvHD was histologically con-
firmed (positive biopsies). However, the sensitivity (53.8%; 95% CI 25.1-80.8%) and 
specificity (86.7%; 95% CI 69.3-96.2%) of the CK18 test needs to be validated in 
larger cohorts of patients before these markers could be considered replacement for 

















response to MSC therapy. However, persistent non apoptotic cell-death is associated 
with lower response to treatment in aGvHD reported by Luft et al. demonstrating 
higher sCK18F to CK18 ratios in steroid refractory versus steroid responsive patients 
after initiation of steroids. Similarly, in our patient cohort, children with a partial 
or no response to MSC treatment had lower sCK18F to CK18 ratios already 7 days 
after MSC infusion. However, the variation amongst the patients did not allow for 
interventions in individual cases. 
Sera of patients included in the randomized controlled studies on MSC therapy in 
steroid-refractory aGvHD should be collected (1) at onset of aGvHD, (2) at time of ran-
domization, and (3) 7 and (4) 28 days after start of the intervention. Determination of 
biomarkers in these successive sera should aim to identify patients likely to respond 
to MSC therapy (1 and 2). In addition, biomarkers at 7 days after randomization may 
be used as early indication for response of no-response to therapy. Validation of the 
reported biomarkers on day 28 may be a substitute for gastrointestinal biopsy in 
the future. Previously reported biomarkers should be determined, but these valuable 
sera should be used to identify new biomarkers by e.g. mass-spectrometry. 
Viral reactivations
In surveillance of patients after HSCT, the clinician is constantly outweighing the 
benefits and the side effects of rapid immune reconstitution. Conditioning, donor 
selection, graft manipulation, and immune modulatory (suppressive) medication 
influence the balance between rapid versus delayed recovery. At the cost of increased 
risk of aGvHD the graft-versus-leukemia effect may be optimized for example by early 
withdrawal of immune suppression. In addition, delayed recovery of lymphocytes 
increases the time period during which the patient is at risk for viral reactivations.
(Broers, 2000; Boeckh, 2003; Walls, 2003) The interactions between viral reactiva-
tions and aGvHD further complicates this challenge. Viral reactivations are associated 
with an increased incidence of aGvHD, potentially causing the trigger in the first 
steps of aGvHD.(Akira, 2006) On the other hand, treatment of aGvHD, using immune 
suppression, decreases the response to viral reactivations, causing high mortality in 
this subgroup of patients.(Cantoni, 2010)
We addressed this issue comparing our MSC cohort to historical controls in chapter 
6. Whereas in adults cytomegalovirus (CMV) reactivations are the most abundant, 
human adenovirus (HAdV), (Flomenberg, 1994; Howard, 1999; Baldwin, 2000) causes 
most morbidity and mortality in children, with no established anti-viral drug at hand. 
(Walls, 2003; Kojaoghlanian, 2003; Leen, 2005; van Tol, 2005b) HAdV infections 
were particularly associated with decreased survival in MSC treated patients. The one-
year overall survival was 100% in children with steroid responsive grade II-IV aGvHD 
despite occurrence of a viral reactivation. In contrast, patients with a viral reactivation 
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and steroid refractory grade II-IV aGvHD, treated with MSCs or with other second-line 
therapy, had a one-year overall survival of 50% or 16%, , respectively. The use of 
high-dose steroids is a major confounder in this analysis. A decrease of the absolute 
number of CD8+ T cells after initiation of methylprednisolone has previously been re-
ported. (Aubert, 2001; Cwynarski, 2001) We demonstrated a similar number of IFN-γ 
producing cells in peripheral blood mononuclear cells (PBMC) prior to and after initia-
tion of aGvHD treatment, whereas the proliferative capacity of T cells is hampered 
from the start of steroid infusion. No CMV-specific proliferation was detected up to 3 
months after MSC infusion in three patients, in whom steroids could not be tapered 
due to a lack of response to MSC infusion. This could be due to decreased cytokine 
production induced by methylprednisolone as has been described.(Ozdemir, 2002) 
Studying the influence of MSCs on virus specific T cells in in vitro experiments 
demonstrated a suppressive effect of MSCs on PBMC proliferation after stimulation 
with virus specific peptides derived from HAdV and CMV. In addition, virus specific T 
cells, cultured for 28 days and mainly consisting of effector memory cells, were sup-
pressed in IFN-γ production and proliferation by MSCs. Although one study reported 
a diverse effect of MSCs on T cells stimulated with a viral antigen compared to an 
alloantigen,(Karlsson, 2008) other reports are in line with our data. A recent publica-
tion supports our findings by presenting data on suppressed proliferation of and 
IFN-γ release by specific CD8+ T cells stimulated with a CMV or influenza virus specific 
peptide or an allo-antigen in co-cultures with MSCs.(Malcherek, 2014) Comparable re-
sults were seen in T cell lines. However, in vitro experiments do not take into account 
the number of MSCs at the site of infection and the complex interplay of antigen 
presentation and lymphocyte proliferation in lymph nodes. This was suggested to be 
of importance based on a murine study demonstrating that decreased specific T cell 
proliferation was based on decreased homing of antigen presenting dendritic cells to 
lymph nodes.(Chiesa, 2011) Interestingly, patients with an onset of viral reactivations 
prior to MSC infusion had better overall survival compared to patients with viral loads 
becoming detectable after MSC infusion. Our data do not support the suggestion by 
Meisel et al. that MSCs should not be given to patients with a CMV infection based on 
the in vitro observed decrease of suppression by CMV infected MSCs. The hypothesis 
that viral antigen triggers MSCs via TLR3 to increase neutrophil activation was also 
not taken into account in our in vitro experiments.(Waterman, 2010) 
We aimed to further understand the side-effects of MSC infusion during steroid-
refractory aGvHD. The in vitro suppressive effect of MSCs on mixed-lymphocyte reac-
tions led to treatment with MSCs for aGvHD, despite a lack of insight in the in vivo 
working mechanism. Interestingly, despite numerous studies reporting a suppressive 
in vitro effect of MSCs on virus specific T cells the in vivo effect is disputed based on 

















data are confounded by persistence of aGvHD and the duration of steroids, but there 
is no reason to believe that MSCs do not negatively affect virus-specific T cells. Still, 
we propose that the virus specific suppressive effect of MSCs is less compared to 
that of high dose steroids and, therefore, administration of MSCs in order to rapidly 
control symptoms and allow steroid tapering is justified in life-threatening aGvHD. 
However, studies infusing MSCs without concomitant systemic steroids aiming to 
support engraftment or to prevent aGvHD, should enable investigation of the direct 
effect of MSCs on viral reactivations.(Ball, 2007)
Treatment of chronic inflammation and auto-immune disorders
The potential of MSCs in the treatment of various chronic diseases has been exten-
sively studied. The in vitro observed interactions with cells of the innate and adaptive 
immune system in combination with the reported prolonged skin graft survival in 
baboons led to studies in auto-immune diseases and chronic inflammatory diseases. 
Response to treatment with MSC infusions in chronic GvHD (cGvHD) varies exten-
sively in literature.(Ringden, 2006; Zhou, 2010; Weng, 2010; Perez-Simon, 2011; 
Herrmann, 2012; Muller, 2008; Lucchini, 2010; Fang, 2007) The reported cases 
differ in affected organs, grade of cGvHD and timing of MSC treatment. Although 
promising results were reported, many challenges remain before MSC infusion will 
be standard treatment in cGvHD. The recent development of a murine cGvHD model 
and a humanized cGvHD model, both resembling the human situation, opens pos-
sibilities to further understand the pathogenesis of cGvHD and the potential of MSC 
treatment.(Fujii, 2015; Srinivasan, 2012) Fibrosis of the targeted organs is seen in 
cGvHD. A potential role of MSC in tissue regeneration has been suggested,(Ringden, 
2007) which may be important in the resolution of GvHD. Of note, we reported ex-
tensive and persistent gut fibrosis in a pediatric patient following successful MSC 
treatment of steroid refractory aGvHD.(Ball, 2008a) Weng et al. and Herrmann et al. 
also observed that patients with cGvHD and end-stage fibrosis did not benefit from 
MSC infusions.(Weng, 2010; Herrmann, 2012) These observations cast doubt on the 
regenerative potential of non-manipulated bone-marrow expanded MSCs when ap-
plied in late stage disease. However, beneficial effects were seen on skin lesions in 
patients with de novo systemic sclerosis after systemic MSC infusion suggesting that 
the sclerodermatous type of chronic skin GvHD may be a candidate disease for MSC 
treatment.(Scuderi, 2013)
Local administration of MSCs into fistulas in adults with Crohn’s disease led to 
better outcome compared to results normally achieved by surgery. Closure of the 
fistula was seen in 70% of the patients.(de la Portilla, 2013) In contrast, only 3 out 
of 10 patients responded to systemic infusion of MSCs.(Duijvestein, 2010) Homing 
of MSCs to the site of inflammation was not assessed in this study, but an overall 
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decrease of inflammatory (TNF-α and IL-1β) cytokines in biopsies obtained 6 weeks 
after infusion was documented. 
Murine models of systemic lupus erythematosus (SLE) showed conflicting results 
after MSC infusion, with one study reporting an increase in disease severity and an-
other amelioration of disease.(Youd, 2010; Sun, 2009) Three human studies, although 
without inclusion of an appropriate control arm, demonstrated a decline in disease 
activity in 80-100% of the included patients systemically receiving either autologous 
bone-marrow derived or allogeneic umbilical cord blood derived MSCs. (Sun, 2010; 
Sun, 2009; Liang, 2010) An increase in the percentage of regulatory T cells after MSC 
infusion supports the suggested interaction between MSCs and regulatory T cells.
(Sun, 2010) Of note, these three studies were reported by one group. 
Both systemic and intrathecal infusion of MSCs has ameliorated disease in multiple 
sclerosis (MS), a progressive neurodegenerative disease thought to originate from 
an auto-immune process. This has recently been reviewed by Gharibi et al. critically 
addressing the absence of controls in the published studies.(Gharibi, 2015) 
Third party allogeneic MSCs have been used in aGvHD, to enable treatment initia-
tion early after start of symptoms.(Le Blanc, 2008) This approach was considered 
safe in patients under intensive immunosuppression. The use of allogeneic MSCs in 
immunocompetent patients without a direct life-threatening disease is controversial. 
Before autologous MSCs can be used in clinical trials, the characteristics of these 
cells, with an emphasis on immunomodulation, need to be defined. In our study, 
the immunomodulatory capacity of the MSCs expanded from the bone-marrow of 
children with systemic juvenile idiopathic arthritis (sJIA) at time of diagnosis was 
comparable to healthy pediatric controls.(Calkoen, 2013a)
Currently a total of 120 studies using MSC therapy in children are registered on 
www.clinicaltrials.gov: i.e., Duchenne Muscular Dystrophy, bronchopulmonary dys-
plasia, type I Diabetes Mellitus, osteogenesis imperfecta, rheumatic diseases, graft-
support, aGvHD, cGvHD, epidermolysis bullosa, medullablastoma (viral transduced 
MSCs for intrathecal infusion), ischemic heart disease, support of nerve regeneration, 
autism and liver failure, illustrating the hope (or hype) on MSC in the therapy of a 
plethora of disorders.
MSCs in disease: Disrupting balance
The function of MSCs in tissue has not been fully elucidated. Promoting a stable 
micro-environment, supporting other cells and acting as precursor for various cell types 
are thought to be the most important functions. These functions have been linked to 

















as a consequence of disease has been hypothesized. This section deals with these 
aspects in paediatric disease with a specific emphasis on hematologic malignancies. 
The bone marrow niche
The bone marrow microenvironment has been extensively studied since the iden-
tification of the hematopoietic and mesenchymal niche.(Friedenstein, 1968) Hema-
topoietic stem cells (HSC) remain in a quiescent state to maintain differentiation 
capacity and to escape toxicity.(Cheshier, 1999) In vitro expansion of the MSCs and 
co-culture experiments of MSCs and HSCs demonstrated the importance of MSCs. 
(Schofield, 1978) However, the mechanisms involved and other potentially important 
factors remained undefined. Murine studies including conditional knock-out models 
and in vivo imaging of the niche have given new insights.(Lo, 2009) The knowledge 
about the cell types and molecules involved in the murine bone marrow microenvi-
ronment is more extensive compared to the situation in humans. Translation of the 
concepts derived from animal studies to the human setting involves confirmation 
by immunohistochemistry,(Kode, 2014; Zhang, 2012b) characterization of expanded 
cells and, recently, transplanting expanded human MSCs on scaffolds in xenogeneic 
models.(Groen, 2012) 
The main challenges in murine studies unravelling the bone marrow niche focus 
on identification of (1) the location of the niche, (2) the cell types involved, and 
(3) associated molecular pathways. These concepts have been extensively reviewed 
by amongst others Schepers et al. and Bianco et al..(Schepers, 2015; Bianco, 2013) 
Based on the distribution of the HSCs (CD34+ cells) in the bone marrow the main site 
of quiescent HSC is thought to be situated close to the trabecular bone surrounding 
the efferent and afferent vasculature.(Kunisaki, 2013) This was confirmed in a human 
study using immunohistochemistry.(Flores-Figueroa, 2012) Mesenchymal stromal 
cells have an essential role in the niche concept. However, based on murine studies, 
MSCs can be subdivided in different subtypes, based on proximity to different vessel 
types (pericyte-like versus reticular-like), cellular markers (a.o. Nestin, leptin recep-
tor and neural/glial antigen 2) and excretion of hematopoietic regulators (CXCL12). 
In addition, MSCs differentiated to osteoblasts or adipocytes have been shown to, 
respectively, support and suppress haematopoiesis.(Winkler, 2010; Naveiras, 2009) 
The supportive function became more recently apparent by selective genetic knock-
down of hematopoietic regulators in osteoblasts resulting in myelodysplasia.(Raaij-
makers, 2010; Schepers, 2012) The altered gene-expression of DKK1 and genes in 
the leptin pathway in JMML patient derived MSCs suggest an altered in vivo balance 




Endothelial cells lining the arterioles and sinusoids are a major source of hemato-
poietic regulators contributing to the hematopoietic niche.(Butler, 2010) In addition, 
differentiated hematopoietic cells, megakaryocytes and macrophages, have also 
been shown to influence haematopoiesis.
Megakaryocytes directly stimulate the quiescent state or proliferation of HSCs 
by secreting exocrine molecules (CXCL4, TGF-β1, TPO and FGF1).(Schepers, 2015) 
Dysfunction of macrophages and osteoclasts leads to disruption of the bone marrow 
niche by inadequate replacement of bone.(Morrison, 2014) Another mechanism af-
fecting the hematopoiesis is the adrenergic nerve system. Nestin expressing MSCs 
and adrenergic nerves co-localized in the bone-marrow environment.(Mendez-Ferrer, 
2010) Stimulation of the adrenergic system is a regulator of the circadian rhythm 
of hematopoiesis and increased cellular efflux after tissue injury.(Courties, 2015; 
Mendez-Ferrer, 2008) Communication between MSCs and hematopoietic cells via 
tunneling nanotubes was added to the complex interaction after the observation 
that blocking of the tunneling nanotubes leads to decreased induction of cytokine 
(e.g. IP10 and IL-8) secretion by MSCs after in vitro exposure to B cell precursor ALL.
(Polak, 2015)
The murine knock-out models targeting a wide variety of pathways in the different 
cell populations resulted in insufficient hematopoiesis with dysplastic characteristics. 
Disturbance of the micro RNA regulation, by knock-down of Dicer1 specifically in 
osteoblastic progenitors, resulted in an MDS like hematopoiesis.(Raaijmakers, 2010) 
In the same study, selective knock-down of the Sbds gene resulted in increased 
dysplasia and apoptosis in the hematopoietic compartment. Altered gene expres-
sion of Dicer was confirmed in MSCs derived from adults with MDS. In contrast, the 
gene-expression of Dicer was comparable in MSCs of children with and without MDS 
in our study. This supports the current understanding that pediatric and adult MDS 
differ substantially. Others have used similar murine models to demonstrate dis-
turbed hematopoiesis after selective knock-down of stem cell factor (SCF), the 5HT4 
serotonin receptor, the retinoblastoma gene or the retinoic acid receptor-γ.(Ding, 
2012; Schepers, 2012; Walkley, 2007) Constitutive activation of the Wnt-pathway in 
osteoblasts leads to a hematopoietic system with characteristics of myeloid leukemia.
(Kode, 2014) 
Malignancies arising from MSCs
MSCs proliferate and differentiate to osteoblasts, adipocytes and chondrocytes. 
Growth during puberty requires cell replacement and renewal. This is the age at 
which osteosarcoma typically occurs. Murine MSCs have been shown to transform to 
osteosarcoma after long term culture.(Mohseny, 2009) Neither in healthy individuals 

















mation in culture have been published,.(Buddingh, 2015; Amaral, 2014) This does 
not exclude MSCs as the progenitor for sarcoma, however, development of sarcoma 
derived from infused MSCs is unlikely. 
Genetic abnormalities in MSCs
Genetic abnormalities specifically in MSCs have been controversial. Raaijmakers 
et al. demonstrated that in a controlled murine setting, specific genetic alterations 
in the bone-marrow stromal cells of mice lead to malignant transformation in the 
hematopoietic compartment.(Raaijmakers, 2010) In humans, the isolation procedure 
of MSCs from the bone-marrow and the in vitro expansion of MSCs complicate the 
analysis of aberrant MSC function because of contamination of isolated cells or 
culture initiated artefacts. In adults, 16 % of MSCs from patients with AML and MDS 
showed genetic abnormalities distinct from the genetic abnormalities in the hema-
topoietic cells.(Blau, 2011) In this cohort, patients without cytogenetic abnormalities 
in MSCs had a better survival suggesting a survival benefit of the hematologic cells 
in the presence of affected MSCs. The supportive characteristics of these two groups 
of MSCS were not evaluated in this study. Other studies in adults report higher 
percentages up to 68%.(Flores-Figueroa, 2008; Flores-Figueroa, 2005; Blau, 2007; 
Song, 2012; Oliveira, 2013) Cytogenetic abnormalities were detected in all adult MDS 
derived MSC using array-CGH.(Lopez-Villar, 2009) However, other studies did not 
find karyotype abnormalities in the MSCs of adult MDS patients.(Zhao, 2012b; Zhao, 
2014; Han, 2007; Soenen-Cornu, 2005) In adults, the acquired abnormalities during 
lifelong exposure to exogenous factors go concomitant in stromal and hematopoietic 
cells. In paediatric samples, no genetic abnormalities were detected in ALL.(Conforti, 
2013) However, in MSCs derived from one specific subset of ALL, MLL-AF4+ with ALL 
starting in utero, the characteristic fusion gene was detected in MSCs and ALL cells.
(Menendez, 2009) We showed that children with MDS or JMML do not have the same 
structural chromosome abnormality in MSCs as in the affected hematopoietic cells 
excluding a common genetic mutation as the explanation for altered gene-expression 
in patient derived MSCs.
MSCs in hematologic disease
As previously described, murine studies have been used to define the different 
pathways involved in the interaction between hematopoietic cells and MSCs. These 
murine models potentially resemble rare inherited diseases like Schwachman Blackfan 
Diamond or osteopetrosis (Mansour, 2012; Raaijmakers, 2010) and their application 
to investigate the contribution of MSCs to the development or expression of human 
hematopoietic disorders is controversial.(Raaijmakers, 2012) On the other hand, 
increasing evidence in adults supports our hypothesis that hematologic malignan-
Chapter 7.
156
cies alter the bone marrow microenvironment. This was previously suggested from 
data obtained in murine models demonstrating altered gene-expression in MSCs 
after infusion of, e.g., CML and AML.(Arranz, 2014; Zhang, 2012b; Schepers, 2013) 
Both the homing of HSCs and the inflammatory signals might be altered. Malignant 
hematopoietic cells are thought to benefit from this altered state by occupying the 
available spaces and by receiving increased proliferative signals, e.g., IL-6 and IL-1.
(Zhang, 2003; Schepers, 2013) In contrast, stromal cell derived IL-6 suppressed the 
in vitro proliferation of chronic lymphocytic leukemia (CLL). (Li, 2015)
Our studies are the first in children addressing the alterations in MSCs induced by 
hematologic malignancies. JMML and MDS are thought to originate from aberrancies 
in the hematopoietic system. In our studies we have shown that in both disease 
entities the MSCs are altered compared to MSCs of age matched controls. This is in 
line with previously reported data on adult MDS and case-reports in children. 
Characteristics of MSC from adults with MDS have been extensively studied focus-
ing on cytogenetic abnormalities(Blau, 2011; Lopez-Villar, 2009; Flores-Figueroa, 
2008; Blau, 2007; Flores-Figueroa, 2005; Song, 2012; Oliveira, 2013) and gene 
and protein expression(Marcondes, 2008; Flores-Figueroa, 2008; Lubkova, 2011; 
Santamaria, 2012; Flores-Figueroa, 2002; Hirayama, 1993; Aanei, 2012; Aanei, 
2011) (Zou, 2015). In addition, abnormal immunomodulation(Wang, 2013b; Zhao, 
2012b; Zhao, 2012a; Marcondes, 2008; Han, 2007) as well as decreased hematopoi-
etic support(Zhao, 2012b; Ferrer, 2013; Aanei, 2012; Varga, 2007; Tennant, 2000; 
Flores-Figueroa, 2012) by MSCs have been reported in adult MDS. However, these 
data remain conflicting with other studies reporting no abnormalities in stromal 
function.(Flores-Figueroa, 2008; Coutinho, 1990; Soenen-Cornu, 2005; Klaus, 2010; 
Alvi, 2001) Different results might be explained by differences in MSC expansion 
protocols and experimental set-up, but also by the heterogeneity of the disease.
(Aizawa, 1999) In our study we describe altered gene expression by pediatric MDS 
derived MSCs with an emphasis on immunomodulatory genes. The altered immu-
nomodulatory gene-expression in JMML derived MSCs was supported by an altered 
immunomodulatory function of the MSCs. A decrease in monocyte to dendritic cell 
differentiation is suggestive for a decrease in immunosurveillance in the bone mar-
row micro-environment. JMML may benefit from this during progression, which may 
explain the therapy resistance of the disease. The different subtypes of pediatric 
MDS differed in their gene expression profile of MSCs. Further evaluation of these 
alterations may help to explain the differences between these subtypes.
Publications on the role of stroma in the ontogeny and maintenance of pediatric 
MDS are limited to a case report from a child with MDS,(Narendran, 2004) a study us-
ing stroma cells of 7 MDS patients (Borojevic, 2004), and a gene-expression analysis 

















these scarce reports suggest an aberrant support of hematopoiesis associated with 
an altered gene expression profile of MSCs. 
The origin of adult MDS is poorly defined. Based on the inability to engraft HPCs 
of MDS patients in xenograft models and on murine models showing a dysfunctional 
bone marrow niche resembling MDS, disturbed MSCs were proposed as the initiator 
and progressive factor in adult MDS.(Medyouf, 2014) In this study, MDS derived HPC 
clones better engrafted in mice after injection of MDS derived MSC than without 
injection of supportive cells and also compared to injection of healthy adult MSC. In-
terestingly, despite loss of the transplanted MSCs after a few weeks, the MDS clones 
could be detected long thereafter. This last observation suggests that the murine 
bone marrow niche was altered by the injected MDS clones. Alterations in the murine 
micro-environment were not reported in this study, but increased leukemia inhibitory 
factor (LIF) expression was detected in healthy adult MSCs after in vitro exposure to 
MDS derived bone-marrow or MDS cell lines. 
The altered gene-expression by MDS and JMML patients derived MSCs is detectable 
despite multiple passages in culture. In addition, in the above mentioned study, the 
characteristics were retained after infusion. This suggests an epigenetic regulation 
of the changes in MSCs. Reversal of the changes after HSCT as described in chapter 3 
and chapter 4 and as reported in literature,(Zhang, 2012b) supports this hypothesis. 
The successful treatment by demethylating agents in adult MDS could potentially be 
explained by changes in MSC function.(Fenaux, 2009) As discussed previously, the 
interaction between MSCs and hematopoietic cells is complex and many processes 
affect these interactions. These specific pathways should be identified and clarified in 
in vitro models. The clinical relevance however, should be studied in murine models 
or in the future using therapeutic interventions in patients.
Directions for future research
Following the first successful reports of treatment with MSCs, randomized con-
trolled trials in steroid refractory acute Graft-versus-Host Disease (aGvHD), such as 
that recently initiated at the LUMC hopefully will provide answers about the efficacy 
of MSCs. Clinical data obtained in these studies in combination with laboratory data 
on serum biomarkers, lymphocyte subsets in blood and histology of biopsies should 
be used to define 1) patients likely to respond to therapy, 2) side effects of treatment 
and, of utmost importance, 3) the working mechanisms of MSC therapy. A better 
understanding of the different pathways involved in restoration of the balance of 
the immune system will be essential to proceed with cellular therapy. Experimental 
studies have identified possible involvement of multiple different pathways, and it 
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is most likely a combination of these that is responsible for the beneficial effects 
of MSC infusion in severe aGvHD. Identification of the most important interactions 
might lead to specific therapies without the need of cellular therapy.
Defining of the response induced by MSCs in aGvHD and the potential therapeutic 
mechanisms will support a more sophisticated exploration of the use of MSCs in 
other auto-inflammatory or auto-immune diseases. The use of standardized criteria 
for the cellular product in combination with proper designed clinical trials including 
collection of biomaterials will also be relevant to pursuit in these studies. Animal 
experiments and descriptive clinical trials have predominantly shown beneficial 
effects in active inflammatory conditions in contrast to ongoing chronic diseases. 
The suggested mechanism of licensing of the MSCs by e.g. double stranded RNA or 
lipopolysaccharides towards predominantly pro- or anti-inflammatory MSCs might 
explain these differences. In this way, it is not the question if MSCs are on one side 
of the equilibrium between anti- or pro-inflammatory responses, they are most likely 
the balance itself.
As previously discussed, the understanding of the interaction between MSCs and 
hematopoiesis is increasing. In addition, evidence supporting aberrant interaction 
during hematologic malignant diseases is more and more available. As demonstrated 
in this thesis, the disturbed immunomodulatory micro-environment is of importance. 
Further understanding of the consequences of the alterations will provide therapeutic 
targets. Support of normal hematopoiesis, resetting of the immune system and dis-
rupting the altered micro-environment should go hand-in-hand.
Clinical trials in pediatric MDS and JMML should aim to 1) target the hematopoietic 
cell – MSC interaction with e.g. anti-IL-6 or CXCR4 antagonist or 2) reverse the aber-
rant interaction by e.g. 5-azacitidine. However, to answer remaining questions three 
separate, but complementary, approaches should further unravel these interactions: 
I. Confirmation of differential RNA expression profiles
The observed differential RNA expression by patient derived MSCs should be 
studied at the protein level ex vivo by staining patient biopsies or measuring serum 
levels. In addition, the effect on MSC function of altered gene-expression should be 
characterized using specific up- and down-regulation of the different genes by e.g. 
siRNA. 
II. Induction of observed alterations in healthy MSC 
In vitro experiments should aim for better understanding of the mechanisms 
involved in induction of aberrant gene expression and normalization after success-
ful treatment. MSCs should be extensively co-cultured with cells of the affected 

















in MSCs and aberrant immunomodulatory capacity and hematopoietic support can 
be induced. The mechanisms of adaptation, potentially hypermethylation, should be 
characterized to be able to reverse the induced adaptations in vitro. 
III. Development of humanized murine models 
Patient material is scarce and in vitro experiments have its limitations. Human-
ized murine models using scaffolds for MSC engraftment have been developed for 
hematologic diseases, e.g., multiple myeloma. These models are not yet available for 
JMML and pediatric MDS. Experimental data have shown that ossification by JMML 
and pediatric MDS MSCs is possible on ossicles in mice. However, engraftment of he-
matopoietic cells has not been performed. In addition, the hematopoietic subset that 
should be transplanted to resemble JMML or pediatric MDS remains to be defined.
The different approaches are complementary and together should give a complete 
understanding of the complex alterations in the bone marrow micro-environment in 
pediatric MDS and JMML. A better insight should lead to therapeutic interventions 
in these rare diseases. Although new approaches will be developed for comparable 
adult diseases, our data show that the alterations in the micro-environment cannot 
be directly translated to pediatric conditions. On the other hand, a complete under-
standing of the alterations induced during active JMML, characterized by its specific 










In het beenmerg is een continu proces gaande om de verschillende bloedcellen te 
vervangen, genaamd hematopoëse. De hematopoëse moet strak worden gereguleerd 
om een tekort of een overmaat aan cellen te voorkomen. Hierbij is het essentieel 
dat de hematopoëtische stamcellen, de bron voor bloedplaatjes en rode en witte 
bloedcellen, in stand worden gehouden. Naast hematopoëtische cellen bestaat het 
beenmerg uit verschillende ondersteunende cellen, zoals vetcellen (adipocyten) en 
botcellen (osteoblasten). Rond 1970 werd bekend dat mesenchymale stroma cellen 
(MSCs) de voorloper zijn van deze hematopoëtische cellen en dat deze cellen struc-
tuur geven aan het beenmerg. In de afgelopen jaren is bekend geworden dat MSCs 
van belang zijn voor de regulatie van de hematopoëse en bij het in stand houden 
van de hematopoëtische stamcellen. De meeste kennis hierover is verworven door 
onderzoek met muizen. Hierbij kwam naar voren dat een niet goed functionerende 
beenmergomgeving (MSCs) zorgt voor verstoring van de hematopoëse; daarnaast 
traden veranderingen op in de MSCs nadat in de muizen bloedkanker was geïndu-
ceerd.
Een andere belangrijke karakteristiek van MSCs is het effect op het immuunsys-
teem. Nadat uit dierproeven bekend werd dat huidtransplantaten veel minder vaak 
werden afgestoten als er ook MSCs werden getransplanteerd, werd meer onderzoek 
gedaan naar de immuunmodulerende effecten van MSCs in in vitro experimenten. 
Dit leidde tot een belangrijke studie waarbij het effect van MSCs op acute graft-
versus-host ziekte werd bekeken. Deze ziekte kan optreden nadat bij patiënten een 
hematopoëtische stamceltransplantatie is verricht. Bij acute graft-versus-host ziekte 
valt het immuunsysteem, afkomstig van de stamceldonor, de huid, lever en darm 
van de patiënt aan. Bij deze levensbedreigende ziekte werd grote verbetering van de 
overleving gezien door toediening van MSCs. 
De onderzoeken beschreven in dit proefschrift richten zich op het verbeteren van 
de rol van MSCs bij de pathofysiologie en de behandeling van ziektes bij kinderen. 
Hierbij hebben wij ons gericht op de karakteristieken van MSCs bij kinderen met sys-
temische juveniele idiopathische artritis, myelodysplastisch syndroom en juveniele 
myelomonocyten leukemie. Daarnaast hebben wij de effecten van de behandeling 
van acute graft-versus-host ziekte met MSCs in kaart gebracht en onderzocht of 
MSCs de anti-virale immuunrespons beïnvloeden. Figuur 1 geeft een overzicht van 
het onderzoek beschreven in dit proefschrift.
Systemische juveniele idiopathische artritis (sJIA) is een chronische auto-inflamma-
toire ziekte waarbij kinderen koorts, recidiverende huiduitslag, hepatosplenomegalie 
en artritis krijgen. De behandeling van deze ziekte is gericht op het remmen van de 
Chapter 7.
162
ontsteking. Hierbij worden zowel aspecifieke middelen zoals NSAIDs en prednison 
als specifieke monoclonale antilichamen gebruikt. Voornamelijk deze laatste mid-
delen zorgen voor een sterke afname van de klachten. Deze middelen bieden echter 
geen genezing en moeten dan ook langdurig worden gebruikt met mogelijk ernstige 
bijwerkingen. Mogelijk kan door toediening van MSCs het eigen immuunsysteem 
hersteld worden zodat de patiënt kan genezen. Deze hypothese wordt ondersteund 
door het feit dat patiënten eerder genezen konden worden door middel van hema-
topoëtische stamceltransplantatie. Hierbij traden echter forse bijwerkingen op die 
onvoldoende opwogen tegen de ziektewinst. Bij behandeling van patiënten met MSCs 
heeft het de voorkeur om MSCs te gebruiken van de patiënt zelf om afstotingsreac-
ties te voorkomen. In hoofdstuk 2 van dit proefschrift hebben wij beschreven dat de 
MSCs van kinderen met sJIA dezelfde immuunmodulerende eigenschappen hebben 
als de MSCs van gezonde kinderen. Dit is een eerste stap in het toepassen van de 
MSCs bij de behandeling van kinderen met sJIA.
Daarnaast hebben wij gekeken naar de eigenschappen van MSCs van kinderen met 
myelodysplastisch syndroom (MDS) en juveniele myelomonocyten leukemie (JMML). 
Voor beide bloedziekten is een hematopoëtische stamceltransplantatie noodzakelijk 
om de ziekte te genezen. De verstoorde hematopoëse bij kinderen met MDS gaat 
gepaard met een verstoorde immuunmodulatie. Dat is dan ook de reden dat wij 
hebben gekeken naar de eigenschappen van de MSCs bij kinderen met MDS. De 
resultaten hiervan staan beschreven in hoofdstuk 3. Allereerst is van belang dat de 
genetische afwijkingen in de hematopoëtische stamcellen niet voorkwamen in de 
MSCs van die patiënten. Het is dan ook onwaarschijnlijk dat een gemeenschappelijke 
afwijking verantwoordelijk is voor de veranderingen in het bloedvormende en het 
ondersteunende compartiment in het beenmerg. De MSCs van kinderen met MDS en 
de MSCs van gezonde kinderen verschillen niet in hun effecten op immuunreacties 
bij in vitro experimenten. Ook zagen wij geen verschil in de ondersteuning van in 
vitro hematopoëse door de MSCs. Bij analyse van de totale genexpressie van de 
verschillende MSCs zagen wij wel verschillen. Hiervoor hebben wij gebruik gemaakt 
van Deep-SAGE, een moderne techniek waarbij de nucleotide volgorde van al het 
messenger -RNA bepaald wordt. Vergelijking van de verkregen profielen toonde 
clustering van de kinderen met MDS ten opzichte van de gezonde kinderen. De 
genen met de grootste verschillen waren interleukine-6, van belang bij inflammatie; 
DKK3, betrokken bij gereguleerde celdood; CRLF1 en DAPK1, beide geassocieerd met 
maligne ontaarding. Daarnaast hebben wij specifiek gekeken naar genen waarvan 
recent is beschreven dat zij differentieel tot expressie komen in MSCs afkomstig van 
volwassenen met MDS. Wij vonden echter geen veranderde expressie bij de kinderen 
met MDS. Dit bevestigt het bestaande idee dat MDS bij kinderen een wezenlijk andere 
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Beenmerg punctie (III) 
Expansie (III) 
MSC-behandeling (III) 
Veranderde beenmerg omgeving (IV) Normale beenmerg omgeving (V) 
MDS/ JMML (VI) 
Gezond kind (I) 
Figuur 1. Een overzicht van de verschillende onderwerpen in dit proefschrift. I: MSCs zorgen bij ge-
zonde kinderen voor ondersteuning van hematopoëse en een stabiel immuunsysteem. II: Tijdens 
momenten van ontsteking, zoals bij acute graft-versus-host ziekte, ontstaat er een toename in ge-
activeerde natural killer cellen (NK) en cytoxische T lymfocyten (T) na activeren door van monocyten 
(Mo) afkomstige dendritische cellen (DC). Gelijktijdig ontstaat een relatieve daling van het aantal regu-
latoire T lymfocyten (Treg) en toename van inflammatoire cytokinen als TNF-α, IL-1 en IFN-γ. III: MSCs 
kunnen in het laboratorium worden gekweekt nadat er beenmerg is afgenomen. In dit proefschrift 
worden de mogelijkheden van MSCs beschreven om de ontregelde immuunrespons weer in balans te 
brengen.
Daarnaast hebben we de interactie tussen MSCs en de hematopoëtische cellen onderzocht bij kin-
deren met MDS en JMML. Wij hebben onderzocht of de MSCs mogelijk IV: intrinsiek anders zijn bij 
deze kinderen of dat er V: door de ziekte veranderingen worden geïnduceerd. VI: de veranderde MSCs 
dragen mogelijk bij aan de resistentie tegen de huidige behandeling van JMML en MDS.
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JMML is een maligne ziekte waarbij verschillende genetische afwijkingen in het 
hematopoëtische compartiment zijn beschreven. Het is een agressieve vorm van 
bloedkanker die voorkomt in de eerste vier levensjaren. Bij 30-50% van de kinde-
ren komt de ziekte terug ondanks in eerste instantie succesvolle hematopoëtische 
stamceltransplantatie. Zoals beschreven in hoofdstuk 4 hebben wij gekeken naar 
de MSCs van deze kinderen omdat wij veronderstelden dat de veranderde beenmer-
gomgeving mogelijk een rol zou spelen bij deze agressieve en therapie resistente 
ziekte. Alhoewel de MSCs niet verschilden op basis van standaardtesten zagen wij bij 
Deep-SAGE analyse grote verschillen tussen de MSCs van gezonde kinderen en JMML 
patiënten. Wij hebben vervolgens specifiek gekeken naar de uitrijping van monocyten 
naar dendritische cellen. Dit proces is van belang voor antigeen presentatie voor 
cellen van het immuunsysteem. MSCs remmen deze uitrijping. Opvallend was dat 
MSCs van JMML patiënten een nog sterker effect hadden op de uitrijping dan MSCs 
van gezonde kinderen. Een verminderde antigeen presentatie speelt mogelijk een rol 
bij de progressie van JMML. Daarnaast waren de verschillen in expressie van genen 
betrokken bij de interactie tussen verschillende celtypen (onder andere CXCL12) en 
genen betrokken bij inflammatie (onder andere de IL-1 familie) opvallend. De ver-
schillen werden niet verklaard door gemeenschappelijke genetische afwijkingen. Na 
succesvolle hematopoëtische stamceltransplantatie waren de genafwijkingen en de 
verschillen in remming van monocyt differentiatie niet meer meetbaar. Dit suggereert 
dat de veranderingen die wij meten in de geëxpandeerde MSCs van kinderen met 
JMML worden veroorzaakt door de ziekte en niet de oorzaak van de ziekte zijn. 
De eerste stap van behandeling van acute graft-versus-host ziekte is immuunsup-
pressie met prednison. Bij onvoldoende of geen respons is er geen verdere stan-
daardbehandeling beschikbaar en is de overlevingskans van kinderen met ernstige 
acute graft-versus-host ziekte die ongevoelig zijn voor prednison ongeveer 30% 
(historische data). Sinds MSCs worden gebruikt als experimentele behandeling is de 
overleving echter sterk gestegen. In hoofdstuk 5 beschrijven wij een groot cohort 
van kinderen die behandeld zijn in het LUMC. Van deze kinderen zijn uitgebreid 
gegevensbekend en is frequent serum afgenomen. Bovendien is bij deze kinderen 
gestart met het afnemen van darmbiopten na behandeling. Een darmbiopt is bij 
de diagnose van acute graft-versus-host ziekte de gouden standaard. Bij de eerste 
kinderen die waren behandeld met MSCs zagen wij frequent diarree na start van 
therapie; soms na een in eerste instantie klachtenvrije periode. Bij deze kinderen is 
een darmbiopt genomen om duidelijkheid te krijgen over de diagnose. Hierbij werd 
gedacht aan een recidief van de ziekte, een virale infectie of aan diarree geassocieerd 
met het herstarten van normale voeding. Meerdere keren zagen wij dat bij patiënten 
geen sprake was van actieve ziekte en dat de immuunsuppressie succesvol kon wor-








diarree een darmbiopt verricht. In totaal werd bij acht kinderen geen actieve ziekte 
gezien, maar bij vier kinderen was ondanks MSC behandeling sprake van tekenen 
van acute graft-versus-host ziekte. Bij deze kinderen werden opnieuw MSCs gegeven 
met een goede respons bij drie van hen. De afname van biopten is bij alle kinderen 
ongecompliceerd verlopen. Wel is het een ingreep die onder narcose moet gebeuren 
en een procedure die wordt verricht bij zieke kinderen. Wij hebben dan ook geke-
ken naar een alternatief door analyse van eerder beschreven biomarkers voor de 
diagnose acute graft-versus-host ziekte in serum monsters. Opvallend is dat bij de 
start van de behandeling met steroïden de concentratie TNFr1 hoger is bij kinderen 
die niet reageren op MSC infusie. Dit effect is sterker 28 dagen na de start van MSC 
behandeling. Daarnaast hebben wij gekeken naar REG3α een biomarker specifiek 
voor acute graft-versus-host ziekte van de darm. Een lage REG3α waarde 28 dagen 
na start van de behandeling is een goede voorspeller van de eenjaarsoverleving. 
Alhoewel de concentraties van REG3α, IL2-Rα en cytokeratine 18 (een marker voor 
cel apoptose) wel significant verhoogd zijn op het moment van biopsie bevestigde 
ziekte, zijn de specificiteit en sensitiviteit onvoldoende om een biopsie te vervangen. 
Dit geldt specifiek voor biopten genomen na start van de behandeling. Wij raden 
dan ook sterk aan om bij toekomstige klinische studies naar acute graft-versus-host 
ziekte in ieder geval darmbiopten te nemen bij het persisteren van gastro-intestinale 
klachten op het moment van evaluatie van de respons op behandeling.
Het werkingsmechanisme van MSCs bij immuunmodulatie is onvoldoende duide-
lijk. Ook de bijwerkingen van de behandeling zijn onvoldoende beschreven. In ons 
cohort hebben we gekeken naar het effect van MSC behandeling op virus infecties. 
Eerdere studies rapporteren een wisselend effect op T lymfocyten specifiek tegen 
het cytomegalovirus. Over het effect op de afweer tegen adenovirus, een specifiek 
probleem bij kinderen na hematopoëtische stamceltransplantatie, was nog niets 
beschreven. In hoofdstuk 5 wordt de incidentie van cytomegalovirus, adenovirus 
en Epstein-Barr-virus infecties vergeleken bij kinderen met acute graft-versus-host 
ziekte van wie 22 patiënten werden behandeld met MSCs; bij 21 kinderen werd alleen 
prednison gegeven en dertien kinderen kregen een andere tweedelijnsbehandeling 
dan MSCs. Er werden geen verschillen gezien in de incidentie van de verschillende 
virale infecties. Opvallend genoeg was de overleving bij kinderen behandeld met 
MSCs die een adenovirus infectie kregen significant lager. In in vitro experimenten 
werd de specifieke respons van T lymfocyten tegen cytomegalovirus en adenovirus 
onderdrukt door MSCs. Bij kinderen met een virus infectie rondom de behandeling 
met MSCs werd geen verandering gezien in het percentage virus-specifieke T lym-
focyten. Wel is de proliferatie van de specifieke T lymfocyten onderdrukt bij deze 
kinderen vanaf het moment dat prednison wordt gestart. 
Hoofdstuk 6 geeft een blik in de toekomst met ideeën en adviezen voor toekomstig 
onderzoek. De gerandomiseerde studies die worden verricht naar de behandeling 
van acute graft-versus-host ziekte kijken primair naar het effect van MSCs, maar 
daarnaast vormen MSCs een unieke populatie waarbij door kritische en gedetail-
leerde analyse meer inzicht kan worden verkregen in het werkingsmechanisme en de 
bijwerkingen van MSCs. Biopten, serum analyse, maar ook lymfocyten subset analyse 
zijn hierbij essentieel. Verbeterd inzicht kan vervolgens worden gebruikt voor een 
beter gefundeerde behandeling van chronische auto-immuun- en auto-inflammatoire 
ziekten met MSCs.
Het onderzoek naar de interactie tussen hematologische maligniteiten en MSCs 
richt zich op een beter begrip van de pathofysiologie van deze ziekten. Ons onder-
zoek toont aan dat bij kinderen met myelodysplastisch syndroom (MDS) en juveniele 
myelomonocyten leukemie (JMML) het gen expressie profiel van de MSCs is veranderd 
gedurende actieve ziekte. Na succesvolle behandeling herstelt dit profiel zich weer. 
Voor verder inzicht is bevestiging nodig van onze bevindingen in ex vivo botbiopten, 
in vitro inductie van veranderde genexpressie in gezonde MSCs en in vitro herstel 
van veranderde genexpressie in patiënten MSCs. Daarnaast zijn recent beschreven 
3D modellen, al dan niet in een gehumaniseerd muismodel, essentieel voor een beter 
begrip van de complexe interactie tussen MSCs en hematopoëtische cellen. Deze 
nieuwe inzichten kunnen op termijn consequenties hebben voor de behandeling van 
kinderen met MDS of JMML. Mogelijke aanknopingspunten hiervoor zijn de immuun-
modulatie en de interactie tussen MSC en hematopoëtische cellen.
Het onderzoek naar MSCs ontwikkelt zich snel op vele gebieden. Beter begrip van 
de complexe mechanismen zal bijdragen aan de zorg voor patiënten. Niet alleen op 
het gebied van immuunmodulatie en weefselherstel, maar ook bij maligniteiten en 
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